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ABSTRACT 
NANOPARTICLE AS SUPRAMOLECULAR PLATFORM FOR DELIVERY AND 
BIOORTHOGONAL CATALYSIS 
SEPTEMBER 2017 
GULEN YESILBAG TONGA, B.S., BOGAZICI UNIVERSITY  
M.S., BOGAZICI UNIVERSITY 
Ph.D., UNIVERSITY OF MASSACHUSETTS AMHERST 
Directed by: Professor Vincent M. Rotello 
 
Nanoparticles (NPs) are being investigated widely for many applications including 
imaging, drug delivery, therapeutics, materials, and catalysis due to their unique and tunable 
physical and chemical properties. Among NPs, gold nanoparticles (AuNPs) have attracted great 
attention due to ease of synthesis and surface functionalization, inertness of the core, 
biocompatibility, and functional versatility. Introducing supramolecular chemistry into the 
nanoparticle-based platforms brings out controllable properties, dynamic self assembly processes, 
and adjustable performance. My research has focused on the synthesis of AuNPs bearing different 
surface functionalities and their host-guest interactions with synthetic small molecules or 
commercially available hydrophobic catalysts for delivery and therapeutic applications. My 
research is consisted of two main sections. First part is the regulation of the exocytosis of AuNPs 
using host-guest interactions and characterization of these interactions in solution using 
isothermal titration calorimetry and inside cells using laser desorption/ionization/matrix assisted 
laser desorption/ionization mass spectrometry. Second part is about encapsulating various 
hydrophobic transition metal catalysts into the monolayer of AuNPs. These catalyst-embedded 
vii 
 
AuNPs were used to catalyze industrially important reactions in aqueous environment. For 
biological applications, this system was called as ‘nanozyme’ because it was used as an enzyme 
mimic to perform bioorthogonal activation of profluorophores and prodrugs for imaging and 
therapeutic applications, respectively. Using the host-guest chemistry, intracellular catalysis was 
supramolecularly regulated. Lastly, different monolayer designs were engineered to increase the 
catalyst loading and improve catalytic efficiency. 
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CHAPTER 1 
GOLD NANOPARTICLES IN DELIVERY AND THERAPEUTICS 
1.1 Introduction 
Nanoparticles with tunable properties are promising platforms for myriad applications in 
delivery,
1
 therapeutic, sensing,
2
 materials,
3
 and catalysis.
4
 Especially monolayer protected 
inorganic nanoparticles have been widely employed in biotechnology and nanotechnology due to 
their tunable and controllable core and surface properties. Monolayer protected nanoparticles are 
hybrid materials where metal core is protected with self-assembled monolayers (SAMs) of 
organic ligands. The SAMs are chemisorbed onto metal/semiconductor core surfaces to make the 
nanoparticle stable, soluble in water, biocompatible and chemically diverse.
5,6
 The applications of 
these nanoparticles take advantages of properties of both rigid core material and soft monolayer 
ligands. 
Nanoparticles exhibit a number of special properties relative to bulk material. 
Nanoparticles possess unique chemical and physical properties that can be tailored for the 
intended application. Among the physicochemical properties of inorganic nanoparticles, size, 
shape and surface functionality are the key attributes that dictate the behaviour of nanoparticles 
and their fate within biosystems.
7
 Tuning these three features during chemical synthesis of 
nanoparticles bring out distinct optical, electronic, catalytic, or magnetic properties.
8
 At the same 
time, uptake, distribution, cytotoxicity, and interaction with biomolecules are highly affected by 
these three features.
9
 Especially, decorating the surface of nanoparticles with a wide range of 
appropriate functionalities reveals structurally and dynamically well-defined architectures that 
provide efficient drug delivery platforms.
10
 Addition to size, shape, and surface functionality, 
surface area to volume ratio in nanoparticles has a significant effect on the nanoparticles 
properties. Nanoparticles have a very high surface area to volume ratio compared to larger 
particles and this allows multiple copies of a ligand to be attached per nanoparticle resulting in 
2 
 
multivalency, a crucial feature that provides enhanced interaction with the surrounding 
environment. These unique properties of nanoparticles have made them attractive platforms for 
many applications from studying the nanoparticle-biomolecule interactions to their use in 
delivery and therapeutics. 
Among the inorganic nanoparticles, gold nanoparticles (AuNPs) have attracted great 
attention due to ease of synthesis and surface functionalization, inertness of the core, 
biocompatibility and functional versatility (Figure 1.1). After the pioneering work of Brust et al., 
thiol-protected AuNPs has been the mostly investigated monolayer protected nanoparticle 
system.
11
 AuNPs have been widely studied for many purposes such as catalysis,
12
 sensing,
13
 
delivery,
14
 and therapeutics.
15
  
 
Figure 1.1: Schematic illustration of monolayer-protected gold nanoparticles. The rigid inorganic 
core is protected by a soft organic monolayer that can be chemically tailored for various 
applications. 
 
The most common way of functionalization of AuNPs is performed using Brust-
Schriffrin reduction followed by Murray place-exchange reaction
16
 with appropriate ligands that 
are synthesized for the intended application. After the place exchange reaction and purification 
steps that involve washing/centrifugation cycles and dialysis, nanoparticles that are of 
commensurate size to many biological components such as DNA, protein, and cell membrane are 
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obtained. This biomimetic size provides multiple applications at the bio-nano interface such as 
gene transfection, regulating DNA transcription, protein-protein interactions, etc. This thesis uses 
AuNPs as a scaffold for catalysis, delivery and therapeutic applications using supramolecular 
chemistry. Therefore, as a background to following chapters, AuNPs in delivery and therapeutics, 
supramolecular interactions between small molecules and the monolayer of AuNPs, 
bioorthogonal catalysis, and some applications of AuNPs related to this thesis will be discussed in 
this chapter.  
1.2 Application of Gold Nanoparticles in Drug Delivery and Therapeutics 
AuNP-based drug delivery systems are highly attractive platforms for the efficient 
delivery and release of drugs to targeted tissues and cells. There are two major strategies for 
conjugating drugs to AuNPs: covalent or non-covalent association.
17
 Mirkin et al. have employed 
a covalent attachment strategy to conjugate paclitaxel (a potent chemotherapeutic drug) to AuNPs 
via DNA linkers, thereby enhancing the solubility and overall effectiveness of the drug.
18
 Also, 
Zubarev et al. have attached a flexible hexaethylene glycol linker to the C-7 position of paclitaxel 
to conjugate it to phenol-terminated AuNPs.
19
 Using this strategy, 70 molecules of paclitaxel 
were able to be loaded onto an AuNP in a controlled manner. Mirkin, Lippard and coworkers 
have combined the properties of DNA, AuNPs and Pt(IV) prodrugs into a single agent for drug 
delivery using the covalent association approach. The particles were incubated with HeLa cells 
for different time periods. After 6 h, they had localized in vesicles (Figure 1.2a), and after 12 h, 
they were released into the cytosol (Figure 1.2b). Oregon Green 488 taxol bisacetate, which stains 
microtubules, showed colocalization of these nanoparticles with the microtubules in HeLa cells 
(Figure 1.2c). Overall, they have demonstrated that the acidic environment in cancer cells 
facilitate reduction of the Pt(IV) and yield the cytotoxic Pt(II) species. 
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Figure 1.2: Top scheme-synthesis of Pt-DNA-AuNP. Bottom a) Live cell imaging of HeLa cells 
after incubation with platinum-tethered Cy5-DNA-Au NPs for 6 h and (b) 12 h, and (c) 
colocalization of the particles with the cytoplasmic microtubules. 
 
Rotello et al. have used the hydrophobic interior of AuNP monolayers to non-covalently 
encapsulate and deliver a hydrophobic drug molecule.
20
 Depending on the strategy used, the 
release of a drug from its carrier can be triggered by a wide range of stimuli, such as 
hydrophobicity, pH, temperature, magnetic fields, enzymes, UV-light, and NIR 
photoluminescence.
21
 For instance, Burda et al. have shown that a photodynamic therapy (PDT) 
drug such as silicon phthalocyanine 4 could be successfully adsorbed on PEGylated AuNPs and 
used as an effective PDT drug delivery vector for both in vitro and in vivo applications.
22
 
Furthermore, inorganic nanomaterials can be designed to improve drug efficacy through 
enhanced targeting delivery.
23
 For instance, El-Sayed et al. have quantified the degree of tumor 
cell uptake of Au nanorods covalently conjugated to tumor-targeting peptides.
24
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1.3 Supramolecular Chemistry 
Supramolecular chemistry studies the non-covalent interactions in and between 
molecules, as well as the interactions between formed multimolecular complexes.
25
 Natural 
molecules, such as proteins, oligonucleotides and lipids have been the source of inspiration for 
supramolecular chemistry and supramolecular chemists aim to design and synthesize novel 
supramolecular architectures using various building blocks that can reach the complexity and 
functionality of these natural molecules. Supramolecular chemistry mainly focuses on how 
molecules recognize each other, assemble and function on a molecular scale.
26
 It brings a bottom 
up approach where nanoscale systems are generated from self assembling molecules using 
hydrogen bonding, host–guest recognition, metal coordination or electrostatic interactions..27 
Supramolecular chemistry has been involved in many applications ranging from biology to 
materials science.
28
  
1.3.1 Supramolecular Chemistry in Drug Delivery 
Non-covalent interactions provide a flexible method of engineering various building 
blocks with tailored properties. Due to the reversible nature of the non-covalent interactions, the 
supramolecularly engineered systems have exhibited unique features such as facile preparation 
and functionalization, controllable morphologies and structures, dynamic self assembly processes, 
and adjustable performance.
29
 Furthermore, the self-assembled supramolecular structures have 
been applied in various biomedical fields including bioimaging,
30
 gene transfection,
31
 protein 
delivery,
32
 regenerative medicine,
33
 tissue engineering, sensing, and drug delivery.
34
 Especially, 
when drug delivery is considered, excellent biocompatibility and biodegradability, responsive 
nature, and possibility of incorporating multiple arrays of different functional units through 
intermixing of different building blocks render supramolecular platforms very promising delivery 
systems.
35
 All of these features are of great importance for designing and producing drug carriers. 
Compared to those of the covalent assemblies, the self-assembly and disassembly processes of 
6 
 
supramolecularly engineered assemblies are easier to control due to the existence of reversible 
non-covalent interactions, which makes the supramolecular assemblies an ideal vehicle for drug 
delivery. For example, Scherman et al. reported triple stimuli-responsive supramolecular double 
hydrophilic block copolymer micelles for controlling drug release (Figure 1.3).
36
 In their design, a 
stimuli responsive micelle was fabricated by connecting a thermo-responsive polymer (poly(N-
isopropylacrylamide), PNIPAM) and a pH-responsive polymer 
(poly(dimethylaminoethylmethacrylate), PDMAEMA) together using a host molecule, 
cucurbituril[8] (CB[8]). These micelles were loaded with Doxorubicin (Dox) and its release was 
triggered by the disassembly of the carrier by decreasing the temperature, lowering the pH or 
adding competitive guests. Compared to the covalently connected micelles, these supramolecular 
micelles exhibited a faster release rate and a tunable release profile that was controlled using 
these three stimuli.  
 
Figure 1.3: Schematic representation of hierarchical self-assembly of the supramolecularly 
engineered polymers to yield micelles and drug release after being exposed to three different 
triggers. 
 
7 
 
1.3.2 Supramolecular Platforms Using Gold Nanoparticles  
AuNPs with a large number of surface ligands are promising scaffolds as the building 
blocks of self assembly process. Proper design of the interactions between AuNPs and 
complementary units such as proteins, polymers, and small molecules results in unique materials 
with tunable properties and desirable functions. Various supramolecular interactions including 
electrostatic attractions,
37
 hydrogen bonding,
38
 π-π stacking and van der Waals interactions 
between nanoparticle and complementary units have been designed to control nanoparticle self-
assemblies. Rotello et al. have developed a ‘chemical nose’ sensing system using supramolecular 
interactions between functionalized AuNPs, transducers (fluorescent proteins), and analytes. The 
sensor was generated by non-covalent conjugation of AuNPs with fluorescent proteins (EBFP2, 
EGFP and tdTomato). The fluorescent proteins serve the dual roles of exhibiting differential 
supramolecular affinities with the particle and transducing the binding events. In these AuNP–
fluorescent protein supramolecular complexes, the cationic AuNP binds strongly with the anionic 
fluorescent proteins, resulting in quenching of the fluorescent protein fluorescence by the particle 
core. The binding equilibria between AuNP and the fluorescent proteins (FBs) are altered in the 
presence of analytes due to the competitive binding to analytes, resulting in rapid 
(seconds/minutes) displacement of fluorescent proteins from the particle surface, with consequent 
restoration of the fluorescence. The fluorescence ‘turn-on’ of the emission channels differs 
considerably depending on the signatures of the analyte surfaces. Specific signal patterns of this 
system can be used for identifying proteins, cell surface glycomic signatures,
39
 bacteria,
40
 and 
cancer drug mechanisms.
41
 Introducing host-guest chemistry into the sensor system doubled the 
information content of the array-based sensor for cancer diagnostics. In this approach, the 
interaction of the particle with both the fluorescent protein transduction elements and the cell 
lysate analytes were modulated by non-covalent modification of nanoparticle surface with a 
complementary cucurbit[7]uril (CB[7]) moiety.
42
 As a result, the change in competitive binding 
effectively resulted in doubling the number of output channels from three to six while 
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maintaining the one-well configuration with 100 % accuracy and minimal sample quantity (200 
ng, ~1000 cells) (Figure 1.4).  
 
Figure 1.4: (A) Six channel-output in a single well. The fluorescence of FPs is quenched when 
the NP-FP complexes are formed. Upon addition of cell lysates, three emission channels are 
obtained from the released FPs. In the same well, CB[7] is added to obtain three additional 
channels from the three FPs as a result of changed interactions between the analyte and newly 
formed complex, NP-CB[7]. (B) Linear Discriminant Analysis (LDA) with the fluorescence 
responses from all six channels showed well separation of all cell types. 
 
Rotello and coworkers used supramolecular chemistry to regulate the therapeutic 
efficiency of AuNPs. This supramolecular system includes cucurbit[7]uril (CB[7]), a synthetic 
host molecule and AuNPs with head group functionality which is complementary to CB[7] 
(Figure 1.5). After forming complexes of AuNPs and CB[7], a non-toxic assembly that is readily 
taken up by cells was obtained. This host-guest complex can be disassembled intracellularly by 
using an orthogonal competitive molecule, 1-adamantylamine (ADA), which has a very high 
affinity for CB[7]. Intracellular removal of CB[7] from the nanoparticle surface results in 
endosomal escape of toxic AuNPs and concomitant cell death. This result shows the utility of 
supramolecular host-guest interactions in drug delivery and therapeutics.  
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Figure 1.5: (A) Schematic showing the activation of AuNP-NH2-CB[7] cytotoxicity by 
dethreading of CB[7] from the nanoparticle surface by ADA. (B) Cytotoxicity of AuNP-NH2 and 
AuNP-NH2-CB[7] measured by Alamar blue assay after 24 h incubation in MCF-7. (C) 
Triggering cytotoxicity using ADA. After 3h incubation of AuNP-NH2-CB[7] (2 µM) in MCF-7 
cell, different concentrations (0, 0.2 and 0.4 mM) of ADA in medium added and further incubated 
at 37 ºC for 24 h. The cell viability was then determined by using an Alamar blue assay. 
 
1.3.3. Characterization and Monitoring of Host-Guest Interactions in Solution and Living 
Cells  
Characterization of intermolecular interactions and their binding equilibria in solution are 
performed using techniques such as NMR,
43
 fluorescence, UV/Vis spectroscopy,
44
 and surface 
plasmon resonance (SPR).
45
 However, all these techniques have certain drawbacks such as the 
requirement of large quantities of the samples, the necessity to introduce labels, or long 
measurement times. ITC (isothermal titration calorimetry), a useful analytical tool, is widely used 
by biochemists and supramolecular chemists to characterize interacting systems and study 
host−guest interactions.46 In contrast, sample preparation is very easy for ITC and also it offers a 
fast calorimetric response and thermal equilibration. The most important features of ITC include 
the determination of the entire thermodynamic profile (ΔH, ΔS, ΔG, KB, and the stoichiometry n) 
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of an interaction in only one experiment.
47
 This method is based on the repetitive addition of a 
solution of one of the interacting molecules (ligand or host molecule), via automated injection at 
constant temperature, into a cell containing a solution of the second molecule (guest molecule). 
The heat exchange is measured and reveals quantitative information about the interaction between 
molecules. The binding stoichiometry and thermodynamic parameters of binding (host-guest 
complexation) including association and dissociation constants as well as changes in enthalpy, 
entropy, and free energy can be derived from a single ITC titration. Supramolecular interactions 
of protein-protein,
48
 small molecule/drug-protein,
49
 protein-polymer
50
, biomolecule-
nanoparticle,
51
 and enzyme kinetics have already been successfully examined using ITC.
52
 Self-
assembling monocomponent systems can also be studied by ITC to monitor the dissociation 
event. A concentrated solution of the self-assembled compound is placed in the syringe and 
injected into the cell containing pure solvent. If the final concentration is low enough, the 
supramolecular assemblies are dissociated and the heat exchange is characteristic of the 
dissociation event. This procedure has been used to measure the critical micelle concentration of 
low-molecular-weight surfactants,
53
 to study amphiphilic polyelectrolytes,
54
 and to derive the 
partition coefficient of solutes in lipid vesicles.
55
  
Due to the complex environments in cells, the aforementioned methods including ITC 
cannot be used to analyze supramolecular interactions in biological systems. Mass spectrometry 
(MS) is an effective tool for characterizing host-guest interactions in solution
56
 and in biological 
environment.
57
 For example, electrospray ionization (ESI) MS and matrix assisted laser 
desoption/ionization (MALDI) MS have been utilized for the detection of host-guest complexes.
58
 
Nau and coworkers investigated host-guest inclusion complexes between a macrocyclic host, 
cucurbit[n]urils (CBn, n=6–8) and the bicyclic azoalkanes by mass spectrometry, and studied 
thermally activated, selective retro-Diels–Alder reactions in the gas phase.59 
11 
 
Among MS techniques, laser desorption/ionization (LDI)-MS has been shown to 
selectively detect ligands on intact NPs in complex biological samples.
60
 This method relies on 
the selective desorption/ionization process of the surface ligands on NPs under the laser 
irradiation. It is a highly sensitive and selective method that enables to detect NP monolayer in 
cell lysates.
61
 Supramolecular complexes formed by the surface ligands of NPs and host 
molecules serve as “mass barcodes” to indicate complex formation inside cells. By this method, 
host-guest interactions can be monitored without using an additional labeling process. 
1.4 Bioorthogonal Catalysis 
Bioorthogonal chemistry is a powerful strategy that allows to do artificial chemistries in 
the same physical space where biological processes take place continuously, yet do not interfere 
with each other.
62,63
 Bertozzi`s benchmark works demonstrated the potential of bioorthogonal 
chemical reactions in studying biomolecules in their native settings.
64,65
 Visualization of 
biomolecules and/or dynamic cellular processes in real time and in real life has been achieved by 
bioorthogonal platforms that utilize reactions such as Staudinger ligation and Cu-free click 
chemistry. Staudinger ligation which forms an amide bond between the azide and an ester-
derivatized phosphine is highly biocompatible in cells and living animals. However, slow reaction 
kinetics and oxidation issues of the phosphine reagents
66
 limit the use of this bioorthogonal 
ligation method to detect low-abundance species or to visualize rapid biological processes. On 
contrary, click chemistry which is the azide-alkyne cycloaddition reaction, is highly reactive and 
sensitive bioorthogonal functionalization method. Click chemistry has been developed by 
Sharpless and coworkers
67
 and Meldal and colleagues
68
 using copper catalyst (Figure 1.6). This 
copper mediated cycloaddition has been used for probing enzyme activities in cell lysates
69
 or 
visualizing biomolecules in fixed cells.
70
 However, for dynamic processes in living systems, this 
system was not suitable due to the cytotoxic nature of copper catalyst.  
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Figure 1.6: (A) The copper-catalyzed azide–alkyne cycloaddition. (B) The Cu-free click reaction 
of azides and DIFOs. 
 
Bertozzi et al. designed a bioorthogonal reaction for dynamic cellular imaging that 
combines the biocompatibility of the Staudinger ligation with the fast reaction kinetics of click 
chemistry (Figure 1.7). They explored the use of cyclooctynes as an alternative to activating 
alkynes for [3+2] cycloaddition with azides.  Due to the ring strain, they achieved bioorthogonal 
labeling of azides without using copper catalyst.
71
 To increase the sensitivity of the cyclooctynes 
for azide detection, they incorporated an electron withdrawing group, difluoromethylene (DIFO) 
moiety.
72
 
 
 
 
 
 
 
 
 
Figure 1.7: (A) Comparison of Cu-free click chemistry with Cu-catalyzed click chemistry. (B) 
Schematic showing cell surface labeling using Cu-free click chemistry. (C) Comparison of Cu-free 
click chemistry with other bioorthogonal ligations using alkyne containing Alexa Fluor 488. (D) 
Labeling using alkyne containing biotin. 
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Beside these applications, bioorthogonal chemistry has been widely used for the 
intracellular
73
 and extracellular
74
 generation of molecules for therapeutic,
75
 imaging,
76-77
 and 
sensing applications.
78-79
 Bioorthogonal catalysis enables scientists to selectively activate 
molecules for the aforementioned applications under complex environments with high efficiency. 
However, these bioorthogonal systems must possess fast rates under physiological conditions and 
be inert to myriad of functionalities found in vitro and in vivo.  
1.4.1 Bioorthogonal Catalysis Using Transition Metal Catalysts 
Transition metal catalysts (TMCs) are excellent candidates for use in bioorthogonal 
chemistry, as they provide platforms that rapidly catalyze a wide range of transformations where 
enzymes are not able to perform.
80
 In some studies, TMCs are used to build up artificial 
metalloenzymes where the naturally occurring metalloenzyme was redesigned by replacement of 
the native metal with a suitable transition metal to develop highly new selective hybrid catalysts 
for several asymmetric catalytic reactions.
81
 However, in some studies, TMCs are incorporated in 
totally synthetic platforms or used directly to perform bioorthogonal selective transformations 
(Figure 1.8).
82,83
 
 
Figure 1.8: Bioorthogonal nanocatalysis designed and demonstrated by Meggers (2006, 2012), 
Bradley and Unciti-Broceta (2014, 2016) and Rotello (2015). 
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Meggers and co-workers were pioneers to report the first example of bioorthogonal 
catalysis by cleaving protecting groups using nanocatalysts based on organometallic catalysts in 
cellular environment.
84,85
 In one of their work, they found that ruthenium(II) half-sandwich 
complex [Cp*Ru(COD)Cl] (Ru1), with Cp* = pentamethylcyclopentadienyl and COD = 1,5-
cyclooctadiene can catalyze the uncaging reaction of allylcarbamates under bio-relevant 
conditions (Figure 1.9). To evaluate the catalytic efficiency in living mammalian cells, they chose 
a non-fluorescent profluorophore N,N-bis-allyloxycarbonyl protected rhodamine 110 as a cellular 
probe. HeLa cells were incubated with the substrate for 30 minutes followed by washing with 
phosphate buffered saline (PBS). Upon addition of Ru-catalyst and thiophenol, rapid increase in 
fluorescence was observed due to cleavage of the both allylcarbamate-protecting groups (Figure 
1.9 c-f).  
 
Figure 1.9: Fluorescence microscopy images of uncaging process of allylcarbamate-protected 
rhodamine 110 (pro-fluorophore) inside HeLa cells using ruthenium nanocatalyst. a) Right after 
catalyst addition and b) after 15 min. c)–f): Fluorescence generation after indicated times. Cells 
were incubated with pro-fluorophore and the membrane carbocyanine dye DiIC18(5) for 30 min 
and then treated with [Cp*Ru(cod)Cl] and thiophenol. 
 
The direct application of TMC-mediated reactions in living cells is challenging due to 
issues of biocompatibility, water solubility/stability, and rapid efflux from living cells.
86
 In order 
to overcome such limitations, Bradley et al. pioneered on the uses of nanoparticles for carrying 
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out bioorthogonal catalysis.
87
 They investigated several bioorthogonally chemical processes using 
3 nm palladium nanoparticles entrapped in a 500 nm polystyrene microsphere.
88
 After a day of 
interaction, 75% of HeLa cells engulfed one or more of microspheres and 91% of them were 
viable after 48 h. The cells internalized in microparticles were used to carry out several catalytic 
processes such as allylcarbamate cleavage and C-C bond formation through Susuki-Miyaura 
cross coupling reaction (Figure 1.10). More recently, Bradley, Unciti-Broceta and coworkers used 
palladium catalyst loaded polystyrene composite with particle size of 150 μm for extracellular 
activation of prodrugs such as propargyl caged 5-Flurouracil (5-FU).
74
 Other cytotoxic drugs like 
Gemcitabine
89
 and Floxuridine
90
 were also transformed into prodrugs that are activated by Pd 
chemistry.  
 
 
Figure 1.10: Scheme of the bioorthogonal reactions taking place inside the cell internalized 
PdNP@PStyr composite. (A) Allylcarbamate deprotection (cleavable unit highlighted in red). (B) 
Confocal microscope image of cell stained through the generation of highly fluorescent 
Rhodamine 110 after the allylcarbamate cleavage process. (C) Scheme of the Susuki-Miyaura 
transformation on the fluorescein triflate ester taking place on the surface of the cell internalized 
PdNP@PStyr composite. (D) Confocal image of the generated fluorescein derivative staining 
mitochondria. 
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1.4.2 Non-Covalent Incorporation of Hydrophobic Transition Metal Catalysts into AuNP 
Monolayers 
Non-covalent drug delivery utilizing NPs involves either an encapsulation mechanism or 
a stabilizing pocket.
91
 Efficient release of the cargo in the hydrophobic pocket is dictated by 
external changes in hydrophobicity. If the NP carrier encounters more hydrophobic environment 
such as a cell membrane, drug molecules can simply diffuse into the membrane. AuNPs posses 
some hydrophobic interior (pockets) in the monolayer that can be used to encapsulate various 
hydrophobic cargos such as transition metal catalysts, cancer drugs, dye molecules, or 
antibiotics.
92
 These hydrophobic pockets are formed due to the hydrophobic section of the ligands 
that are used to functionalize AuNPs. Structurally, the radial nature of the monolayer results in a 
decrease in ligand density as one goes farther from the core of small AuNP cores (< ~6 nm).
93
 
Consequently “hydrophobic pockets” are created inside the monolayer of AuNP into which 
hydrophobic materials can be partitioned. Pasquato et al. demonstrated the encapsulation of 
radical probes in AuNP monolayers, using EPR spectroscopy to monitor the partition of the 
lipophilic probe between a monolayer of AuNP and bulk water.
94
 As expected, smaller particles 
featuring more strongly radial monolayers favor guest encapsulation. 
Rotello et al. have utilized hydrophobic pockets of AuNP monolayers to encapsulate 
highly hydrophobic dyes/therapeutics.
95
 They have demonstrated that hydrophobic dyes/drugs 
can be stably entrapped in a hydrophobic pocket of small sized AuNPs (hydrodynamic diameter 
∼10 nm) coated with non-interacting monolayers (zwitter ionic layers). They have chosen three 
different hydrophobic guest compounds: 4,4-difluoro-4-bora-3a,4a-diaza-s-indacene (Bodipy) as 
a fluorescent probe and the highly hydrophobic therapeutics tamoxifen (TAF) and-lapachone 
(LAP) as the drugs (Figure 1.11). The nanoparticle-payload conjugates (AuNPZwit-Bodipy, TAF, 
and LAP) were prepared by a solvent displacement method.
96
 Payloads have released into the cell 
by membrane-mediated diffusion without uptake of the carrier nanoparticle. Importantly, the 
small size of these nanocarriers coupled with their biocompatible surface functionality should 
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provide long circulation lifetimes and preferential accumulation in tumor tissues by the enhanced 
permeability and retention (EPR) effect.
97
 
 
Figure 1.11: (A) Delivery of payload to cell due to change in hydrophobicity through monolayer-
membrane interactions (B) Structure of particles and guest molecules: Bodipy, TAF, and LAP, 
the number of encapsulated guests per particle, and log P of the guests. 
  
Burda et al. have also utilized hydrophobic pocket concept to deliver a hydrophobic 
photodynamic therapy drug Pc 4 using PEG functionalized AuNPs, and reported an increase in 
drug tumor accumulation.
 98
 The drug was found to reside deep within the PEG layer, and only 
after the delivery and release, the fluorescence of the drug was observed. However, when a 
covalent attachment of Pc 4 to Au surface is used, almost no drug was found to be delivered. 
1.5. Dissertation Overview 
Incorporating supramolecular chemistry into AuNPs combines the unique features of 
both systems into a single platform. While dynamic nature of supramolecular interactions brings 
reversibility, tunable physical and chemical properties of AuNPs render them as controllable 
platforms with potential applications in delivery and bioorthogonal catalysis. My research has 
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been oriented toward the fabrication of functional AuNPs scaffolds using host-guest interactions. 
In some of my studies, ligand head groups on AuNPs serve as the guest molecules that are ready 
to interact with synthetic host molecules. In other studies, I used AuNP as a host for hydrophobic 
transition metal catalyst (guest molecules) encapsulation and solubilization. To achieve my goals, 
I have combined organic synthesis, surface science, analytical chemistry, and biology to develop 
supramolecularly engineered AuNP platforms. In the following chapters, details of designing 
functionalized AuNPs and their use in delivery as well as catalysis are described.  
In chapter 2, regulation of exocytosis of AuNPs using a simple host-guest interaction will 
be discussed. AuNPs carrying quaternary ammonium head groups were internalized into the cells 
through endocytosis. Subsequent in situ treatment of a complementary cucurbit[7]uril (CB[7]) to 
the head groups induced the particle-CB[7] complexation inside cells, rendering the particles 
assembled each other. This complexation followed by the concomitant formation of larger 
assemblies resulted in the inhibition of exocytosis of particles without creating toxicity, due to the 
sequestered particles in endosomes. This approach would provide a potential strategy for 
prolonged retention of drug carriers within endosome, enabling sustained release of the loaded 
therapeutics in the carriers. 
In chapter 3, quantification of host–guest interactions between CB[7] molecule and 
AuNPs using ITC titrations will be described. In this study, AuNPs featuring ligands with a 
monomethyl-benzylammonium (MMBA) or dimethyl-benzylammonium (DMBA) head groups 
were served as guest scaffold and CB[7] as the host molecule. We have investigated the changes 
in the binding event considering two features: (1) the effect of different functionalities at the para 
position of the benzene ring and (2) the effect of carrying a permanent positive charge on the 
head group.  
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Chapter 4 will discuss a new mass spectrometric approach for the characterization and 
detection of supramolecular host-guest interaction in complex environment such as cell lysates. 
Using this simple method, both association and dissociation of host-guest complexes between 
AuNPs and synthetic macrocyclic molecules were monitored inside cells. Also, a selective 
triggering process for the dissociation of host-guest interactions of three AuNPs with different 
surface functionalities was successfully demonstrated.   
Chapter 5 will discuss the solubilization of hydrophobic transition metal catalysts through 
encapsulation into the water soluble nanoparticle hosts. We report the solubilization of various 
hydrophobic catalysts achieved by using hydrophobic pockets of water soluble gold 
nanoparticles. Besides preserving original catalyst activity, this nanoparticle platform provides a 
protective environment for the hydrophobic catalyst. Grubbs, Cp*Ru(cod)Cl, Pd(dppf)Cl2, and 
Wilkinson catalysts encapsulated in the water soluble AuNPs are used for ring opening 
metathesis polymerization, allyl carbamate cleavage and hydrogenation of alkenes, respectively. 
Recyclability of a nanoparticle-catalyst system is examined for the Wilkinson catalyst. This work 
demonstrates a versatile platform for the encapsulation of different hydrophobic catalysts, 
allowing the utilization of a wide range of catalysis in water.  
Chapter 6 will describe the engineering of AuNP monolayer to increase the catalyst 
loading. Hydrophobic catalyst was encapsulated into the hydrophobic pocket in the monolayer. 
The extension of hydrophobic layer of surface monolayer and introduction of aromatic functional 
group resulted in the increase of the loading amount of transition metal catalysts per particle as 
well as the catalytic activity of nanozyme in aqueous solution and inside cells.   
In chapter 7, supramolecular regulation of bioorthogonal catalysis in cells will be 
discussed. This AuNP-catalyst complex is named as “nanozyme” as it mimics the allosteric 
regulation of enzymes and possesses biomimetic size and surface functionalities. Hydrophobic 
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transition metal catalysts were encapsulated into the hydrophobic pockets in the monolayer to 
create active sites for bioorthogonal catalysis. Effectively delivering and regulating the activity of 
protein-sized, catalytic systems is challenging due to both the complex intracellular environment 
and catalyst instability. The activity of these catalysts could be reversibly controlled by binding a 
supramolecular cucurbit[7]uril ‘gate-keeper’ onto the monolayer surface, providing a biomimetic 
allosteric control mechanism. The efficacy of this gated nanozyme was demonstrated by the 
triggered cleavage of protecting units on the substrates (profluorophores and prodrugs) inside 
living cells, providing a new type of nanozyme for use in imaging and therapeutic applications. 
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CHAPTER 2 
REGULATING EXOCYTOSIS OF NANOPARTICLES VIA HOST-GUEST 
CHEMISTRY 
2.1 Introduction 
Drug delivery systems (DDSs) improve the efficacy of conventional pharmaceutics 
through enhanced pharmacokinetics and biodistribution.
1
 Finely tuned and engineered 
nanoparticle platforms
2
 are used to design DDSs to achieve the release of drugs at a controlled 
rate.
3
 Trigger sensitive release mechanisms of covalently
4
 or non-covalently
5
 attached drugs are 
widely employed for on-target site activation strategies.
6
 Furthermore, much effort has focused on 
increasing the uptake of the carrier into targeted tissues passively through the enhanced 
permeability and retention (EPR) effect
7
 and/or actively by using targeting modalities.
8
 However, 
for effective DDSs, the sustained therapeutic effect inside cells relies not only on the cellular 
uptake of nanocarriers but also on their subsequent long-term retention in the cells.
5c, 9 
One of the main obstacles of DDSs is the rapid removal of the internalized drug carriers 
through the exocytosis before the drug release.
10 
Exocytosis is the process of expelling wastes and 
other large molecules out of the cells,
11
 which is also commonly observed with a wide variety of 
drug carriers.
12 
As an example, internalized poly (D,L-lactide-co-glycolide) nanoparticles undergo 
exocytosis to the extent of 65 % at 30 min and 85 % at 6 h.
13
 Reducing exocytosis of the 
nanoparticulate drug carriers thus prolong their retention time and concurrently release the loaded 
drugs gradually inside cells, enhancing the therapeutic efficiency of the DDSs. Developing 
strategies for orthogonal control of exocytosis in the cellular environment is a major challenge 
because of the intracellular chemical complexity and a potential toxicity of relevant reagents.  
Supramolecular chemistry generates controlled assemblies from molecular building 
blocks through non-covalent interactions including hydrogen bonding, hydrophobic, and van der 
Waals interactions. Due to their reversible modularity, supramolecular complexes are useful for 
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creating responsive host-guest systems for many therapeutic applications. Cucurbit[n]rils (CB[n]) 
are water-soluble macrocyclic hosts with a hydrophobic cavity that form strong inclusion 
complexes with many types of guests, including positively charged ligands on the gold 
nanoparticle (AuNP) surface. Various CB[n]-guest systems have been developed to create 
delivery vectors for therapeutic materials including drugs and an actuator system to control 
catalytic activity of an enzyme. Moreover, engineering host-guest systems provide the capability 
of actuation for the regulation of therapeutics in living cells. Among the cucurbituril family, 
cucurbit[7]ril (CB[7]) is attractive as a building block for the construction of supramolecular 
architectures due to its remarkable guest binding behavior in aqueous media and non-toxic 
behavior in vitro and in vivo.   
In this work, we describe a new approach to regulate the exocytosis of AuNPs by using 
host-guest interactions between AuNPs and CB[7] molecules. Quaternary ammonium 
functionalized cationic gold nanoparticles (AuNP-TBen) were readily taken up by the cells via 
endocytosis (Figure 2.1). Afterward, in situ treatment of complementary CB[7] molecules 
resulted in threading of CB[7]s on the terminal functionalities of AuNP-TBen inside the cells, 
resulting in AuNP-TBen-CB[7] complexes. This complexation rendered the surface of the 
particles less hydrophilic, inducing the self-assembly of AuNP-TBen-CB[7] sequestered in the 
endosomes. Exocytosis of the AuNP-TBen-CB[7] was then blocked by the increased size of the 
induced assemblies. This approach provides a new strategy for improving efficacy of drug 
delivery systems through prolonged retention of drug carriers within the cells. 
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Figure 2.1: Controlling exocytosis of AuNPs by using intracellular host-guest complexation. (a) 
Inhibition of AuNP-TBen exocytosis by the threading of CB[7] onto the nanoparticle surface. (b) 
Formation of the AuNP-TBen-CB[7] assemblies. 
 
2.2 Results and Discussion 
2.2.1 Complexation between AuNP-TBen and CB[7] 
Exocytosis of nanoparticles is dependent on their size
9a 
and surface functionality.
14
 
Compared to their smaller counterparts, larger nanoparticles (more than 100 nm in diameter) tend 
to undergo exocytosis at slower rate and lower amount. Therefore, an efficient way of regulating 
exocytosis could be inducing in situ growth of assemblies from the internalized individual 
nanoparticles entrapped in endocytic vesicles by using a host-guest supramolecular system. The 
exocytosis of the particles then would be blocked by the increased size of the induced 
assemblies
15
 and the host-guest system provides an orthogonal stimulus, allowing temporal 
control of the exocytosis (Figure 2.1 (b)). 
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We have synthesized a water-soluble AuNP-TBen featuring a tetra(ethylene glycol) and 
quaternary benzyl amine head group prepared via a Murray place-exchange reaction.
16
 The 
detailed syntheses and characterization of the AuNPs are available at the end of this chapter. The 
gold core had an average size of 2.1 ± 0.5 nm with hydrodynamic diameter of the AuNP-TBen 
being 9.7 ± 0.1 nm determined by transmission electron microscope (TEM) and dynamic light 
scattering (DLS), respectively. The AuNP-TBen had a zeta potential of + 14.2 mV. The terminal 
quaternary benzyl amine moiety serves as a recognition unit for the formation of a host-guest 
inclusion complex with CB[7] with the association constant of ~ 108 M
-1
. This higher binding 
constant is strong enough for the complexes to remain stable under biological conditions.  
2.2.2 Inducing Assemblies of AuNP-TBen-CB[7] 
The complexation between AuNP-TBen and CB[7] was investigated by performing DLS 
experiments whose results are shown in Figure 2.2 (a). At the molar ratio of 1:1 and 1:2 (AuNP-
TBen:CB[7]), the hydrodynamic diameter of the AuNP-TBen slightly increased from 9.7 ± 0.1 to 
11.6 ± 0.5 nm. At a ratio of 1:4 (AuNP-TBen:CB[7]), the particles began to assemble together 
and completely aggregated at the ratio of 1:10 (AuNP-TBen:CB[7]) to give a clear solution with a 
precipitation on the bottom of vial as shown in Figure 2.1 (b). The hydrodynamic sizes of control 
nanoparticles including AuNP-TTMA and AuNP-TCOOH showed no observable change upon 
addition of CB[7] because both particles have no significant binding affinities to CB[7].    
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Figure 2.2: Inducing nanoparticle assemblies upon binding with CB[7] and the effect of surface 
functional group on the assembly formation. (a) Size changes of nanoparticle assemblies at 
different NP:CB[7] ratios. (b) AuNP-ADA and AuNP-TMC6 induce the larger assemblies upon 
binding with CB[7], but no assembly formation was observed for AuNP-TMOH and AuNP-
TMNH2 with polar end groups. 
 
The formation of the assemblies upon binding with CB[7] was carried out with AuNPs 
having different surface functional groups (Figure 2.2 (b)). AuNP-ADA and AuNP-TMC6 
behaved similar to AuNP-TBen and induced the large assemblies upon binding with CB[7] at the 
ratio of 1:10 (AuNPs:CB[7]). In contrast, AuNP-TMOH and AuNP-TMNH2 did not show any 
aggregate formation although the NP-CB[7] complexes were formed. This indicates that the 
surface end group of the AuNPs plays an important role in inducing the assembly formation.  
The amphiphilic nanoparticle, AuNP-TBen (also AuNP-ADA and AuNP-TMC6) is 
soluble in both aqueous and organic solvents (e.g. dichloromethane). In the aqueous solution, the 
hydrophobic benzyl units on the particles are hidden from the external environment, making the 
surface of the particles more hydrophilic and soluble in the aqueous media. NOESY NMR 
showed the interaction of benzyl peaks with tetraethylene glycol and 11-undecane peaks as an 
indication of bending over of benzyl head group (Figure 2.3). Addition of CB[7] resulted in a 
binding competition of pulling AuNP-TBen from its hydrophobic shell to be encapsulated by 
CB[7] host molecules. Upon binding with CB[7], the benzyl units on the particle became 
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stretched out along the particle, rendering the surface of the particle less hydrophilic. This process 
decreases particle solubility and induces the formation of large assemblies/aggregates (Figure 2.1 
(b)). AuNP-TMOH and AuNP-TMNH2 can bind with CB[7] but the hydroxyl and amine end 
groups presumably keep the surface of particles hydrophilic enough even after binding with 
CB[7] and therefore no assembled structures were observed. It indicates that inducing assemblies 
is dependent on not only CB[7] binding but also end group surface functionality of AuNPs. 
 
Figure 2.3: NOESY 2D NMR shows the interaction of benzyl moiety with TEG and C11 units, 
indicating head group is bending in towards the monolayer (red circle). 
 
When the particle assemblies of AuNP-TBen-CB[7] were treated with excess of 1-
adamantyl amine (ADA), a competitive guest molecule for CB[7] binding, CB[7] dethreaded 
from the NP surface through creation of more favorable 1:1 ADA-CB[7] complexes (Ka = 1.7 x 
10
12
).
21c
 Addition of ADA triggered disassembly of the particles, indicating that host-guest 
interaction can be used to control the solubility (hydrophobicity) of AuNPs by using the precise 
‘lock and key’ modulation over their molecular-level interactions (Figure 2.4) 
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Figure 2.4: CB[7] treatment induced the formation of large assemblies. AuNP-TBen-CB[7] were 
treated with excess of 1-adamantyl amine (ADA), ADA triggered the particle assemblies to 
disassemble, making the particles soluble back in PBS. 
 
2.2.3 Controlling Exocytosis of AuNP-TBen-CB[7] Inside Cells 
Cellular uptake behaviour of the AuNPs was investigated by TEM analysis of the cell. 
After 3 h incubation of the cationic AuNP-TBen (200 nM), TEM images showed that the AuNPs 
were trapped in the endosomal vesicles in cytoplasm as shown in Figure 2.5(a). This observation 
is consistent with an endocytotic behaviour of other cationic nanoparticles previously reported in 
literature.
17, 18
 To study the exocytotic behaviours of the nanoparticle, the cells were washed off 
after 3 h incubation with the AuNP-TBen and incubated with fresh media or CB[7] (0.2 mM) 
containing media for an additional 24 h. When the cells were treated by fresh media, the number 
of the particle-entrapped in vesicles was significantly decreased (Figure 2.5 (b)). Only a few 
particles remained within the vesicles or dispersed in various organelles, indicating a major 
portion of the AuNP-TBen are removed from the cells through exocytosis. In contrast, when the 
cells were treated by the CB[7] containing media, the AuNPs remained trapped in the endosomes 
(Figure 2.5 (c)). These results indicate that treatment of CB[7] caused the intracellular assembly 
formation of the AuNP-TBen-CB[7] as the CB[7] can cross the cell membrane
19
 and the large 
bulky assemblies remained sequestered in endocytic vesicles without exocytosis.  
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Figure 2.5: Cellular uptake and intracellular behavior of the AuNPs. (a) TEM images of MCF-7 
cells incubated with AuNP-TBen. The cationic AuNP-TBen is trapped in organelles (e.g. 
endosome, red circle). TEM images MCF-7 cells incubated with AuNP-TBen and then washed 
and further incubated with (b) only cell culture media or (c) culture media with CB[7] for 24 h. 
(d) Quantification of the amount of gold retained in cells at different time after incubation with 
free media or media containing CB[7]. Cellular uptake experiments with each gold nanoparticle 
were repeated 3 times, and each replicate was measured 5 times by ICP-MS. Error bars represent 
the standard deviations of these measurements. 
 
2.2.4 Tracking Exocytosis of CB[7]-complexed Nanoparticles Inside Cells Using Inductively 
Coupled Plasma Mass Spectrometry 
The exocytosis of the nanoparticles was further quantified by using inductively coupled 
plasma mass spectrometry (ICP-MS). After 3 h incubation of AuNP-TBen (200 nM), the cells 
were completely washed off and replaced by fresh cell culture media or CB[7] (0.2 mM) 
containing media. The cells were then further incubated for different time intervals (0 h, 3 h, 12 h, 
and 24 h). The amount of the AuNPs retained by the cells was determined by using ICP-MS. 
Retention of the AuNP-TBen inside cells treated by free cell culture media decreased to 34 % at 
24 h while no significant change was observed for cells treated with CB[7] containing media 
(Figure 2.5 (d)). Along with the observed TEM results, ICP-MS data shows that the treatment of 
the CB[7] on the cells effectively inhibited the exocytosis of the AuNP-TBen. 
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The effect of the AuNP end group on the exocytosis was further investigated and the 
retention of other AuNPs with different functional head groups in the cells was measured by 
using ICP-MS. AuNP-TTMA and AuNP-TMOH (Figure 2.6 (a) and (b)) exhibited no significant 
difference of exocytotic behavior for both free media and media containing CB[7], showing no 
effect of CB[7] on exocytosis of these AuNPs. 
 
Figure 2.6: Effect of surface functional groups on exocytotic behavior of AuNPs. ICP-MS 
measurements of  (a) AuNP-TTMA, (b) AuNP-TMOH, (c) AuNP-TMC6, and (d) AuNP-ADA. 
Quantification of exocytosis of the AuNPs was determined by analyzing ICP-MS on MCF-7 cell 
with same experimental condition carried out for the AuNP-TBen. Error bars represent the 
standard deviations of these measurements. 
 
Regardless of CB[7] treatment, retention of the AuNP-TTMA and AuNP-TMOH 
decreased to ~ 62 % and ~ 70 % at 24 h, respectively. On the other hand, exocytosis of AuNPs 
including AuNP-ADA and AuNP-TMC6 was blocked when the cells were treated by the media 
containing CB[7] similar to the AuNP-TBen (Figure 2.6 (c) and (d)). Amount of the retained 
AuNP-ADA and AuNP-TMC6 in the cells reduced to ~ 75 % and ~ 70 % at 24 h for the media 
treatment. Both AuNP-ADA and AuNP-TMC6 induced assemblies of the particle upon binding 
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with CB[7]. This result indicates that CB[7] itself does not affect cellular uptake of the particles 
and exocytosis of the particles was regulated due to the increased size of the assemblies. 
2.2.5 Cellular Viability of the Induced Assemblies 
Cellular proliferative activity was measured by the Alamar blue assay to evaluate 
possible toxicity that can arise from retained nanoparticles in the cells. As shown in Figure 2.7, 
all the nanoparticles exhibited no decrease in cell viability for the treatment of both free media 
and media containing CB[7]. This result indicates that the induced assemblies of the particles 
sequestered in endocytic vesicles do not affect cell viability. 
 
Figure 2.7: Cytotoxicity of AuNPs. After 3h incubation of AuNPs (200 nM), MCF-7 cells were 
washed off and further incubated with media and media of CB[7] (0.2 mM) at 37 ºC for 24 h. As 
a control, cell viability of CB[7] (0.2 mM) was measured after 24 h incubation. 
 
2.3 Summary and Future Outlook  
In conclusion, we have demonstrated a strategy for regulating exocytosis of the 
internalized nanoparticles. Using a supramolecular host-guest system on the AuNPs induced the 
assemblies of the particles in the living cells, preventing their exocytosis without any observed 
cytotoxicity. This approach provides a potential strategy for prolonged retention of drug carriers 
within endosomes, enabling sustained therapeutic effect of the carriers. We are currently 
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exploring this strategy with AuNPs featuring prodrugs tethered with labile linkages that can be 
degraded by external stimuli. Additionally, this approach also will be applied to other 
nanomaterials with potential utility of their prolonged transplantation in a wide variety of cells for 
in vivo cellular tracking
20
 and tumor-targeted delivery of therapeutic systems.
21
 
2.4 Synthesis of Materials and Experimental Methods 
2.4.1 General 
All the chemicals were purchased from Sigma-Aldrich or Fisher Scientific unless 
otherwise specified. The chemicals were used as received. AuNPs used in this work have been 
reported previously.
22
 
1
H NMR spectra were recorded at 400 MHz on a Bruker AVANCE 400 
machine. A Hewlett-Packard 8452A UV-Vis spectrophotometer was used to record UV-Vis 
spectra. Dynamic light scattering (DLS) was measured by Zetasizer Nano ZS. The fluorescence 
from the Alamar blue assay was measured in a SpectraMax M5 microplate spectrophotometer. 
2.4.2 Synthesis of Ligands and Their Characterization 
 
Figure 2.8: Synthesis of benzyl-ligand (compound 6) for functionalizing AuNP-TBen. 
 
Compound 2: 11-bromo-1-undecanol (8.22 g, 32.74 mmol) was dissolved in 80 mL 1:1 
ethanol/toluene mixture. Triphenylmethanethiol (10.86 g, 39.29 mmol) dissolved in 80 mL 1:1 
ethanol/toluene was added to 11-bromo-1-undecanol in solution. Then, sodium hydroxide (1.96 g, 
49.11 mmol) was dissolved in 2 mL water and added to the mixture. The reaction mixture was 
stirred for 24 hours at 50
o
C. Upon completion, the reaction mixture was extracted twice with a 
satrated solution of sodium bicarbonate (NaHCO3) The organic layer was extracted, dried over 
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sodium sulfate (Na2SO4), and concentrated using a rotavapor. The crude product was purified by 
column chromatography over silica gel using hexane/ethyl acetate (1:1, v/v) as the eluent. The 
solvent was removed in vacuum to obtain compound 2 as colorless oil (Yield: 13.88 g, 95%).
 1
H 
NMR (400 MHz, CDCl3, TMS) of Compound 2 : δ 7.48-7.40 (m, 6H, HAr-), 7.37-7.27 (m, 6H, 
HAr-), 7.26-7.18 (m, 3H, HAr-), 3.65 (t, J = 6.7Hz, 2H,CH2OH), 2.16 (t, J = 7.2Hz, 2H,-CH2-), 
1.66-1.52 (m, 2H, -SCH2CH2) , 1.44-1.12 (m, 16H, -CH2CH2OH + -(CH2)8 CH2OH).
 
Compound 3: Compound 2 (13.88 g, 31.1 mmol) in 150 mL dry dichloromethane 
(DCM) was mixed with triethylamine (TEA) (4.72g, 6.48 mL, 46.65 mmol), followed by 
dropwise addition of methanesulfonyl chloride (3.92 g, 2.65mL, 34.21 mmol) in ice bath. After 
30 minutes the reaction mixture was warmed to room temperature and stirred for 12 hr. After the 
reaction was completed (by TLC), solvent was evaporated. The compound was diluted again with 
100 mL DCM and extracted with 100 mL 0.1 M HCl twice. The organic layer was collected, 
neutralized with a saturated NaHCO3 solution, and washed with water three times. Following 
extraction, the organic layer was dried over Na2SO4 and concentrated at reduced pressure. The 
crude product was purified by column chromatography over silica gel using hexane/ethyl acetate 
(1:1, v/v) as the eluent. Solvent was removed in vacuum to obtain the mesylated compound as 
light yellow oil (yield: 15 g, 92%). 
1
H NMR (400 MHz, CDCl3, TMS) of intermediate mesylation 
product: δ 7.48-7.40 (m, 6H, HAr-), 7.34-7.27 (m, 6H, HAr-), 7.26-7.19 (m, 3H, HAr-), 4.24 (t, J 
= 6.8Hz, 2H, -CH2SO3CH3), 3.01 (s, 3H, -SO3CH3), 2.16 (t, J = 7.6Hz, -SCH2-), 1.76 (p, J = 
6.8Hz, 2H, -CH2CH2SO3CH3), 1.41 (p, J = 7.2Hz, 4H, -SCH2CH2- + -SCH2CH2CH2-), 1.35-1.1 
(m, 12H, -(CH2)6 CH2CH2SO3CH3). 
To synthesize compound 3, NaOH (1.37 g, 34.3 mmol) solution (1 mL) was added to 
99.24 mL of tetraethyleneglycol (TEG) (111.15 g, 57.22 mmol) and stirred for 2 hr at 80 °C. To 
this reaction mixture, 15 g of 11-(tritylthio)undecyl methanesulfonate was added and stirred for 
48 hr at 100 °C. The product was extracted in hexane/ethyl acetate (4:1, v/v) six times. Then, the 
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organic layer was concentrated at reduced pressure and the crude product was purified by column 
chromatography over silica gel using ethyl acetate as the eluent. The solvent was removed in 
vacuum to obtain compound 3 as light yellow oil (yield: 15.28 g, 68%). 
1
H NMR (400 MHz, 
CDCl3, TMS) of Compound 3: δ 7.47-7.40 (m, 6H, HAr-), 7.34-7.26 (m, 6H, HAr-), 7.25-7.19 
(m, 3H, HAr-), 3.77-3.57 (m,16H, -CH2-(OCH2CH2)4-OH), 3.46 (t, J = 6.8 Hz, 2H, -CH2-
(OCH2CH2)4-OH), 2.95 (br, s, 1H, -TEG-OH), 2.15 (t, J = 7.2Hz, -SCH2-), 1.59 (p, J = 7.2Hz, 
2H, -CH2CH2TEG-OH), 1.4 (p, J = 7.6Hz, 2H, -SCH2CH2-), 1.35-1.13(m, 14H, -(CH2)7 
CH2CH2TEG-OH). 
Compound 4: Triethylamine (3.26g, 4.49 mL, 32.2 mmol) was added to compound 3 (10 
g, 16.1 mmol) in 100 mL dry DCM in an ice bath. Methanesulfonyl chloride (2.77 g, 1.87 mL, 
24.1 mmol) was added dropwise to the reaction mixture in ice-bath. After 30 minutes the reaction 
mixture was warmed up to room temperature and stirred overnight. The reaction mixture was 
worked up and the organic layer was extracted. The extracted DCM layer was dried over Na2SO4 
and concentrated at reduced pressure. The crude product was purified by column chromatography 
over silica gel using ethyl acetate as the eluent. Solvent was removed in vacuum to obtain 
compound 4 as light yellow oil (yield 10.7 g, 95 %). 
1
H NMR (400 MHz, CDCl3, TMS) of 
Compound 4: δ 7.44-7.37 (m, 6H, HAr-), 7.31-7.23 (m, 6H, HAr-), 7.22-7.16 (m, 3H, HAr-), 
4.40-4.34 (m, 2H,  -CH2OSO3CH3), 3.78-3.54 (m, 14H, CH2-(OCH2CH2)3-CH2CH2OSO3CH3), 
3.44 (t, J = 6.8Hz, 2H, CH2-CH2-(OCH2CH2)3-), 3.07 (s, 3H, -OSO3CH3), 2.12 (t, J = 7.2Hz, 2H, 
-SCH2-), 1.56 (p, J = 7.2Hz, 2H, -CH2CH2TEG-N(CH3)2), 1.38 (p, J=7.6Hz, 2H, -SCH2CH2-), 
1.32-1.11 (m, 14H, -(CH2)7CH2CH2TEGOSO3 CH3). 
Compound 5: Compound 4 (1.075 g, 1.53 mmol) was added to dimethylbenzylamine 
(0.62 g, 0.7 ml, 4.6 mmol) in 10 mL ethanol. The reaction mixture was stirred at 40 
o
C for 72 hr. 
After evaporating ethanol at reduced pressure, the light yellow residue was purified by successive 
washings with hexane (10 mL, 4 times) and hexane/diethylether (1:1 v/v, 10 mL, 6 times) and 
45 
 
then dried in high vacuum. The product formation was quantitative and was confirmed by NMR. 
1
H NMR (400MHz, CDCl3, TMS) of Compound 5: δ 7.64-7.58 (m, 2H, HAr-), 7.38-7.32 (m, 9H, 
HAr-), 7.24-7.17 (m, 6H, HAr-), 7.16-7.09 (m, 3H, HAr-), 4.9 (s, 2H, -CH2-C6H5), 3.94 (s, br, 2H, 
-OCH2CH2N(CH3)2-), 3.8 (s, br, 2H, -OCH2CH2N(CH3)2-), 3.77-3.22 (m, 12H, -(OCH2CH2)3-
CH2CH2N(CH3)2-), 3.33 (t, J = 6.8Hz, 2H, -CH2CH2O-), 3.23 (s, 6H, -N(CH3)2-), 2.06 (t, J = 
7.2Hz, 2H, -SCH2-), 1.51-1.42 (p, J = 6.8Hz, 2H, -CH2CH2O-), 1.36-1.28 (p, J = 7.6Hz, 2H, -
SCH2CH2-), 1.24-1.08 (m, 14H, -(CH2)7 CH2CH2O-).  
Compound 6: An excess of trifluoroacetic acid (TFA, 20 equivalents, 3.69 g, 2.5 mL, 
32.4 mmol) was added to compound 5 (1.2 g, 1.62 mmol) in 10 mL dry DCM. The color of the 
solution turned yellow upon addition of TFA. Then, triisopropylsilane (TIPS, 3 equivalents, 
0.77g, 1 mL, 4.86 mmol) was added to the reaction mixture. The reaction mixture was stirred for 
12 hr under N2 at room temperature. The solvent, most of TFA, and TIPS were evaporated under 
reduced pressure. The yellow residue was purified by repeated washing with hexane (10 mL, 4 
times) and dried in high vacuum. The final product formation was quantitative and was confirmed 
by NMR spectroscopy. 
1
H NMR (400 MHz, CDCl3, TMS) of Compound 6: δ 7.57-7.47 (m, 5H), 
4.61 (s, 2H, -CH2-C6H5), 4.01 (s, br, 2H, -OCH2CH2N(CH3)2-), 3.74-3.48 (m, 14H, -(OCH2CH2)3-
CH2CH2N(CH3)2-), 3.41 (t, J = 6.8Hz, 2H, -CH2CH2O-), 3.14 (s, 6H, -N(CH3)2-), 2.52 (q, J = 
7.2Hz, HSCH2-), 1.65-1.48 (m, 4H, -CH2CH2O-,+ HSCH2CH2-), 1.43-1.20 (m, 15H, -(CH2)7 
CH2CH2O- + HS-). 
13C NMR(400 MHz, CDCl3, TMS) of Compound 6: δ 132.92, 131.11, 
129.39, 126.65, 116.69, 114.10, 71.51, 70.31, 70.21, 70.03, 69.92, 69.78, 64.59, 63.34, 50.69, 
34.01, 29.49, 29.45, 29.37, 29.34, 29.18, 29.02, 28.31, 25.91, 24.60. 
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Figure 2.9: MALDI-MS spectrum of AuNP-TBenz. The molecular ion (MH
+
) was detected at 
m/z =498. 
 
2.4.3 Synthesis of Benzyl-Ligand Protected Gold Nanoparticle (AuNP-TBenz) 
The gold salt was purchased from Strem Chemicals Inc. We followed two-step method 
for synthesizing AuNP-TBen, where a gold nanoparticle core was synthesized followed by place-
exchange with the ligand of interest. First, pentanethiol-coated AuNPs with core diameter ~2 nm 
were synthesized using the Brust-Schiffrin two-phase synthesis protocol.
23,24
 Subsequently, 
Murray place-exchange method
25
 was followed to obtain the benzyl-ligand protected AuNPs. 
Pentanethiol conjugated AuNPs (10 mg) and compound 6 (27 mg) was dissolved in a mixture of 
5 mL dry DCM, and 1 mL methanol and stirred under N2 atmosphere for 72 hr at room 
temperature. Then, solvents were removed under reduced pressure and the resulting precipitate 
was washed with hexane (10 mL) three times and with DCM (10 mL) twice. Then the precipitate 
was dissolved in distilled water and dialyzed for 72 hr (membrane molecular weight cut-off 
=10,000) to remove excess ligands, pentanethiol, acetic acid, and other salts present in the 
nanoparticle solution. After dialysis, the particle was lyophilized to yield a solid brownish 
product. The particles were then redispersed in deionized water. The presence of ligands on 
AuNP was also confirmed by mass spectrometry (Figure 2.10).
 1
H NMR-spectra in D2O showed 
substantial broadening of the proton peaks with no sign of free ligands (Figure 2.12). 
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Figure 2.10: MALDI-MS spectrum of AuNP-TBenz. The molecular ion (MH
+
,
 
m/z =498) was 
detected, and the disulfide ion formed by the benzyl ligand and the original pentanethiol was also 
detected at m/z 600. 
 
 
 
 
 
 
 
 
 
Figure 2.11: Transmission electron micrograph of AuNP-TBen. 
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Figure 2.12: 
1
H-NMR of AuNP-TBen showing the ligand attachment on AuNP surface. 
 
2.4.4 Monitoring CB[7]-Nanoparticle Complexation Using  Proton and NOESY 2D NMR 
AuNP-TMNH2 was chosen to run NMR experiments before and after CB[7] 
complexation. 5 µM nanoparticle solution was prepared in D2O and 
1
H-NMR and NOESY 2D 
NMR of AuNP-TMNH2 was obtained (Figure 2.13 and Figure 2.15). Mixing AuNP-TMNH2 
with CB[7] yielded AuNP-TMNH2-CB[7], CB[7] peaks around 4.3, 5.5, and 5.7 ppm were 
appeared in the 
1
H-NMR and NOESY 2D NMR of AuNP-TMNH2-CB[7] (Figure 2.14 and 
Figure 2.16).  
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Figure 2.13: 
1
H-NMR of AuNP-TMNH2 in D2O. 
 
 
 
 
 
 
Figure 2.14: 
1
H-NMR of AuNP-TMNH2-CB[7] in D2O. 
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Figure 2.15: NOESY 2D NMR of AuNP-TMNH2. 
 
 
 
 
Figure 2.16: NOESY 2D NMR of AuNP-TMNH2-CB[7] showing the host-guest interactions 
between CB[7] and AuNP-TMNH2 (black circles). 
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2.4.5 ICP-MS Sample Preparation and Measurements 
ICP-MS measurements were performed on a Perkin Elmer Elan 6100. Operating 
conditions of the ICP-MS are listed below: RF power: 1200 W; plasma Ar flow rate: 15 L/min; 
nebulizer Ar flow rate: 0.96 L/min; isotopes monitored: 
197
Au; dwell time: 50 ms; nebulizer: cross 
flow; spray chamber: Scott. AuNPs (200 nM, 0.5 ml) were incubated with pre-seeded MCF-7 cell 
line in 24 well plates (20,000 cells/well). After 3 h incubation, cells were washed three times with 
PBS buffer and then 0.5 mL of media or media of CB[7] (0.2 mM) was added to the cells. The 
wells of the plates then connected to a peristaltic pump which provides a continuous flow of the 
media or media of CB[7] to remove exocytosed nanoparticles. The cells were then incubated for 
different additional times (0 h, 3 h, 12 h, and 24 h). Cells were washed three times with PBS 
buffer and then a lysis buffer (300 l) was added to the cells. The resulting cell lysate was 
digested overnight using 3 mL of HNO3 and 1 mL of H2O2. On the next day, 3 mL of aqua regia 
was added and then the sample was allowed to react for another 2-3 h. The sample solution was 
then diluted to 100 mL with de-ionized water and aqua regia. The final AuNP sample solution 
contained 5% aqua regia. The AuNP sample solution was measured by ICP-MS under the 
operating conditions described above. Cellular uptake experiments with each gold nanoparticle 
were repeated 3 times, and each replicate was measured 5 times by ICP-MS. A series of gold 
standard solutions (20, 10, 5, 2, 1, 0.5, 0.2, 0 ppb) were prepared before each experiment. Each 
gold standard solution contained 5% aqua regia. The resulting calibration line was used to 
determine the gold amount taken up in the cells in each sample. 
2.4.6 Preparation of Cellular TEM Samples and Their Measurements 
For a preparation of cellular TEM samples, MCF-7 cells (100,000 cells per well in a 24 
well plate) were seeded and incubated on 15 mm diameter Theramanox
®
 coverslips (Nalge Nunc 
International, NY) in 1 mL of serum containing media for 24 h prior to the experiment. The 
media was replaced by 0.5 mL of 200 nM AuNP-TBen in serum containing media and incubated 
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for 3 h. The cells were completely washed with PBS buffer three times and then 0.5 mL of media 
or media of CB[7] (0.2 mM) was added to the cells. After 24 h incubation, the cells were then 
fixed in 2 % glutaraldehyde with 3.75 % sucrose in 0.1 M sodium phosphate buffer (pH 7.0) for 
30 min and then washed with 0.1 M PBS containing 3.75% sucrose three times over 30 min. The 
cells were postfixed in 1 % osmium tetroxide with 5 % sucrose in 0.05 M sodium phosphate 
buffer solution (pH 7.0) for 1 hr and then rinsed with distilled water three times. They were 
dehydrated in a graded series of acetone (10 % per step) and embedded in epoxy resin. The resin 
was polymerized at 70 °C for 12 h. Ultrathin sections (50 nm) obtained with a Reichert Ultracut E 
Ultramicrotome and imaged under a JEOL 100S electron microscopy.   
2.4.7 Cell Culture and Cytotoxicity Measurements 
MCF-7 cells were grown in a cell culture flask using low glucose Dulbecco's Modified 
Eagle Medium supplemented with 10% fetal bovine serum (FBS) at 37°C in a humidified 
atmosphere of 5% CO2. For cytotoxicity testing, MCF-7 cells were seeded at 20,000 cells in 0.2 
mL per well in a 96-well plate 24 h prior to the experiment. During the experiment, old media 
was replaced by 0.2 mL of AuNPs (200 nM) in serum containing media and the cells were 
incubated for 3 h at 37°C in a humidified atmosphere of 5 % CO2. The cells were then completely 
washed with PBS buffer three times and media or media of CB[7] (0.2 mM) was added to the 
cell. After 24 h of incubation, the cells were then completely washed off and 10% Alamar Blue in 
serum containing media was added to each well and further incubated at 37 °C for 4 h. The cell 
viability was then determined by measuring the fluorescence intensity at 570 nm using a 
SpectraMax M5 microplate spectrophotometer. 
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CHAPTER 3 
BINDING STUDIES OF CUCURBIT[7]URIL WITH GOLD NANOPARTICLES 
BEARING DIFFERENT SURFACE FUNCTIONALITIES 
3.1 Introduction 
The chemist`s motive for the synthesis of nanoscale structures through the non-covalent 
interactions has led the development of supramolecular chemistry.
1-5
 Molecular recognition,
6,7
 
self-assembly,
8
 lock-key modality
9
 and reversibility
10
 are among the most important features that 
enabled supramolecular chemistry to be employed in many applications including but not limited 
to catalysis,
11,12
 delivery,
13,14
 sensing,
15-17
 and imaging.
18
 Supramolecular chemistry has been 
described as a lego-chemistry in which each lego piece represents a molecular building block that 
are held together by intermolecular interactions including electrostatic interactions,
19
 hydrogen 
bonding,
20
 π–π interactions,21 ion-dipole interactions,22,23 hydrophobic or solvophobic effects.24   
The choice of building blocks in host-guest chemistry is critical as they determine the 
selectivity, reversibility and tunability of the supramolecular architectures. Gold nanoparticles 
(AuNPs) are useful platforms to play either host or guest role due to their unique features such as 
tunable core size,
25
 monodispersity,
26
 large surface to volume ratio,
27
 and easy surface 
functionalization.
28,29
 Rotello et al. have used AuNP as a host scaffold to encapsulate 
hydrophobic guest molecules into the engineered monolayer.
30
 On the other hand, proper surface 
functionalization of AuNPs renders them to be recognized by macrocyclic compound such as 
crown ethers,
31,32
 calixarenes,
33,34
 cyclodextrins,
35,36
 pillararenes
37
 and cucurbiturils.
38-40
  
Cucurbit[7]uril (CB[7])
41,42
 is a member of cucurbituril family with a heptameric 
macrocyclic structure self-assembled from an acid catalyzed condensation reaction of glycoluril 
and formaldehyde. CB[7] is a water soluble molecule with well-established host properties.
43,44
 It 
has a pumpkin-shaped structure
45
 consisting of a hydrophobic cavity of 7.3 Å diameter and two 
identical carbonyl-laced portals. While the hydrophobic interior provides an encapsulation site for 
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hydrophobic guest molecules,
46
 the polar carbonyl groups at the portals allow CB[7] to bind 
ions
47
 and charged molecules
48,49
 by forming charge-dipole and/or hydrogen bonding interactions. 
In this work, we demonstrated the host-guest interactions between CB[7] molecule and 
AuNPs bearing ligands with a monomethyl-benzylammonium (MMBA) or dimethyl-
benzylammonium (DMBA) head group. We used AuNPs with core diameters of ~2.5 nm as the 
guest scaffold while CB[7] served as a host molecule. We kept the monolayer design same with 
the exception of the head group functionality. We have investigated the changes in the binding 
event considering two features: 1) the effect of different functionalities at the para position of 
benzene ring and 2) the effect of carrying a permanent positive charge on the head group. 
3.2 Result and Discussion 
We have designed a series of nanoparticles with benzylammonium terminal group 
possessing different functionalities at the para position of  the benzene ring, which is the least 
sterically hindered position for binding process based on the reported crystal structures of 
cucurbiturils.
50,51
 Eight DMBA and five MMBA derivatives (Figure 3.1) were synthesized to 
represent a wide range of functionality that brings at least one of the effects into the system: 
hydrophobicity, hydrophilicity, electron-withdrawing, electron-donating, and bulkiness.  
 
Figure 3.1: Structures of DMBA and MMBA derivatives used in the study. The schematic 
represents the binding event between AuNP and CB[7]. 
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3.2.1 Isothermal Titration Calorimetry (ITC) Measurements of NP1-NP8 and 
Thermodynamic Values  
Isothermal titration calorimetry (ITC) is an extremely powerful and sensitive technique 
that measures the heat taken up or evolved depending on the nature of the reaction when one 
solution is titrated against the other solution.
52
 ITC experiments were performed at 30 
o
C in 5 mM 
phosphate buffer at pH 7.4. During the experiment, the reference cell was filled with only 5 mM 
phosphate buffer and the sample cell was containing the AuNP solution (1 µM). Then, CB[7] 
solution (2 mM) was titrated into the sample cell. All AuNPs showed multiple host/guest 
bindings while free ligand (DMBA) showed a binding stoichiometry of 1:1.  
Binding affinities of DMBA head group bearing AuNPs (NP1-NP8) were in the order of 
10
4-6
 M
-1 
(Table 1). NP1 having H atom at the para position showed a binding constant of 
1.60.32 x 105 M-1 (Figure 3.2).  
 
Figure 3.2: ITC measurements of NP1, NP3, and NP8 bearing DMBA head group with H, 
CH2NH2 and NO2 functionalities at the para position of the benzene ring showing similar binding 
constants. 
 
For the NPs with electron donating groups including CH3, CH2NH2, and OMe, binding 
affinities were similar to NP1 except the NP2 with a binding constant of 6.160.15x 104 M-1. The 
NP2 has tBu group located at the para position and although tBu functionality has weakly 
electron donating property, it brings steric hindrance into the system and thus resulting in a lower 
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binding affinity. On the other hand, the NP3 with CH2NH2 functionality demonstrated slightly 
higher association constant compared to NP1 (Figure 3.2 and Table 3.1). This could be originated 
from the hydrogen bonding interactions between the carbonyl portals of CB[7] and amine part of 
CH2NH2 functionality. The NP4 with weakly electron donating methyl group exhibited a binding 
constant of 1.260.18 x 105 M-1 which is slightly lower than that of NP1 as expected. 
Hydrophobic interactions within the inner cavity of cucurbituril play an important role in binding 
event. Electron donating groups make the benzene ring less electron deficient and therefore 
weaken the interaction of benzene ring with the inner cavity of CB[7]. However, the same effect 
was not observed for NP5 carrying a stronger electron donating ‘methoxy group’. 
Thermodynamic values for NP1-8 were listed in Table 1.Titration of CB[7] into NP 
solution represented an exothermic process with negative enthalpy change (H) resulting from 
the robust van der Waals forces inside the hydrophobic cavity of CB[7] as well as additional 
forces including hydrogen bonding and ion-dipole interactions between the carbonyl portals of 
CB[7] and guest molecules. As the sites available on the surface of the AuNPs become 
progressively occupied by CB[7] during the titration, the exothermicity of the peaks decreases 
and eventually saturates (Figure 2). H values for NP1-NP5 were found similar to each other and 
not very large; they were changing between -6.6 and -11.29 kcal/mol. From the entropic 
standpoint, complexation of CB[7] with NP1, NP2, and NP3 is less favorable as -TS values 
were positive. However, overall entropy of complexation for NP4 and NP5 is slightly favorable 
as -TS values were negative but very close to zero. 
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Table 3.1: Thermodynamic data of NP1-8 for binding to CB[7] 
 
AuNPs with electron withdrawing groups at the para position rendered the benzene ring 
more electron deficient, resulting in more stable inclusion complexes. Fluorine, nitro, and nitrile 
functionalities (NP6, NP7, and NP8) were used to bring electron withdrawing property into the 
system. All the three NPs showed somewhat higher binding towards CB[7] molecule compared to 
NP1 whereas the binding for NP6 and NP7 was not greatly so. However, NP8 bearing CN group 
exhibited an association constant of 1.320.69 x 106 M-1 which is about 10 times higher than that 
of NP1. The negative H values for these NPs indicated an exothermic binding process. 
Numerically they were all quite similar to each other but smaller than that of NPs carrying 
electron donating groups. S values were positive indicating favorable complexation between 
CB[7] and NPs bearing electron withdrawing groups. The complexation process for NP1-NP8 
was found spontaneous which is confirmed by negative Gibbs free energy change (G). 
3.2.2 ITC Measurements of NP9-NP13 and Effects of Surface Functionality on Binding 
Affinity  
Binding experiments of MMBA derivatives revealed a drop in the binding affinities; Ka 
values were mostly in the order of 10
4
 M
-1
. This result indicated that a permanent positive charge 
played an essential role in the binding event as ion-dipole interactions between CB[7] and AuNP 
were dominating over the hydrogen bonding interactions. NP9 showed no complexation to CB[7] 
while both the absence of positive charge and bulkiness of the tBu group prevented the 
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recognition event (Table 3.2). On the other hand, NP11 with the methoxy group showed an 
unexpected Ka of 1.200.15 x 10
5
 M
-1
. H values for NP9-13 were very similar to each other, and 
negative showing exothermic binding events. Complexation between CB[7] and NP9-13 was 
found spontaneous as indicted by negative G. 
Table 3.2: Thermodynamic data of NP9-13 for binding to CB[7] 
 
3.2.3 Monitoring Binding of Free Ligand to the Host Molecule 
We have synthesized a ligand containing a DMBA head group same as in NP1 to 
investigate the behavior of free ligand. ITC measurement revealed a binding constant of 
3.690.25 x 105 M-1 when 100 µM of ligand solution was titrated with 2 mM CB[7] in 5 mM 
phosphate buffer Figure 3.3). This value was in the same order with the binding constant of NP1 
(Ka= 1.60.32 x 10
5
 M
-1
) but still 2.3 times higher in magnitude. This result showed that attaching 
the ligand on AuNP showed no dramatic decrease in the binding process between CB[7] and head 
group of the ligand.  
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Figure 3.3: a) Schematic representation of binding between DMBA ligand and CB[7]. b) ITC 
measurement indicated a 1:1 binding stoichiometry between free ligand and CB[7]. 
 
3.3 Summary and Future Outlook
 
We have used isothermal titration calorimetry to monitor the binding interactions of 
CB[7] with thirteen different AuNPs. Binding studies revealed that NP1-NP8 possessing DMBA 
head groups showed a higher binding affinity towards CB[7] compared to NP9-NP13 having 
MMBA head groups. Insertion of tBu group at the para position of the benzene ring led to a lower 
binding due to the steric effect. Although not very strong difference in Ka constants was observed 
between electron donating and withdrawing groups, a slight decrease in the binding was 
monitored for electron donating groups compared to withdrawing derivatives. Methoxy 
functionality behaved differently than expected, computational studies may help to understand the 
process better.
 
3.4 Synthesis of Materials and Experimental Methods  
3.4.1 Synthesis of Ligand  
Dimethyl OMe and Dimethyl NO2 ligands and NPs were synthesized according to the 
reported literature.
53
 We have followed the reported literature for the synthesis of AuNP core and 
place exchange reactions.
54-56
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3.4.1.2 Synthesis of Dimethyl-H Ligand for NP1 
Ph3CS O
O
Ph3CS O
O
DIPEA, THF, 60 ºC
(  )9 (             )3 (  )9 (             )3 N
MeHN
OMs
Compound 1 Compound 2
 
Figure 3.4: Synthesis of compound 2 from compound 1. 
 
To a solution of compound 1 (750 mg, 1.1 mmol) in THF (6.3 mL) was added a solution 
of N-methyl-benzylamine (389 mg, 3.2 mmol) and diisopropylamine (531 µL, 3.2 mmol). After 
being stirred at 60 °C for 2 days, EtOAc was added. The mixture was washed with sat. NaHCO3 
and brine, and dried over Na2SO4. After concentration, the residue was purified by flash 
chromatography over silica gel with EtOAc–MeOH (1:0 to 9:1) to give the desired compound as 
yellow oil (692 mg, 89 %). 
1
H-NMR (400 MHz, CDCl3) 1.18-1.44 (16H, m, -CH2-), 1.55-1.63 
(2H, m, -CH2-), 2.15 (2H, t, J = 7.3 Hz, -SCH2-), 2.28 (3H, s, -NCH3), 2.65 (2H, t, J = 6.1 Hz, -
NCH2-), 3.45 (2H, t, J = 6.8 Hz, -OCH2-), 3.58-3.68 (16H, m, -OCH2-, -NCH2Ar-), 7.20-7.32 
(14H, t, m, Ar), 7.42-7.44 (6H, m, Ar). 
Ph3CS O
OPh3CS O
O
EtOH, CH2Cl2
40 ºC
(  )9 (             )3
(  )9 (             )3 N
N
OTs
MeOTs
Compound 2 Compound 3
 
Figure 3.5: Synthesis of compound 3 from compound 2. 
 
To a solution of compound 2 (300 mg, 0.41 mmol) in EtOH (4.1 mL) and CH2Cl2 (2.01 
mL) was added methyl-p-toluenesulfonate (229 mg, 1.23 mmol). After being stirred at 40 °C for 
15 h, the mixture was concentrated in vacuo. The residue was washed ten times with n-hexane–
diethylether (3:1). The solvent was evaporated to give the desired compound as pale yellow oil 
(390 mg, >99%). 
1
H-NMR (400 MHz, CDCl3) 1.14-1.42 (16H, m, -CH2-), 1.53-1.57 (2H, m, -
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CH2-), 2.15 (2H, t, J = 7.3 Hz, -SCH2-), 2.36 (3H, s, Ar-CH3), 3.26 (6H, s, -N
+
(CH3)2-), 3.41 (2H, 
t, J = 6.9 Hz, -OCH2-), 3.52-3.68 (12H, m, -OCH2-), 3.85 (2H, br, -OCH2-), 4.04 (2H, br, -
N
+
CH2-), 4.82 (2H, s, -N
+
CH2Ar-), 7.16-7.49 (20H, m, Ar), 7.61 (2H, d, J = 8.0 Hz, Ar), 7.81 
(2H, d, J = 8.1 Hz, Ar). 
HS O
O
CH2Cl2, rt
(  )9 (             )3 NPh3CS O
O
(  )9 (             )3 N
TFA, (i-Pr)3SiH
OTs OTs
Compound 3 Compound 4
 
Figure 3.6: Synthesis of compound 4 from compound 3. 
 
To a solution of compound 3 (300 mg, 0.32 mmol) in CH2Cl2 (4.0 mL) was added TFA 
(1.5 mL). After being stirred at rt for 5 min, triisopropylsilane (0.3 mL) was added. After being 
stirred at rt for 1 h, the mixture was concentrated in vacuo. The residue was washed six times 
with n-hexane. The solvent was evaporated to give the desired compound as pale yellow oil (210 
mg, 98%). 
1
H-NMR (400 MHz, CDCl3) 1.28-1.44 (14H, m, -CH2-), 1.53-1.66 (4H, m, -CH2-), 
2.39 (3H, s, Ar-CH3), 2.54 (2H, q, J = 7.5 Hz, -SCH2-), 3.20 (6H, s, -N
+
(CH3)2-), 3.46 (2H, t, J = 
6.9 Hz, -OCH2-), 3.57-3.80 (14H, m, -OCH2-), 4.08 (2H, br, -N
+
CH2-), 4.67 (2H, s, -N
+
CH2Ar-), 
7.20 (2H, d, J = 8.0 Hz, Ar), 7.42-7.56 (5H, m, Ar), 7.78 (2H, d, J = 8.0 Hz, Ar). 
3.4.1.3 Synthesis of Dimethyl-t-Bu Ligand for NP2 
Ph3CS O
O
Ph3CS O
O
DIPEA, THF, 60 ºC
t-Bu
(  )9 (             )3 (  )9 (             )3 N
t-Bu
MeHN
OMs
Compound 1 Compound 2
 
Figure 3.7: Synthesis of compound 2 from compound 1. 
 
To a solution of compound 1 (2.0 g, 2.85 mmol) in THF (17 mL) was added a solution of 
N-methyl-4-(tert-butyl)-benzylamine (1.27 g, 7.1 mmol) and diisopropylamine (1.17 mL, 7.1 
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mmol). After being stirred at 60 °C for 2 days, the mixture was concentrated in vacuo. The 
residue was dissolved in EtOAc. The mixture was washed with sat. NaHCO3 and brine, and dried 
over Na2SO4. After concentration, the residue was purified by flash chromatography over silica 
gel with EtOAc–MeOH (1:0 to 95:5) to give the desired compound as yellow oil (1.6 g, 72 %). 
H-NMR (400 MHz, CDCl3) 1.18-1.31 (14H, m, -CH2-), 1.33 (9H, m, -C(CH3)3), 1.37-1.44 (2H, 
m, -CH2-), 1.54-1.63 (2H, m, -CH2-), 2.15 (2H, t, J = 7.3 Hz, -SCH2-), 2.28 (3H, s, -NCH3), 2.64  
(2H, t, J = 6.1 Hz, -NCH2-), 3.46 (2H, t, J = 6.8 Hz, -OCH2-), 3.54-3.67 (16H, m, -OCH2-, -
NCH2Ar-), 7.20-7.35 (13H, t, J = 8.7 Hz, Ar), 7.42-7.44 (6H, m, Ar). ESI-MS: m/z calculated for 
C50H72NO4S [M+H]
+ 
782.5; found: 783.1. 
Ph3CS O
OPh3CS O
O
EtOH, CH2Cl2
40 ºC
(  )9 (             )3
(  )9 (             )3 N
t-
B
u
N
OTs
t-Bu
MeOTs
Compound 2 Compound 3
 
Figure 3.8: Synthesis of compound 3 from compound 4. 
 
To a solution of compound 2 (363 mg, 0.46 mmol) in EtOH (4.6 mL) and CH2Cl2 (2.3 
mL) was added methyl-p-toluenesulfonate (259 mg, 1.39 mmol). After being stirred at 40 °C for 
24 h, the mixture was concentrated in vacuo. The residue was washed ten times with n-hexane 
and five times with n-hexane–CH2Cl2 (95:5). After concentration, the residue was dissolved in 
EtOAc. The mixture was washed with H2O and dried over Na2SO4. The solvent was evaporated 
to give the desired compound as pale yellow oil (423 mg, 94%). 
1
H-NMR (400 MHz, CDCl3) 
1.13-1.41 (25H, m, -CH2-, -C(CH3)3), 1.51-1.57 (2H, m, -CH2-), 2.14 (2H, t, J = 6.9 Hz, -SCH2-), 
2.35 (3H, s, Ar-CH3), 3.25 (6H, s, -N
+
(CH3)2-), 3.36-3.64 (14H, m, -OCH2-), 3.84 (2H, br, -
OCH2-), 4.01 (2H, br, -N
+
CH2-), 4.76 (2H, s, -N
+
CH2Ar-), 7.15-7.52 (21H, m, Ar), 7.82 (2H, d, J 
= 7.4 Hz, Ar). ESI-MS: m/z calculated for C51H74NO4S [M]
+ 
796.5; found: 797.1. 
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Figure 3.9: Synthesis of compound 4 from compound 3. 
 
To a solution of compound 3 (371 mg, 0.40 mmol) in CH2Cl2 (5.0 mL) was added TFA 
(2.0 mL). After being stirred at rt for 10 min, triisopropylsilane (3.0 mL) was added. After being 
stirred at rt for 6 h, the mixture was concentrated in vacuo. The residue was washed eight times 
with n-hexane. The solvent was evaporated to give the desired compound as pale yellow oil (255 
mg, 99%). 
1
H-NMR (400 MHz, CDCl3) 1.27-1.43 (23H, m, -CH2-), 1.53-1.66 (4H, m, -CH2-), 
2.38 (3H, s, Ar-CH3), 2.54 (2H, q, J = 7.5 Hz, -SCH2-), 3.21 (6H, s, -N
+
(CH3)2-), 3.44 (2H, t, J = 
6.9 Hz, -OCH2-), 3.55-3.77 (14H, m, -OCH2-), 4.07 (2H, br, -N
+
CH2-), 4.65 (2H, s, -N
+
CH2Ar-), 
7.20 (2H, d, J = 8.0 Hz, Ar), 7.45-7.50 (4H, m, Ar), 7.80 (2H, d, J = 8.0 Hz, Ar). ESI-MS: m/z 
calculated for C32H60NO4S [M]
+ 
554.4; found: 555.2. 
3.4.1.4 Synthesis of Dimethyl-CH2NH2 Ligand for NP3 
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Figure 3.10: Synthesis of compound 2 from compound 1. 
 
To a solution of compound 1 (500 mg, 3.1 mmol) in THF (9.4 mL) was added a 2.0 M 
solution of lithiumaluminiumhydride (4.68 mL, 3.0 mmol) at 0 °C. After being stirred at 0 °C for 
15 min, the reaction mixture was warmed to rt. After being stirred at rt for 30 min, the reaction 
mixture was quenched by slow addition of H2O (0.4 mL), 2 M NaOH (0.4 mL), and H2O (1.2 
mL). The resulting mixture was filtered through Celite pad. After concentrarion, the mixture was 
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dissolved in CH2Cl2 (15 mL). Boc2O (1.0 g, 4.7 mmol) were added to the reaction mixture. After 
being stirred at rt for 3 h, the mixture was concentrated in vacuo. The residue was purified by 
flash chromatography over silica gel with EtOAc–triethylamine (99:1) to give the desired 
compound as colorless oil (308 mg, 74 %). 
1
H-NMR (400 MHz, CDCl3) 1.48 (9H, s, -C(CH3)3-), 
2.25 (6H, m, -N(CH3)2-), 3.42 (2H, s, -NCH2Ar), 4.32 (2H, d, J = 5.5 Hz, -NHCH2Ar-), 4.90 (1H, 
br s, -NH-), 7.23-7.29 (4H, m, Ar). MALDI-MS: m/z calculated for C15H25N2O2 [M+H]
+ 
265.191; 
found: 265.340. 
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Figure 3.11: Synthesis of compound 4 from compound 3. 
 
To a solution of compound 3 (353 mg, 0.45 mmol) in MeCN (3.0 mL) was added a 
solution of compound 2 (240 mg, 0.91 mmol). After being stirred at 50 °C for 1 day and 65 °C for 
2 days, the mixture was concentrated in vacuo. The residue was washed five times with n-hexane 
and twice with n-hexane–diethylether (3:1). The solvent was evaporated to give the desired 
compound as pale yellow oil (471 mg, >99%). 
1
H-NMR (400 MHz, CDCl3) 1.13-1.33 (14H, m, -
CH2-), 1.34-1.44 (2H, m, -CH2-), 1.49 (9H, m, -C(CH3)3-), 1.53-1.59 (2H, m, -CH2-), 2.14 (2H, t, 
J = 7.3 Hz, -SCH2-), 2.36 (3H, s, Ar-CH3), 3.25 (6H, s, -N
+
(CH3)2-), 3.42 (2H, t, J = 6.9 Hz, -
OCH2-), 3.53-3.68 (12H, m, -OCH2-), 3.85 (2H, br, -OCH2-), 4.02 (2H, br, -N
+
CH2-), 4.35 (2H, d, 
-NHCH2-), 4.83 (2H, s, -N
+
CH2Ar-), 5.09 (1H, br s, -NH-), 7.19-7.35 (13H, m, Ar), 7.41-7.44 
(6H, m, Ar), 7.58 (2H, d, J = 8.0 Hz, Ar) , 7.83 (2H, d, J = 8.1 Hz, Ar). MALDI-MS: m/z 
calculated for C53H77N2O6S [M]
+ 
869.550; found: 869.954. 
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Figure 3.12: Synthesis of compound 5 from compound 4. 
 
To a solution of compound 4 (400 mg, 0.38 mmol) in CH2Cl2 (0.5 mL) was added a 
mixture of TFA (18.5 mL), H2O (0.5 mL), 1,2-ethanedithiol (0.5 mL), and triisopropylsilane (0.5 
mL) was added at 0 °C. After being stirred at rt for 1 h, the mixture was concentrated in vacuo. 
The residue was washed five times with n-hexane, five times with n-hexane–diethylether (3:1), 
and ten times with diethylether. The solvent was evaporated to give the desired compound as pale 
yellow oil (267 mg, 88%). 
1
H-NMR (400 MHz, CDCl3) 1.26-1.43 (14H, m, -CH2-), 1.53-1.65 
(4H, m, -CH2-), 2.36 (3H, s, Ar-CH3), 2.53 (2H, q, J = 7.5 Hz, -SCH2-), 3.05 (6H, s, -N
+
(CH3)2-), 
3.43 (2H, t, J = 6.8 Hz, -OCH2-), 3.53-3.60 (14H, m, -OCH2-), 3.83 (2H, br, -NH3
+
CH2-), 4.02 
(2H, br, -N
+
CH2-), 4.67 (2H, s, -N
+
CH2Ar-), 7.19 (2H, d, J = 7.9 Hz, Ar), 7.41 (4H, m, Ar), 7.74 
(2H, d, J = 7.9 Hz, Ar). MALDI-MS: m/z calculated for C29H55N2O4S [M]
+ 
527.388; found: 
527.417. 
3.4.1.5 Synthesis of Dimethyl-Me Ligand for NP4 
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Figure 3.13: Synthesis of compound 2 from compound 1. 
 
To a solution of compound 1 (701 mg, 1.0 mmol) in THF (3.1 mL) was added a solution 
of N-methyl-4-methylbenzylamine (338 mg, 2.5 mmol) and diisopropylamine (413 µL, 2.5 
mmol) in THF (5.0 mL). After being stirred at 60 °C for 2 days, the mixture was concentrated in 
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vacuo. The residue was purified by flash chromatography over silica gel with EtOAc–MeOH (1:0 
to 9:1) to give the desired compound as yellow oil (313.4 mg, 42 %). 
1
H-NMR (400 MHz, 
CDCl3) 1.18-1.30 (14H, m, -CH2-), 1.30-1.62 (4H, m, -CH2-), 2.15 (2H, t, J = 7.3 Hz, -SCH2-), 
2.27 (3H, s, -NCH3), 2.64 (2H, t, J = 6.1 Hz, -NCH2-), 3.45 (2H, t, J = 6.8 Hz, -OCH2-), 3.54-3.67 
(16H, m, -OCH2-, -NCH2Ar-), 7.13 (2H, t, J = 7.8 Hz, Ar), 7.20-7.31 (11H, m, Ar), 7.41-7.44 
(6H, m, Ar), ESI-MS: m/z calculated for C47H66NO4S [M+H]
+ 
740.5; found: 740.9. 
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Figure 3.14: Synthesis of compound 3 from compound 2. 
 
To a solution of compound 2 (300 mg, 0.41 mmol) in EtOH (4.0 mL) and CH2Cl2 (2.0 
mL) was added methyl-p-toluenesulfonate (235 mg, 1.22 mmol). After being stirred at 40 °C for 
14 h, the mixture was concentrated in vacuo. The residue was washed ten times with n-hexane–
diethylether (1:1). The solvent was evaporated to give the desired compound as pale yellow oil 
(384 mg, >99%). 
1
H-NMR (400 MHz, CDCl3) 1.17-1.32 (14H, m, -CH2-), 1.35-1.59 (4H, m, -
CH2-), 2.15 (2H, t, J = 7.3 Hz, -SCH2-), 2.36 (3H, s, Ar-CH3), 2.40 (3H, s, Ar-CH3), 3.23 (6H, s, -
N
+
(CH3)2-), 3.41 (2H, t, J = 6.9 Hz, -OCH2-), 3.52-3.69 (12H, m, -OCH2-), 3.84 (2H, br, -OCH2-
), 4.03 (2H, br, -N
+
CH2-), 4.74 (2H, s, -N
+
CH2Ar-), 7.16-7.31 (13H, m, Ar), 7.41-7.47 (8H, m, 
Ar), 7.80 (2H, d, J = 8.2 Hz, Ar). ESI-MS: m/z calculated for C48H68NO4S [M]
+ 
754.5; found: 
755.0. 
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Figure 3.15: Synthesis of compound 4 from compound 3. 
 
To a solution of compound 3 (336 mg, 0.36 mmol) in CH2Cl2 (3.0 mL) was added TFA 
(1.0 mL). After being stirred at rt for 10 min, triisopropylsilane (1.0 mL) was added. After being 
stirred at rt for 1 h, the mixture was concentrated in vacuo. The residue was washed ten times 
with n-hexane. The solvent was evaporated to give the desired compound as pale yellow oil (161 
mg, 70%). 
1
H-NMR (400 MHz, CDCl3) 1.28-1.44 (14H, m, -CH2-), 1.53-1.66 (4H, m, -CH2-), 
2.38 (3H, s, Ar-CH3), 2.42 (3H, s, Ar-CH3), 2.54 (2H, q, J = 7.5 Hz, -SCH2-), 3.20 (6H, s, -
N
+
(CH3)2-), 3.43 (2H, t, J = 6.9 Hz, -OCH2-), 3.54-3.78 (14H, m, -OCH2-), 4.07 (2H, br, -N
+
CH2-
), 4.65 (2H, s, -N
+
CH2Ar-), 7.20 (2H, d, J = 8.0 Hz, Ar), 7.27 (2H, d, J = 8.0 Hz, Ar), 7.42 (2H, d, 
J = 8.0 Hz, Ar), 7.79 (2H, d, J = 8.0 Hz, Ar). ESI-MS: m/z calculated for C29H54NO4S [M]
+ 
512.4; 
found: 512.5. 
3.4.1.6 Synthesis of Dimethyl-F Ligand for NP6 
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Figure 3.16: Synthesis of compound 2 from compound 1. 
 
To a solution of compound 1 (701 mg, 1.0 mmol) in THF (5.0 mL) was added a solution 
of N-methyl-4-fluorobenzylamine (418 mg, 3.0 mmol) and diisopropylamine (496 µL, 3.0 mmol) 
in THF (5.0 mL). After being stirred at 60 °C for 2 days, the mixture was concentrated in vacuo. 
The residue was purified by flash chromatography over silica gel with EtOAc–MeOH (1:0 to 9:1) 
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to give the desired compound as yellow oil (455 mg, 61 %). 
1
H-NMR (400 MHz, CDCl3) 1.17-
1.32 (14H, m, -CH2-), 1.35-1.61 (4H, m, -CH2-), 2.15 (2H, t, J = 7.4 Hz, -SCH2-), 2.26 (3H, s, -
NCH3), 2.63  (2H, t, J = 6.0 Hz, -NCH2-), 3.45 (2H, t, J = 6.8 Hz, -OCH2-), 3.51-3.78 (16H, m, -
OCH2-, -NCH2Ar-), 7.00 (2H, t, J = 8.7 Hz, Ar), 7.20-7.43 (17H, m, Ar). ESI-MS: m/z calculated 
for C46H63FNO4S [M+H]
+ 
744.5; found: 745.0. 
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Figure 3.17: Synthesis of compound 3 from compound 2. 
 
To a solution of compound 2 (443 mg, 0.55 mmol) in EtOH (2.7 mL) and CH2Cl2 (1.4 
mL) was added methyl-p-toluenesulfonate (305 mg, 1.65 mmol). After being stirred at 40 °C for 
27 h, the mixture was concentrated in vacuo. The residue was washed seven times with 
diethylether. The solvent was evaporated to give the desired compound as pale yellow oil (370 
mg, 61%). 
1
H-NMR (400 MHz, CDCl3) 1.17-1.32 (14H, m, -CH2-), 1.36-1.43 (2H, m, -CH2-), 
1.51-1.58 (2H, m, -CH2-), 2.15 (2H, t, J = 7.3 Hz, -SCH2-), 2.36 (3H, s, Ar-CH3), 3.24 (6H, s, -
N
+
(CH3)2-), 3.41 (2H, t, J = 6.9 Hz, -OCH2-), 3.52-3.77 (14H, m, -OCH2-), 3.99 (2H, br, -N
+
CH2-
), 4.86 (2H, s, -N
+
CH2Ar-), 7.10 (2H, t, J = 8.0 Hz, Ar), 7.16-7.31 (11H, m, Ar), 7.41-7.44 (6H, 
m, Ar), 7.65 (2H, dd, J = 8.0, 5.4 Hz, Ar) , 7.79 (2H, d, J = 8.1 Hz, Ar). ESI-MS: m/z calculated 
for C47H65FNO4S [M]
+ 
758.5; found: 758.8. 
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Figure 3.18: Synthesis of compound 4 from compound 3. 
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To a solution of compound 3 (371 mg, 0.40 mmol) in CH2Cl2 (5.0 mL) was added TFA 
(2.0 mL). After being stirred at rt for 10 min, triisopropylsilane (3.0 mL) was added. After being 
stirred at rt for 6 h, the mixture was concentrated in vacuo. The residue was washed eight times 
with n-hexane. The solvent was evaporated to give the desired compound as pale yellow oil (270 
mg, 99%). 
1
H-NMR (400 MHz, CDCl3) 1.28-1.42 (14H, m, -CH2-), 1.52-1.67 (4H, m, -CH2-), 
2.38 (3H, s, Ar-CH3), 2.54 (2H, q, J = 7.3 Hz, -SCH2-), 3.24 (6H, s, -N
+
(CH3)2-), 3.42 (2H, t, J = 
6.8 Hz, -OCH2-), 3.59-3.78 (14H, m, -OCH2-), 4.05 (2H, br, -N
+
CH2-), 4.79 (2H, s, -N
+
CH2Ar-), 
7.14-7.21 (4H, m, Ar), 7.63 (2H, dd, J = 8.5, 6.0 Hz, Ar), 7.79 (2H, d, J = 8.1 Hz, Ar). ESI-MS: 
m/z calculated for C28H51FNO4S [M]
+ 
516.4; found: 516.4. 
3.4.1.7 Synthesis of Dimethyl-CN Ligand for NP7 
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Figure 3.19: Synthesis of compound 2 from compound 1. 
 
To a solution of compound 1 (500 mg, 0.64 mmol) in CH3CN (10 mL) was added a 
solution of 4-(dimethylaminomethyl)benzonitrile (310 mg, 1.93 mmol) CH3CN (10 mL), and the 
mixture was stirred under reflux for 64 h. After concentration, the residue was washed three times 
with ethyl ether and seven times with n-hexane. The solvent was evaporated to give the desired 
compound as pale yellow oil (596 mg, 99%). 
1
H-NMR (400 MHz, CDCl3) 1.10-1.31 (14H, m, -
CH2-), 1.37-1.44 (2H, m, -CH2-), 1.51-1.58 (2H, m, -CH2-), 2.15 (2H, t, J = 7.3 Hz, -SCH2-), 2.38 
(3H, s, Ar-CH3) 3.32 (6H, s, -N
+
(CH3)2-), 3.41 (2H, t, J = 6.9 Hz, -OCH2-), 3.52-3.70 (12H, m, -
OCH2-), 3.85-3.87 (2H, m, -OCH2-), 4.04-4.06 (2H, m, -N
+
CH2-), 5.06 (2H, s, -N
+
CH2Ar-), 7.19-
7.32 (11H, m, Ar), 7.41-7.44 (6H, m, Ar), 7.74 (2H, d, J = 8.4 Hz, Ar), 7.82 (2H, d, J = 8.1 Hz, 
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Ar), 7.90 (2H, d, J = 8.4 Hz, Ar). ESI-MS: m/z calculated for C48H65N2O4S [M]
+ 
765.5; found: 
766.0. 
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Figure 3.20: Synthesis of compound 3 from compound 2. 
 
To a solution of compound 2 (320 mg, 0.64 mmol) in CH2Cl2 (10 mL) was added TFA (1 
mL). After being stirred at rt for 10 min, triisopropylsilane (1 mL) was added. After being stirred 
at rt for 3 h, the mixture was concentrated in vacuo. The residue was washed four times with n-
hexane and seven times with n-hexane–CH2Cl2. The solvent was evaporated to give the desired 
compound as pale yellow oil (190.7 mg, 86%). 
1
H-NMR (400 MHz, CDCl3) 1.27-1.42 (14H, m, -
CH2-), 1.51-1.66 (4H, m, -CH2-), 2.38 (3H, s, Ar-CH3), 2.54 (2H, q, J = 7.5 Hz, -SCH2-), 3.26 
(6H, s, -N
+
(CH3)2-), 3.42 (2H, t, J = 6.9 Hz, -OCH2-), 3.53-3.75 (14H, m, -OCH2-), 4.03 (2H, br t, 
J = 4.4 Hz, -N
+
CH2-), 4.89 (2H, s, -N
+
CH2Ar-), 7.22 (2H, d, J = 7.9 Hz, Ar), 7.74-7.82 (6H, m, 
Ar). ESI-MS: m/z calculated for C29H51N2O4S [M]
+ 
523.4; found: 523.5. 
3.4.1.8 Synthesis of Monomethyl-t-Bu Ligand for NP9 
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Figure 3.21: Synthesis of compound 2 from compound 1. 
 
To a solution of compound 1 (626 mg, 0.80 mmol) in CH2Cl2 (6.0 mL) was added TFA 
(1.5 mL). After being stirred at rt for 10 min, triisopropylsilane (1.0 mL) was added. After being 
stirred at rt for 1 h, the mixture was concentrated in vacuo. The residue was washed eight times 
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with n-heptane and three times with n-hexane. The solvent was evaporated to give the desired 
compound as pale yellow oil (430 mg, 82%). 
1
H-NMR (400 MHz, CDCl3) 1.27-1.42 (23H, m, -
CH2-), 1.53-1.66 (4H, m, -CH2-), 2.54 (2H, q, J = 7.5 Hz, -SCH2-), 2. 86 (3H, s, NCH3), 3.16-
3.22 (1H, m, -CH2N-), 3.42-3.47 (3H, m, -OCH2-, -CH2N-), 3.56-3.68 (12H, m, -OCH2-), 3.89-
3.92 (2H, m, -OCH2-), 4.28 (1H, d, J = 13.0 Hz, -NCH2Ar-), 4.39 (1H, d, J = 13.0 Hz, -NCH2Ar-
), 7.38 (2H, d, J = 8.4 Hz, Ar), 7.47 (2H, d, J = 8.7 Hz, Ar), 8.30 (1H, br, -N
+
H-). MALDI-MS: 
m/z calculated for C31H58NO4S [M+H]
+ 
540.409; found: 540.645. 
3.4.1.9 Synthesis of Monomethyl-Me Ligand for NP10 
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Figure 3.22: Synthesis of compound 2 from compound 1. 
 
To a solution of compound 1 (350 mg, 0.47 mmol) in CH2Cl2 (4.0 mL) was added TFA 
(1.0 mL). After being stirred at rt for 10 min, triisopropylsilane (0.8 mL) was added. After being 
stirred at rt for 1 h, the mixture was concentrated in vacuo. The residue was washed eight times 
with n-heptane and three times with n-hexane. The solvent was evaporated to give the desired 
compound as pale yellow oil (213 mg, 74%). 
1
H-NMR (400 MHz, CDCl3) 1.28-1.42 (14H, m, -
CH2-), 1.53-1.66 (4H, m, -CH2-), 2. 39 (3H, s, -ArCH3), 2.54 (2H, q, J = 7.5 Hz, -SCH2-), 2.83 
(3H, s, NCH3), 3.15-3.21 (1H, m, -CH2N-), 3.39-3.48 (3H, m, -OCH2-, -CH2N-), 3.56-3.67 (12H, 
m, -OCH2-), 3.89-3.92 (2H, m, -OCH2-), 4.26 (1H, d, J = 13.0 Hz, -NCH2Ar-), 4.38 (1H, d, J = 
13.0 Hz, -NCH2Ar-), 7.25 (2H, d, J = 8.1 Hz, Ar), 7.34 (2H, d, J = 8.1 Hz, Ar). MALDI-MS: m/z 
calculated for C28H52NO4S [M+H]
+ 
498.354; found: 498.563. 
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Figure 3.23: Synthesis of compound 2 from compound 1. 
 
To a solution of compound 1 (311 mg, 0.41 mmol) in CH2Cl2 (4.0 mL) was added TFA 
(2.0 mL). After being stirred at rt for 10 min, triisopropylsilane (2.0 mL) was added. After being 
stirred at rt for 1.5 h, the mixture was concentrated in vacuo. The residue was washed four times 
with n-heptane and four times with n-hexane. The solvent was evaporated to give the desired 
compound as pale yellow oil (265 mg, >99%). 
1
H-NMR (400 MHz, CDCl3) 1.28-1.41 (14H, m, -
CH2-), 1.53-1.66 (4H, m, -CH2-), 2.54 (2H, q, J = 7.5 Hz, -SCH2-), 2. 84 (3H, s, NCH3), 3.15-
3.21 (1H, m, -CH2N-), 3.38-3.48 (3H, m, -OCH2-, -CH2N-), 3.56-3.67 (12H, m, -OCH2-), 3.85 
(3H, s, -OCH3), 3.90 (2H, m, -OCH2-), 4.25 (1H, d, J = 13.1 Hz, -NCH2Ar-), 4.38 (1H, d, J = 
13.1 Hz, -NCH2Ar-), 6.96 (2H, d, J = 8.7 Hz, Ar), 7.38 (2H, d, J = 8.7 Hz, Ar), 8.50 (1H, br, -
N
+
H-). MALDI-MS: m/z calculated for C28H52NO5S [M+H]
+ 
514.357; found: 514.583. 
3.4.1.11 Synthesis of Monomethyl-CN Ligand for NP12 
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Figure 3.24: Synthesis of compound 2 from compound 1. 
 
To a solution of compound 1 (460 mg, 0.66 mmol) in THF (2.0 mL) was added a solution 
of N-methyl-4-cyanobenzylamine (289 mg, 2.0 mmol) and diisopropylamine (327 µL, 2.0 mmol) 
in THF (2.0 mL). After being stirred at 60 °C for 2 days, the mixture was concentrated in vacuo. 
The residue was dissolved in EtOAc. The mixture was washed with sat. NaHCO3 and brine, and 
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dried over Na2SO4. After concentration, the residue was purified by flash chromatography over 
silica gel with EtOAc–MeOH (1:0 to 9:1) to give the desired compound as yellow oil (381 mg, 77 
%). 
1
H-NMR (400 MHz, CDCl3) 1.15-1.45 (16H, m, -CH2-), 1.54-1.62 (2H, m, -CH2-), 2.15 (2H, 
t, J = 7.3 Hz, -SCH2-), 2.29 (3H, br s, -NCH3), 2.70 (2H, t, J = 7.3 Hz, -NCH2-), 3.44 (2H, t, J = 
6.8 Hz, -OCH2-), 3.56-3.69 (16H, m, -OCH2-, -NCH2Ar-), 7.20-7.34 (11H, m, Ar), 7.41-7.44 
(6H, m, Ar), 7.62-7.7.67 (2H, m, Ar). MALDI-MS: m/z calculated for C47H63N2O4S [M+H]
+ 
752.091; found: 751.813. 
HS O
O
CH2Cl2, rt
(  )9 (             )3 N
H
CN
Ph3CS O
O
(  )9 (             )3 N
CN
TFA, (i-Pr)3SiH
Otfa
Compound 2 Compound 3
 
Figure 3.25: Synthesis of compound 3 from compound 2. 
 
To a solution of compound 2 (293 mg, 0.39 mmol) in CH2Cl2 (3.0 mL) was added TFA 
(1.0 mL). After being stirred at rt for 10 min, triisopropylsilane (1.0 mL) was added. After being 
stirred at rt for 1 h, the mixture was concentrated in vacuo. The residue was washed ten times 
with n-hexane. The solvent was evaporated to give the desired compound as pale yellow oil (241 
mg, quant). 
1
H-NMR (400 MHz, CDCl3) 1.27-1.42 (14H, m, -CH2-), 1.52-1.66 (4H, m, -CH2-), 
2.54 (2H, q, J = 7.3 Hz, -SCH2-), 2.90 (3H, s, NCH3), 3.36 (2H, br s, -CH2N-), 3.46 (2H, t, J = 6.9 
Hz,  -OCH2-), 3.58-3.70 (12H, m, -OCH2-), 3.93 (2H, br s, -OCH2-), 4.43 (1H, br s, -NCH2Ar-), 
4.54 (1H, br s, -NCH2Ar-), 7.72 (2H, d, J = 8.3 Hz, Ar), 7.77 (2H, d, J = 8.3 Hz, Ar). MALDI-
MS: m/z calculated for C28H49N2O4S [M+H]
+ 
509.341; found: 509.347. 
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3.4.1.12 Synthesis of Monomethyl-NO2 Ligand for NP13 
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Figure 3.26: Synthesis of compound 2 from compound 1. 
 
To a solution of compound 1 (476 mg, 0.68 mmol) in THF (2.0 mL) was added a solution 
of N-methyl-4-nitrobenzylamine (338 mg, 2.0 mmol) and diisopropylamine (337 µL, 2.0 mmol) 
in THF (2.0 mL). After being stirred at 60 °C for 2 days, the mixture was concentrated in vacuo. 
The residue was dissolved in EtOAc. The mixture was washed with sat. NaHCO3 and brine, and 
dried over Na2SO4. After concentration, the residue was purified by flash chromatography over 
silica gel with EtOAc–MeOH (1:0 to 9:1) to give the desired compound as yellow oil (416 mg, 79 
%). 
1
H-NMR (400 MHz, CDCl3) 1.15-1.44 (16H, m, -CH2-), 1.56-1.62 (2H, m, -CH2-), 2.15 (2H, 
t, J = 7.3 Hz, -SCH2-), 2.29 (3H, br s, -NCH3), 2.70 (2H, t, J = 7.4 Hz, -NCH2-), 3.44 (2H, t, J = 
6.8 Hz, -OCH2-), 3.56-3.69 (16H, m, -OCH2-, -NCH2Ar-), 7.20-7.34 (9H, m, Ar), 7.41-7.44 (6H, 
m, Ar), 7.54 (2H, m, Ar), 8.21 (2H, m, Ar). MALDI-MS: m/z calculated for C46H63N2O6S [M+H]
+ 
771.441; found: 771.551. 
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Figure 3.27: Synthesis of compound 3 from compound 2. 
 
To a solution of compound 2 (300 mg, 0.39 mmol) in CH2Cl2 (3.0 mL) was added TFA 
(1.0 mL). After being stirred at rt for 10 min, triisopropylsilane (1.0 mL) was added. After being 
stirred at rt for 1 h, the mixture was concentrated in vacuo. The residue was washed ten times 
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with n-hexane. The solvent was evaporated to give the desired compound as pale yellow oil (241 
mg, 99%). 
1
H-NMR (400 MHz, CDCl3) 1.26-1.42 (14H, m, -CH2-), 1.51-1.66 (4H, m, -CH2-), 
2.54 (2H, q, J = 7.5 Hz, -SCH2-), 2.91 (3H, s, NCH3), 3.38 (2H, br s, -CH2N-), 3.45 (2H, t, J = 6.8 
Hz, -OCH2-), 3.58-3.70 (12H, m, -OCH2-), 3.93 (2H, br t, J = 4.3 Hz, -OCH2-), 4.55 (1H, br s, -
NCH2Ar-), 7.79 (2H, d, J = 8.6 Hz, Ar), 8.32 (2H, d, J = 8.6 Hz, Ar). MALDI-MS: m/z calculated 
for C27H49N2O6S [M+H]
+ 
529.331; found: 529.354. 
3.4.1.13 Synthesis of DMBA Ligand 
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Figure 3.28: Synthesis of compound 2 from compound 1. 
 
To a solution of compound 1
57
 (450 mg, 1.57 mmol) in EtOH (1.57 mL) was added N,N-
dimethylbenzylamine (705 µL). After being stirred at 45 °C for 1 day, the mixture was 
concentrated in vacuo. The residue was washed six times with diethylether. The solvent was 
evaporated to give the desired compound as colorless oil (670 mg, quant). 
1
H-NMR (400 MHz, 
CDCl3) 2.83 (3H, s, -CH3), 3.26 (6H, s, -NCH3), 3.35 (3H, s, -CH3-), 3.50-3.69 (12H, m, -OCH2-
), 3.86 (2H, br s, -OCH2-), 4.04 (2H, br s, -CH2N-), 4.83 (2H, s, -NCH2Ar-), 7.45-7.65 (5H, m, 
Ar). MALDI-MS: m/z calculated for C18H32NO4 [M]
+ 
326.233; found: 326.107. 
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CHAPTER 4 
MASS SPECTROMETRIC DETECTION OF NANOPARTICLE HOST-GUEST 
INTERACTIONS IN CELLS 
4.1 Introduction 
Host-guest chemistry using engineered molecular systems provides controllable 
platforms for biomedical applications such as cell targeting,
1,2 
 biosensing,
3
 imaging,
4
 drug 
delivery,
5-7 
and cancer therapeutics.
8 
The reversibility of the association/dissociation process plays 
a vital role in these applications, allowing host systems to regulate the release of drug guests.
9,10 
Multifunctional nanomaterials provide particularly versatile scaffolds for these host-guest 
systems due to their biocompatibility and functional versatility.
8-11
 For example, the cytotoxicity 
of gold nanoparticles (AuNPs) can be triggered in cancer cells using competitive host-guest 
binding molecules, providing a new strategy for potential therapeutic applications.
8
 
Effective use of nanomaterial-based supramolecular chemistry in biomedical applications 
requires the ability to monitor the association and dissociation of the non-covalent conjugates 
inside cells.
12
 Characterization of host-guest interactions is traditionally performed in simple 
solutions using techniques such as NMR
13,14 
and isothermal titration calorimetry (ITC).
15,16
 These 
methods, however, cannot be used to analyze host-guest interactions in biological systems due to 
the complex environments in cells and tissues. Fluorescence spectroscopy is an alternate strategy 
to detect host-guest complexes in complicated biological samples.
17
 The use of florescent probes, 
especially when additional labeling steps are required, can affect the biological behavior of 
original host-guest complexes due to the alteration of surface properties by the dye.
18-20 
Moreover, 
it is challenging for this method to simultaneously probe multiple host-guest complexes.  
Mass spectrometry (MS) is an effective tool for characterizing host-guest interactions in 
solution.
12,21-24 
For example, electrospray ionization (ESI) MS
25-27 
and matrix assisted laser 
desoption/ionization (MALDI) MS
28,29 
have been utilized for the detection of host-guest 
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complexes. However, to the best of our knowledge, detecting host-guest interactions inside cells 
using MS has not been reported, due in large part to the large number of interfering ions 
generated from biological samples. 
 
Scheme 4.1: (a) Schematic illustration of the MALDI-MS detection process of supramolecular 
complexes in cells. AuNP-CB[7] complexes are measured as complex ions between CB[7] and 
AuNP surface ligands, and these ions appear at m/z values above 1600. (b) Monitoring the 
selective dissociation of the supramolecular complexes after adding the competitive binding 
molecule ADA. The addition of ADA dissociates some AuNP-CB[7] complexes and also leads to 
a new ADA-CB[7] complex ion at m/z 1314. 
 
In this chapter, we report here a direct method to monitor the association and dissociation 
of multiple NP-based host-guest complexes inside cells (Scheme 4.1 (a)) using a standard 
MALDI mass spectrometer. Supramolecular complexes formed by the surface ligands of AuNPs 
and cucurbit[7]uril (CB[7]) serve as “mass barcodes” to indicate the presence of AuNP-CB[7] 
complexes inside cells. This method integrates NP-mediated laser desorption ionization (LDI-
MS)
30-34
 with MALDI using an organic matrix and acts to selectively desorb/ionize 
supramolecular complexes of the ligands, allowing observation of these species in the presence of 
other cellular materials. Using this method, the intracellular association and dissociation of 
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AuNP-CB[7] complexes were monitored, as well as competitive dissociation of these complexes 
using 1-adamantylamine (ADA) (Scheme 4.1 (b)). 
4.2 Results and Discussion 
4.2.1 Detection of Host-Guest Complexes in Aqueous Solution 
We chose the cucurbituril (CB) supramolecular family for our studies. These host-guest 
complexes are particularly promising for biomedical applications due to their solubility in 
aqueous media, high affinity and non-toxicity.
35-39  
We probed intracellular CB interactions using 
AuNPs with three types of surface functionalities (Figure 4.1 (a)). The AuNP-CB[7] complexes 
were formed by mixing AuNPs with excess CB[7] (molar ratio of AuNP:CB[7] = 1:200). The 
initial LDI/MALDI-MS detection of the AuNP-CB[7] host-guest complexes was first in simple 
aqueous solutions (Figure 4.2).  
 
 
Figure 4.1: (a) Structures of the surface functionalities on the AuNPs used in this work. (b) The 
mass-to-charge (m/z) ratios of ligands and their corresponding supramolecular complexes 
monitored by MALDI-MS. Letter code key: molecular ions of the surface ligands (L ions), 
disulfide ions (D ions) formed by surface ligands and pentanethiol ligands, supramolecular 
complex ions (C ions) formed by surface ligand and CB[7], and disulfide ions formed by CB[7] 
and D ions (DC ions). 
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The molecular ion of the surface ligand (L1) of AuNP 1, which has a diaminohexyl 
ending group was readily detected using LDI/MALDI-MS (Figure 4.2 (a)). The disulfide ion 
(D1), previously reported in LDI/MALDI-MS analysis of self-assembled monolayer surfaces,
40-43 
and the molecular ion (L1) confirmed the presence of AuNP 1. The supramolecular complex ions 
C1 and DC1 (formed by the D1 ion and CB[7]) indicate the detection of the host-guest complexes 
(Figure 4. 2 (a), see the inset for the enlarged region between m/z 1600 and 1800; ion identities 
are shown in Figure 1 (b)). This MALDI-MS method for monitoring the AuNP-CB[7] host-guest 
interactions is able to detect the intact supramolecular complexes without generating fragments of 
the gold clusters
 
or ionizing the intact AuNPs,
 
and thus provides information on the ligand-CB[7] 
interaction. We applied this method to supramolecular complexes formed by CB[7] and AuNPs 
with different surface functionalities, and analogous mass spectra were acquired using AuNP 2-
CB[7] and AuNP 3-CB[7] containing solutions (Figure 4.2 (b), (c)). The LDI/MALDI-MS 
characterization of the AuNP-CB[7] supramolecular structures can also be applied to NPs with a 
wide range of surface functionalities. 
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Figure 4.2: Monitoring AuNP-CB[7] interaction in solution using MALDI-MS. (a) AuNP 1-
CB[7]. (b) AuNP 2-CB[7]. (c) AuNP 3-CB[7]. [AuNP]=2 µM, [CB[7]]=400 µM. See the Figure 
1 caption for the identities of the L, D, C, and DC ions. 
 
4.2.2 Detection of Host-Guest Complexes inside Cells 
Building on the solution phase experiments, we next explored the ability of this method 
to selectively ionize and detect NP host-guest complexes in cells. HeLa cells were incubated with 
uncomplexed (250 nM) and complexed (250 nM AuNP, 200 equivalents of CB[7]) and washed 
with PBS three times to remove the AuNPs and AuNP-CB[7] complexes that were not taken up 
by the cells. After the cells were lysed, the resulting samples were transferred to centrifuge tubes, 
and the pellets containing AuNPs or AuNP-CB[7] complexes were collected after the 
centrifugation (Scheme 4.1 (a)). The high density of AuNPs relative to the biomolecules in the 
cells allows one to concentrate the AuNPs and AuNP-CB[7] complexes to some extent, 
minimizing interferences from biological molecules in the cell lysate. We then transferred the 
pellets to the MALDI-MS sample carrier and applied a thin layer of matrix on top of the pellets 
(Scheme 4.1 (a)). Figures 4.3 (a) and 4.3 (b) show typical LDI/MALDI mass spectra that are 
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obtained. The surface ligand ions (L1 and D1) are observed, indicating the existence of AuNPs in 
the pellets (Figure 4.3 (a)). The supramolecular ions (C1 and DC1) are also readily observed, 
showing successful detection of host-guest complexes inside cells (Figure 4.3 (b)). The gold cores 
of the AuNPs and the added matrix seem to work together to enable the selective ionization of the 
surface ligands and complexes that are attached to the AuNPs. Interestingly, the relative 
intensities of the complexed and uncomplexed ligands in cells (Figure 4.3 (b)) are different than 
in solution (Figure 4.2 (a)); we are investigating the origins of this disparity.  
 
Figure 4.3: Monitoring AuNP-CB[7] interactions using MALDI-MS. (a) Detection of AuNP 1 in 
cells after incubation with 250 nM AuNP. (b) Detection of AuNP 1-CB[7] ([AuNP]=250 nM, 
[CB[7]] = 50 µM) taken up by the cells. (c) The dissociation of the host-guest complex by adding 
ADA (4 µM) to the cells containing AuNP 1-CB[7]. 
 
4.2.3 Dissociation of Host-Guest Complexes Using a Competitive Guest Molecule 
We next used LDI/MALDI to monitor the dissociation of host-guest complexes using 
ADA, a strong binding competitor for CB[7]. Since a similar amount of particle was taken up 
with each of the ligands the same amount of ADA was added for each particle. The host-guest 
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complex “mass barcodes,” both C1 and DC1 ions, disappear after the cells containing AuNP-
CB[7] complexes are treated with ADA (Figure 4.3 (c)), indicating the dissociation of 
supramolecular complexes. Comparing the results in Figure 4.3 (a) and 4.3 (c), ADA treatment of 
cells incubated previously with AuNP 1-CB[7] complexes leads to very similar mass spectra as 
the cells treated with only AuNP 1. Figure 4.3 demonstrates the successful tracking of the 
association and dissociation of AuNP-CB[7] supramolecular complexes in cells by LDI/ MALDI-
MS.  
4.2.4 Multiplexed Detection of Association and Dissociation of Host-Guest Complexes  
Multiple supramolecular complexes can be followed simultaneously using MALDI-MS.
30
 
This multiplexed detection could provide direct ratiometric measurements, significantly reducing 
the variability introduced from studying different supramolecular complexes in separate cell 
populations. Cells were incubated with three AuNP-CB[7] complexes (AuNP 1-CB[7], AuNP 2-
CB[7] and AuNP 3-CB[7]) to demonstrate this multiplexing capability. Ions corresponding to the 
surface ligands (L1, L2, and L3) of three AuNPs and the host-guest complexes (C1, C2, and C3) 
are readily detected (Figure 4.4 (a); however, the intensities of the complex ions detected by 
MALDI-MS vary due to the different amounts and different ionization efficiencies of the 
supramolecular complexes. 
As above, ADA was used to trigger the dissociation of the AuNP-CB[7] complexes 
inside the cells. In this study, 1.8 µM and 3.6 µM of ADA (total ADA amount: 0.9 nmol and 1.8 
nmol, respectively) were added to the cells containing AuNP-CB[7] complexes. We used the 
intensity ratios of all the supramolecular complex ions (C and DC ions) and all the ligand related 
ions (L, D, C, and DC ions) to evaluate the ADA-triggered dissociation of the complexes. All the 
ion intensity ratios were then normalized (Figure 4.4 (b)) relative to cells without ADA treatment. 
The decrease in the normalized ion intensity ratios shows the dissociation of these three 
supramolecular complexes are different. A more detailed examination using one-way ANOVA 
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reveals that AuNP 3-CB[7] complexes are much more stable to ADA treatment than the other two 
ligands. This observation of selectivity illustrates the utility of the of the LDI/MALDI-MS 
method to screen multiple host-guest interactions in cells.  
 
Figure 4.4: Monitoring the dissociation of three AuNP-CB[7] complexes in cells. (a) Typical 
mass spectrum of cell samples incubated with a mixture of three AuNP-CB[7] complexes. (b) 
Normalized ion intensity ratios indicating the relative amount of the remaining supramolecular 
complexes after ADA treatments. n.s., no significant difference. **, 0.001<p≤0.01; ***, p≤0.001 
through one-way ANOVA (n=9), see detail p values in the Table 4.1 (c) The residual complexes 
in the cell lysates after ADA treatment based on relative ionization efficiencies (Table 4.2). 
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4.3 Summary and Future Outlook  
In summary, we have demonstrated the use of LDI/MALDI-MS to detect AuNP-CB[7] 
complexes in cells, confirming that both formation and dissociation of host-guest interactions 
inside cells can be monitored. We predict that this method is adaptable for monitoring other host-
guest systems with various types of NPs,
30
 with the inherent multiplex capabilities of the mass 
barcode approach facilitating high-throughput screening. 
4.4 Experimental Section  
4.4.1 Cell Culture Experiments 
60k HeLa cells per well were plated into a 24 well plate 24 h before the experiment. Cells 
were incubated with AuNP-CB[7] complexes (250 nM, 500 uL) for 24 h in DEMEM media 
containing 10% FBS and 1% antibiotics and then washed 3 times with phosphate-buffered saline 
(PBS) (500 uL each washing). Beta Gal lysis buffer (250 uL per well, 5 times diluted) was used 
to lyse the cell, with the cell culture plate kept at room temperature on a vibrator for 30 minutes.  
4.4.2 Treatment of Competitive Guest Molecule, ADA  
60k HeLa cells were treated with a single type of NP-CB[7] complex or a mixture of 
three NP-CB[7] complexes for 24 h. Then, they were washed 3 times with PBS (500 uL), and 
treated with ADA at a concentration of 1.8 µM and 3.6 µM for 1 h (total ADA amount: 0.9 nmol 
and 1.8 nmol, respectively). After that, cells were washed 3 times with PBS and lysed with Beta 
Gal lysis buffer. 
4.4.3 Cell Sample Preparation for MALDI-MS 
The cell lysate samples were transferred from the 24-well cell culture plate to 1.5 ml 
centrifuge tubes. Then, they were centrifuged at 14000 rpm for 30 min.  After removal of the 
supernatant containing the lysis buffer, the pellets were transferred to the stainless steel MALDI-
MS sample carrier. A saturated solution of the matrix α-cyano-4-hydroxycinnamic acid (α-
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CHCA) solution was prepared in 70% acetonitrile and 30% water for the MALDI-MS analysis. 
2.5 µL of the matrix solution was applied on top of each pellet. The samples were air-dried before 
MALDI-MS analysis. 
4.4.3.1 MALDI-MS Instrumentation and Analysis of Additional AuNP-CB7 Complexes 
MALDI-MS experiments were carried out on a Bruker Autoflex III MALDI-TOF mass 
spectrometer (Bruker Daltonics, Bremen, Germany), equipped with a Smartbeam 2 Nd:YAG 
laser.  MALDI-MS operating conditions were as follows: ion source 1 = 19.00 kV, ion source 2 = 
16.60 kV, lens voltage = 8.44 kV, reflector voltage = 20.00 kV, reflector voltage 2 = 9.69 kV, and 
positive reflectron mode in a mass range of m/z 400−3000. A total of 200 laser shots were fired 
per measurement. The laser energy was optimized to ~ 40 µJ/pulse. Data processing was 
performed using the Bruker flexAnalysis (version 3.3) software. 
 
 
Figure 4.5: Various AuNPs which bind CB[7] that have been successfully characterized by 
MALDI-MS. The ones in the red box have been utilized for the selective dissociation study. 
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Figure 4.6: Mass spectra of the AuNP-CB[7] complexes. (a) AuNP 4-CB[7], (b) AuNP 5-CB[7], 
(c) AuNP 6-CB[7], (d) AuNP 7-CB[7]. 
 
Table 4.1: Detail p values for the comparison between different NP-CB[7] complexes. 
 
p value 0.9 nmol ADA 1.8 nmol ADA 
AuNP 1 vs. AuNP 2 0.7330 0.2207 
AuNP 1 vs. AuNP 3 0.0001 0.0019 
AuNP 2 vs. AuNP 3 0.0002 0.0005 
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Table 4.2: The ion intensity ratios of MALDI-MS analysis of AuNP-CB[7] complexes in 
solutions. 
Ion Intensity 
Ratio Average SD  
AuNP 1 - CB[7] 0.76 0.08 
AuNP 2 - CB[7] 0.41 0.08 
AuNP 3 - CB[7] 0.025 0.010 
 
4.4.4 Sample Preparation for ICP-MS and Analysis of the Cellular Uptake 
After the cellular uptake, the cells were lysed and transferred to 15 mL centrifuge tubes. 
0.5 mL of fresh aqua regia (highly corrosive and must be treated with extreme caution!) were 
added to each sample. Each sample was then diluted to 10 mL with de-ionized water. A series of 
gold standard solutions (0, 0.2, 0.5, 1, 2, 5, 10, and 20 ppb) were prepared for the ICP-MS 
measurements. Each standard solution also contained 5% aqua regia. The gold standard solutions 
and cellular uptake sample solutions were measured on a Perkin-Elmer NexION 300X ICP mass 
spectrometer. 
197
Au was measured under standard mode. Operating conditions are listed as below: 
nebulizer flow rate: 0.95-1 L/min; rf power: 1600 W; plasma Ar flow rate: 18 L/min; dwell time: 
50 ms.   
 
Figure 4.7: Cellular uptake amount per well of AuNP-CB[7] complexes measured by ICP-MS. 
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4.4.5 Synthesis of Ligands and AuNPs 
4.4.5.1 Synthesis of Ligands 
 
Scheme 4.2: Synthesis scheme of dimethyldiaminohexyl ligand (DMAH, L2). 
 
Compound 1: 11-bromo-1-undecanol (8.22 g, 32.74 mmol) was dissolved in a solution 
of ethanol/toluene (1:1, 100 mL). Then, triphenylmethanethiol (10.86 g, 39.29 mmol) was also 
dissolved in a solution of ethanol/toluene (1:1, 50 mL) and added to the 11-bromo-1-undecanol 
mixture. NaOH (1.96 g, 49.11 mmol) in 3 mL of H2O was also added into the mixture. The 
reaction mixture was stirred for 24 h at 50
o
C. Once the reaction was completed (checked by 
TLC), the reaction mixture was extracted with a saturated solution of NaHCO3 twice. The organic 
layer was separated and extracted with a saturated NaCl solution twice. Afterward the organic 
layer was separated, dried over Na2SO4, and concentrated using a rotavapor. The crude product 
was purified by column chromatography over silica gel using hexane/ethyl acetate (1:1, v/v) as an 
eluent. The solvent was removed in vacuum to obtain compound 1 as colorless oil (Yield 13.88 g, 
95 %). 
97 
 
 
Figure 4.8: 400 MHz 
1
H NMR spectra of compound 1 in chloroform-D (D, 99.8%). 
 
Compound 2: Compound 1(13.88 g, 31.1 mmol) was dissolved in dry DCM. Then, 
triethylamine (4.72g, 6.48 mL, 46.65 mmol) was added into this solution at 4 
o
C. 
Methanesulfonyl chloride (3.92 g, 2.65mL, 34.21 mmol) was added dropwise to the solution kept 
in ice bath. After 30 minutes the reaction mixture was warmed up to room temperature and stirred 
overnight. After the reaction was completed (according to TLC), solvent was evaporated. The 
compound was again diluted with DCM and extracted with 0.1 M solution of HCl twice. Organic 
layer was collected and treated with a saturated solution of NaHCO3 and washed three times. The 
organic layer was separated and added into saturated NaCl solution and extracted three times. 
After extraction, organic layer was separated, dried over Na2SO4 and concentrated at reduced 
pressure. The crude product was purified by column chromatography over silica gel using 
hexane/ethyl acetate (1:1, v/v) as an eluent. Solvent was removed in vacuum to obtain mesylated 
compound as light yellow oil (Yield 15 g, 92 %). To synthesize  compound 2, NaOH (1.37 g, 
34.3 mmol) dissolved in 1 mL of H2O was added to 99.24 mL of tetraethyleneglycol (111.15 g, 
57.22 mmol) and stirred for 2 h at 80 °C. To this reaction mixture, 15 g of 11 (tritylthio)undecyl 
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methanesulfonate was added and stirred for 48 h at 80 °C. The reaction mixture was extracted by 
washing with a solution of hexane/ethyl acetate (4:1, v/v) six times. Then, the organic layer was 
separated and concentrated at reduced pressure. The crude product was purified by column 
chromatography over silica gel using ethyl acetate as an eluent. The solvent was removed in 
vacuum to obtain compound 2 as light yellow oil (Yield 15.28 g, 68%). 
 
Figure 4.9: 400 MHz 
1
H NMR spectra of compound 2 in chloroform-D (D, 99.8%). 
 
Compound 3: Compound 2 (10 g, 16.1 mmol) was dissolved in dry DCM at 4 °C. 
Triethylamine (3.26g, 4.49 mL, 32.2 mmol) was added into the solution. Methanesulfonyl 
chloride (2.77 g, 1.87 mL, 24.1 mmol) was added drop by drop to the reaction mixture that was 
kept in ice-bath. After 30 minutes the reaction mixture was warmed up to room temperature and 
stirred overnight. Afterward, DCM solvent was evaporated under reduced pressure. The viscous 
compound was again diluted with DCM and was extracted with 0.1 M solution of HCl twice. The 
organic layer was poured into a saturate solution of NaHCO3 and washed three times. Organic 
layer was separated and added into saturated NaCl solution and also washed for three times. 
Then, the organic layer was separated, dried over Na2SO4 and concentrated at reduced pressure. 
99 
 
The crude product was purified by column chromatography over silica gel using ethyl acetate as 
an eluent. Solvent was removed in vacuum to obtain compound 3 as a light yellow oil (Yield 10.7 
g, 95 %).  
 
Figure 4.10: 400 MHz 1H NMR spectra of compound 3 in chloroform-D (D, 99.8%). 
 
Compound 4: Compound 3 (2 g, 2.85 mmol) was added to dimethylamine solution (25 
ml, 2 M solution in THF, 57 mmol) in THF. The reaction mixture was stirred at 25
o
C for 24 h. 
Crude product was checked by TLC and THF and excess of dimethylamine were eliminated at 
reduced pressure. The product formation was quantitative and their structure was confirmed by 
NMR. 
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Figure 4.11: 400 MHz 
1
H NMR spectra of compound 4 in chloroform-D (D, 99.8%). 
 
Compound 5: Compound 4 (0.6 g, 9.23 mmol) and compound 7 (0.8 g, 27.7 mmol) were 
dissolved in ethanol (5 mL) and stirred at 40 
o
C for 48 h. Crude product was checked by TLC and 
ethanol was eliminated at reduced pressure. The light yellow residue was purified by successive 
hexane (4 times) and diethylether (4 times) washings with support of sonication and then dried in 
a high vacuum system. The product formation was quantitative and their structure was confirmed 
by NMR.  
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Figure 4.12: 400 MHz 
1
H NMR spectra of benzyl ligand in chloroform-D (D, 99.8%). 
 
Compound 6: Compound 5 (0.4 g, 0.47 mmol) was dissolved in dry dichloromethane 
(DCM, 5 mL) and an excess of trifluoroacetic acid (TFA, 20 equivalents, 1.072 g, 0.72 mL, 9.41 
mmol) was added. The color of the solution was turned to yellow upon addition of TFA.  Then, 
triisopropylsilane (TIPS, 1.5 equivalents, 0.11 g, 0.15 mL, 0.705 mmol ) was added to the 
reaction mixture. The reaction mixture was stirred overnight under N2 at room temperature. The 
solvent and most TFA and TIPS were evaporated under reduced pressure. The yellow residue was 
purified by hexane washings (5 times) and dried in a high vacuum system. The product formation 
was quantitative and their structure was confirmed by NMR. 
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Figure 4.13: 400 MHz 
1
H NMR spectra of dimethyldiaminohexane ligand in chloroform-D (D, 
99.8%). 
 
 
 
 
 
Figure 4.14: 400 MHz 
1
H NMR spectra of benzyl ligand in chloroform-D (D, 99.8%). 
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Figure 4.15: 400 MHz 
1
H NMR spectra of diaminohexane ligand in chloroform-D (D, 99.8%). 
 
Diaminohexyl (DAH, L1) and benzyl (BEN, L3) ligand were synthesized according to the 
procedure in literature.
44,45
 
4.4.5.2 Synthesis of AuNPs 
Brust-Schiffrin two-phase synthesis method was used to synthesize pentanethiol-coated 
AuNPs with core diameter ~2 nm.
46
 Murray place-exchange method
47
 was followed to obtain the 
benzyl NPs. Pentanethiol conjugated AuNPs (20 mg) and thiol ligand (compound 6) (60 mg) was 
dissolved in mixture of dry DCM/methanol (4:1, 5 ml) and stirred under N2 atmosphere for 3 
days at room temperature. The solvents were removed under reduced pressure and the resulting 
precipitate was washed with hexane three times and DCM three times. Then the precipitate was 
dissolved in distilled water and dialyzed for 3 days (membrane molecular cut-off =10000) to 
remove excess ligands and pentanethiol, acetic acid and other salts present in the nanoparticle 
solution. After dialysis, the particle was lyophilized to yield a solid brownish product. The 
particles are then redispersed in deionized water. 
1
H NMR-spectra in D2O showed substantial 
broadening of the proton peaks with no sign of free ligands. 
104 
 
 
Figure 4.16: TEM image of pentanethiol (C5) coated AuNPs. 
 
4.4.6 Complexation of AuNP with CB[7] 
CB[7] solution in deionized water was added into AuNP solution and stirred for 24 h. 
Ratio between CB[7]/AuNP was kept at 200:1. For example, 200 µL AuNP DAH solution (30 
µM) was mixed with 200 µL CB[7] solution (6 mM).  
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CHAPTER 5 
SOLUBILIZATION OF HYDROPHOBIC CATALYSTS USING NANOPARTICLE 
HOSTS 
5.1 Introduction 
Transition metal-mediated catalysis (TMC) in aqueous media
1 
diminishes the dependence 
on expensive and environmentally unfriendly organic solvents.
2,3
 However, most TMC reactions 
are performed in organic solvents due to limited solubility,
4
 activity,
5
 and stability
6
 of the 
catalysts in water. Therefore, designing a general platform that solubilizes hydrophobic catalysts 
in water while preserving their activity and stability remains critical for environmental and 
economical benefits. 
Covalent and non-covalent modifications to transition metal (TM) catalysts have been 
used to improve catalyst solubility in aqueous environments. Widely investigated approaches 
include covalent conjugation of the catalysts with hydrophilic ligands
7
 or anchoring charged 
substituents to the coordinating hydrophobic ligands.
8
 These covalent modifications demand 
specific ligand designs for each catalyst, which can affect the stability and reactivity of the native 
catalyst.
9
 Meanwhile, improving the solubility of TM catalysts does not inherently protect the 
catalysts from aqueous degradation. Covalent modification can change the steric and electronic 
environment of metal center, weakening the bond between the ligand and metal, resulting in poor 
initiation efficiency,
6a
 decomposition of catalyst,
10
 and loss of activity.
11
 Non-covalent 
approaches such as host–guest assembly of catalysts with cyclodextrins,12 calixarenes,13 and 
cucurbiturils
14
 have been shown as effective methods to solubilize catalysts without the need to 
alter the structure of the catalysts.
15 
These supramolecular approaches, however, require the 
catalysts to possess suitable guest sites.
16
 
Another emerging approach to address the challenges associated with catalyst solubility 
and stability is encapsulating catalysts into platforms such as micelles,
17
 dendrimers,
18 
polymeric 
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capsules,
19 
and hallow polymer shells.
20
 These constructs provide solubility to the catalyst and 
result in high yield under ambidient conditions due to the ability of confined nanocatalysis.
21
 
However, issues such as the use of stabilizing agent and additives
22
/surfactants
23 
and their 
removal, multistep preparation procedures,
24 
lack of robustness due to the dynamic nature of these 
systems,
25
 and lack of complete template removal
26 
impede the effective use of the 
aforementioned platforms. Furthermore, these scaffolds are more suitable for the entrapment of 
catalyst made up from metal nanoparticles with size of larger than 10 nm.
27
 However, majority of 
homogeneous catalysts including TM catalysts are in the size range of 1-2 nm.  
Nanoparticles (NPs) with their unique tunable physical and chemical properties are 
promising platforms to encapsulate/immobilize a variety of catalysts including small-sized TM 
catalysts.
28
 Performing catalysis using NP systems brings the advantages of both homogenous and 
heterogeneous catalysis into the same system.
29
 While efficient and diverse reactions are 
catalyzed within these NPs, reaction products are easily separated using simple separation 
methods such as filtration.
30 
In this work, we present a general method to solubilize and stabilize 
hydrophobic TM catalysts while preserving catalytic activity using a water soluble AuNP 
platform (Scheme 5.1). This water soluble NP host was designed bearing two crucial features: an 
aliphatic interior to create hydrophobic pockets for catalyst encapsulation and a water soluble 
exterior for aqueous solubility.
[31] 
In our method, there is no need for covalent modification of the 
catalyst, and the supramolecular template supplies a protective niche for hydrophobic catalysts. 
Using this platform we demonstrate the efficiency of two commercially important reactions. 
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Scheme 5.1: a) The encapsulation process of hydrophobic catalysts in water soluble NP hosts. b) 
Schematic illustrating catalytic reaction within NP monolayer. 
 
5.2 Results and Discussion 
5.2.1 Encapsulation of Hoveyda-Grubbs 2
nd 
Generation (HG2) Catalyst into AuNP 
Monolayer 
Our initial catalysis studies focused on commercially available Hoveyda-Grubbs 2
nd
 
generation (HG2), widely used for ring opening metathesis polymerization (ROMP). 
Hydrophobic (HG2) catalysts were encapsulated using a solvent displacement method.
31 
Water 
soluble NP hosts and hydrophobic HG2 catalysts molecules were dissolved in acetone/water 
mixtures and then the organic solvents were allowed to evaporate slowly. During the evaporation 
process, HG2 catalysts were encapsulated into the hydrophobic pockets in the monolayer of 
AuNP, providing HG2 catalyst-encapsulated nanoreactors (AuNP-HG2), while excess 
hydrophobic catalyst precipitated out. Then filtrations using molecular weight cutoff filters were 
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performed to unbound catalysts followed by dialysis against water (Scheme 5.1 (a)) Other 
catalyst encapsulations were prepared in analogous fashion to obtain AuNP-cat nanoreactors.  
To determine parameters for effective catalyst design, two different sized gold cores (2 
and 7 nm), each with two different ligand structures (TTMA and TMA, Figure 2a) were 
investigated. Both TTMA and TMA ligands posses a hydrophobic chain, crucial for hydrophobic 
pocket formation and a charged ammonium head group for water solubility (Figure 5.1 (a)).  
 
Figure 5.1: a) The structure of NP hosts (core 2 and 7 nm) and the structure of TTMA and TMA 
ligands. b) The encapsulation efficacy of various NP hosts that have different core sizes and 
monolayer structures for HG2. 
 
Qualitative confirmation of catalyst presence in the monolayer of nanoreactor was 
monitored by 
1
H-NMR in D2O after encapsulation. Peaks observed at ~6.8-7.8 ppm demonstrate 
that 2
nd
 generation Hoveyda-Grubbs catalysts (HG2) were entrapped inside the nanoreactor 
(Figure 5.2). 
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Figure 5.2: a) Structure of the TTMA functionalized AuNP, b) NMR spectrum of HG2 catalyst 
encapsulated AuNP, c) Enlarged section of NMR spectrum in the range from 6 to 8 ppm.  
 
The aggregation of NPs during the encapsulation and intense purification steps can be an 
issue for the stability of the nanoreactor. The size of the NP host was monitored before and after 
encapsulation of HG2 as well as after the purification process by transmission electron 
microscopy (TEM). TEM images showed no size change or aggregation of the NP host-HG2 
compared to the NP host, displaying the stability of the nanoreactor (Figure 5.3). 
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Figure 5.3: TEM images of HG2 catalyst encapsulated AuNPs. 
  
Loaded catalyst amount in the monolayer of NP was calculated by tracking TM ions 
using KCN-induced decomposition experiments
 
followed by inductively coupled plasma mass 
spectrometry (ICP-MS) measurements. The results indicate that 7 nm core NP hosts can hold 
more catalysts, however, 2 nm core NPs shows higher encapsulation yield according to weight 
ratio between catalyst and NP core (Figure 5.1 (b)). When same core size but different ligand 
structure was considered, NP bearing TEG groups showed a higher catalyst loading efficiency. 
The surface ligand coverage was obtained using the laser desorption/ionization mass 
spectrometry
32
 to probe the effect of ligand coverage on encapsulation yield. The results revealed 
that the TTMA AuNPs possess more remaining pentane thiols after place exchange reaction than 
TMA AuNPs do, indicating that the pentane thiols provide a larger space to encapsulate the 
catalysts (Figure 5.4). Based on ICP-MS results, 2nm core sized TTMA NP host is the most 
efficient one among other NP hosts; therefore, catalytic reactions were performed using 2 nm 
TTMA NPs (Figure 5.1 (b)).  
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Figure 5.4: Ion intensity ratio of TMA and TTMA coated 2 and 7 nm AuNPs. 
 
5.2.2 Ring Opening Metathesis Polymerization in Aqueous Solution Using AuNP-HG2 
Our initial catalysis studies focused on commercially available HG2 catalyst, one of the 
most used hydrophobic catalysts for ring opening metathesis polymerization (ROMP). In our 
system, ROMP was performed in deionized water by using 2 nm TTMA AuNP-HG2 catalyst and 
a positively charged norbornene monomer (Figure 5.5 (a)-(b)).
33
 After 24 hours, white suspension 
was observed as an indication of polymer formation. However, when the exact same conditions 
except no catalyst encapsulated in the AuNPs was used, polymer generation was not detected. 
Effect of reaction time on polymerization was monitored by using gel permeation 
chromatography (GPC).  Polymers collected at different time points were characterized in terms 
of molecular weight and PDI (polydispersity index) (Figure 5.5 (d)). Results show a typical linear 
trend of living polymerization that molecular weight increases with elevated reaction time. 
Narrow PDI values were obtained as expected from a living ROMP reaction, indicating that our 
AuNP-HG2 system supplies the fine molecular weight control (Figure 5.5 (c)-(d)). 
Catalysts containing ruthenium carbene complexes in their structure generally decompose 
quickly in aqueous solvents
34
 and consequently, they are unable to catalyze ROMP reactions. In 
the literature, results indicated that instability originated from water coordination at ruthenium in 
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the methylidene-propagating species.
35
 We have checked the stability of free HG2 catalyst and 
found that in the presence of monomer and free HG2 catalyst in 1:1 acetone/water mixture, the 
reaction failed to produce any polymer. Therefore, GPC could only detect the unreacted monomer 
at various reaction time points (Figure 5.5 (d), 5 (f)). However, HG2 catalyst embedded into the 
monolayer of AuNPs successfully catalyzed the ROMP reaction under same conditions (Figure 
5.5 (d)-(e)). From these results, we deduce that our NP hosts can provide a protective 
environment blocking water molecules from coordinating to metal center and as a result prevent 
decomposition. 
 
Figure 5.5: a) The structure of 2
nd
 generation Hoveyda-Grubbs catalyst (HG2). b) The reaction 
scheme of ROMP using NP host and water soluble monomer. c) The molecular weight and PDI 
values of polymers in terms of reaction time. d) While the free HG2 in acetone/water mixture 
failed to produce the polymers, the polymers formation was detected in the presence of the 
AuNP-HG2, showing increased molecular weight in terms of reaction time. e) GPC result of NP 
host-HG2-monomer mixture after 24 h. f) GPC result of free catalyst-monomer mixture after 24 
h, no polymerization was observed. 
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5.2.3 Cleavage of Allylcarbamate Bonds Using Ruthenium or Palladium Catalyst 
Embedded AuNP 
The versatility of our encapsulation strategy was demonstrated by catalyzing the cleavage 
of allylcarbamate bonds using the hydrophobic [(pentamethylcyclopentadienyl) Ru(1,5-
cyclooctadiene)Cl] catalyst (Cp*Ru(cod)Cl) (Figure 5.6 (a), (c)).
36
 We have quantified that there 
are 22.7 ± 1.9 Cp*Ru(cod)Cl catalysts per one NP host.  Rhodamine 110 is a green fluorescent 
dye with amine functionality that can be protected with allylcarbamate. After caging, Rhodamine 
110 becomes nonfluorescent, however, upon allycarbamate deprotection, strong green 
fluorescence is recovered as an indication of catalytic cleavage (Figure 5.6 (c)-(e)). Reaction 
activity was monitored using UV absorbance of the Rhodamine 110 dye at a wavelength of 500 
nm wavelength. While absorbance increased linearly in the presence of substrate (Rhodamine 110 
derivative) and AuNP-Cp*Ru(cod)Cl, it stayed constant when only AuNP and substrate were 
used. 
 
 
 
 
 
 
 
 
 
 
Figure 5.6: The structure of a) Cp*Ru(cod)Cl and b) Pd(dppf)Cl2 catalyst. c) The reaction 
scheme of ruthenium-induced (or palladium-induced) allylcarbarmate cleavage using NP hosts 
and non-fluorescent Rhodamine 110 derivative. d) Catalytic activity of NP host- Cp*Ru(cod)Cl 
and only NP host. e) Photographs of the NP host reaction with and without ruthenium catalyst 
under UV-irradiation. f) Catalytic activity of NP host-Pd(dppf)Cl2 versus substrate and NP host. 
g) Photograph of the palladium catalysis under UV-irradiation with the control reactions. 
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Similar to ruthenium catalyst, palladium catalysts are also known to cleave the 
allylcarbamate of bis-N,N′-allyloxycarbonyl rhodamine 110.37 We have encapsulated (1,1′-
bis(diphenylphosphino) ferrocene)palladium(II)dichloride catalyst (Pd(dppf)Cl2) (Figure 5.6 (b)) 
in the hydrophobic pockets of the AuNP monolayer to provide AuNP-Pd(dppf)Cl2. The amount 
of palladium catalyst relative to AuNP was quantified using ICP-MS of 
106
Pd relative to 
197
Au. It 
was calculated that 12 ± 0.2 catalyst molecules were encapsulated per AuNP . Fluorescence 
started to increase immediately for AuNP-Pd(dppf)Cl2 after the addition of substrate, while no 
significant change in fluorescence was observed for only AuNP host (Figure 5.6 (f)-(g)). We 
checked the system after one week, results showed that fluorescence increased further for AuNP-
Pd(dppf)Cl2 while controls (only substrate and AuNP host + substrate) showed no fluorescence 
(Figure 5.7 and 5.8). 
 
 
 
 
 
 
Figure 5.7: Catalytic activity of NP host-Pd(dppf)Cl2 versus substrate and NP host after 24 h and 
7 days. 
 
Figure 5.8: Fluorescence increased further for AuNP-Pd(dppf)Cl2 while controls (only substrate 
and AuNP host + substrate without catalyst) showed no fluorescence after one week. 
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5.2.4 Hydrogenation of Alkenes Using Wilkinson’s Catalyst Encapsulated AuNP 
Another type of reaction we have studied for the AuNP host encapsulation process is the 
hydrogenation of alkenes. The complex RhCl(PPh3)3 (also known as Wilkinson’s catalyst ) is a 
hydrophobic, highly active catalyst for hydrogenation reactions. We encapsulated Wilkinson 
catalyst into the AuNP host and ICP-MS detected 29.7 ± 6.9 catalysts per NP host. 0.7 mole 
percent of NP-Wilkinson catalyst were reacted with sodium 4-vinylbenzenesulfonate in water 
under hydrogen (3 atm) at room temperature for various reaction times. Reactions were 
monitored by NMR; after hydrogenation, the alkene peaks coming between 5.2-6.8 ppm in the 
NMR spectrum disappear while triplet and quartet peaks appear due to the formation of ethyl 
group. The integration of those peaks was used to calculate conversion percentage of the 
hydrogenation. Results show ~100% conversion after 24 hours of reaction (Figure 5. 9 (c) and 
Figure 5.10). These hydrogenation experimental conditions prove the AuNP-cat system can 
effectively catalyze not only monophasic water solvent systems (ROMP reaction and 
allylcarbamate bond breakage) but also gas-water biphasic systems (hydrogenation reaction). 
 
 
Figure 5.9: a) The structure of Wilkinson catalyst. b) The reaction scheme of hydrogenation 
using NP host and sodium 4-vinylbenzenesulfonate. c) Hydrogenation conversion profile in 
terms of reaction time for AuNP-Wilkinson. d) Reusability test of AuNP-Wilkinson system for 
five consecutive cycles. 
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Figure 5.10: 
1
H-NMR spectra of the hydrogenation reactions in water at the different times (1, 3, 
6, 24, and 48 h). 
 
Catalytic reusability is an important factor in catalyzed reactions for industrial 
applications. We have examined the reusability of AuNP host-catalyst system for hydrogenation 
reaction. After the first reaction, a molecular weight cutoff filter (10 k) was used to separate 
AuNP-Wilkinson catalyst and the product, 4-ethylbenzenesulfonate. AuNP-Wilkinson catalyst 
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was recovered after three times washing and reacted again with substrate sodium 4-
vinylbenzenesulfonate under the same conditions (room temperature, 3 atm). This cycle repeated 
up to five times and 100% conversion was obtained as a proof of the recyclability of NP-catalyst 
template (Figure 5.9 (d) and Figure 5.11). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.11: 
1
H-NMR spectra of hydrogenation reactions for recyclability test, yielding 4-
ethylbenzenesulfonate as the final product. All of samples were measured after 24 h reaction. 
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5.3 Summary and Outlook 
In summary, we have developed a versatile AuNP-based platform for the encapsulation 
of hydrophobic catalysts through host-guest interactions. This supramolecular system eliminates 
the dependence on organic solvents and provides cost-effective and environmentally safe 
catalysis. Our NP platform is amenable to encapsulate a variety of catalysts and catalyze a 
multitude of reactions in aqueous environments without the need to specifically tailor the host’s 
structure for each hydrophobic catalyst. The functionalized monolayer of the NP host serves as a 
phase transfer agent for the catalyst while concurrently preventing catalyst ‘drowning’ through 
supramolecular stabilization. Future studies will explore the use of this platform in biological 
systems and as multifunctional catalytic reactors. 
5.4 Experimental Section 
5.4.1 Materials and Instruments 
All chemicals and materials for the experiments were obtained from Aldrich or Fisher 
Scientific. Reaction activities were monitored by a microplate reader (Molecular Device 
SpectroMax M2) for fluorescent product (Rhodamine 110). NMR spectroscopy (Bruker 
AVANCE 400 at 400 MHz) for hydrogenation and THF GPC (Agilent Technologies 1260 
Infinity) for ROMP reactions were used. 
5.4.2 Synthesis of TMA and TTMA Coated AuNPs 
First, Brust-Schiffrin two-phase synthesis method
 
was used to synthesize pentanethiol-
coated AuNPs with core diameter ca. 2 nm
38,39 
and 7 nm
40
. Murray place-exchange method
41
 was 
followed to obtain the TTMA or TMA ligand protected AuNPs. Pentanethiol-conjugated AuNPs 
(10 mg, 2 nm) or Dodecanethiol-conjugated AuNP (10 mg, 7 nm) and TTMA or TMA ligand (27 
mg) were dissolved in dry DCM and stirred under N2 atmosphere for 3 days at room temperature. 
The DCM was removed under reduced pressure and the resulting precipitate was washed with 
hexane three times and DCM twice. Then the precipitate was dissolved in distilled water and 
124 
 
dialyzed for three days (membrane molecular weight cut-off =10,000) to remove excess ligands, 
pentanethiol/dodecanetiol, acetic acid, and other salts present in the nanoparticle solution. After 
dialysis, the particle was lyophilized to yield a solid brownish product. The particles were then 
redispersed in deionized water.
42
  
5.4.3 Encapsulation of the Catalysts 
The catalysts (Grubbs, Cp*Ru(cod)Cl, (Pd(dppf)Cl2), or Wilkinson catalysts) and the 
AuNPs were dissolved in an acetone/water or tetrahydrofuran/acetone/water mixture. In the case 
of the 2 nm sized AuNPs, 1 ml of 20 μM AuNP solutions and 1 mg of each hydrophobic catalyst 
in 1 ml of acetone or tetrahydrofuran/acetone (1:9, v/v) were mixed. The 0.5 ml of 400 nM 
solutions was used for 7 nm sized AuNPs.  For the 7 nm AuNPs, 0.1 mg of Grubbs catalyst (HG2 
) was used. Then the acetone and tetrahydrofuran was slowly removed by evaporation. During the 
evaporation, most of the catalysts were encapsulated in monolayers and the remainder of the 
hydrophobic catalysts precipitated. The precipitate was removed by filtration and the AuNPs 
were purified by multiple filtrations through a molecular-weight cutoff filter to remove free 
catalysts, followed by dialysis against water to remove free catalysts in water.
43
  
5.4.4 Quantification of the Catalysts 
The ICP-MS analyses were performed on a Perkin-Elmer NexION 300X ICP mass 
spectrometer. 
197
Au, 
102
Ru, 
106
Pd, and 
103
Rh were measured under the standard mode. Operating 
conditions are listed as below: nebulizer flow rate: 0.95 L/min; rf power: 1600 W; plasma Ar 
flow rate: 18 L/min; dwell time: 50 ms. Standard gold, ruthenium, palladium, and rhodium 
solutions (concentration: 0, 0.2, 0.5, 1, 2, 5, 10, and 20 ppb) were prepared for the quantification.  
5.4.4.1 ICP-MS Sample Preparation for the Quantification of Gold, Ruthenium, Palladium, 
and Rhodium  
0.5 mL of fresh aqua regia was added to the 10 uL sample solution and then the sample 
was diluted to 10 mL with de-ionized water. 
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Table 5.1: Quantification of encapsulated catalysts in the 2 nm TTMA-AuNP. 
 
 
5.4.5 Laser Desorption/Ionization Mass Spectrometry (LDI-MS) Instrumentation: 
The surface ligand coverage comparison was done using the previous reported LDI-MS 
method.
44
 The mixed disulphide ions were formed by TTMA/TMA ligand and original 
alkanethiol ligand. Higher amount of remaining alkanethiol ligands result in higher ion intensity 
ratio between the mixed disulphide ion and the intensity sum of TMA/TTMA ligand and mixed 
disulphide ion.
5
 The quantification data was acquired on a Bruker Autoflex III MALDI-TOF 
mass spectrometer (Bruker Daltonics, Bremen, Germany) (Autoflex III). Operating conditions 
were as follows: ion source 1 = 19.00 kV, ion source 2 = 16.60 kV, lens voltage = 8.44 kV, 
reflector voltage = 20.00 kV, reflector voltage 2 = 9.69 kV, pulsed ion extraction time = 10 ns, 
suppression = 100 Da, and at positive reflectron mode. Molecular ion and mixed disulphide ion 
from each molecule has been chosen as quantification ion in the data analysis, for example: 
TTMA (m/z 422), TMA (m/z 246), TTMA-C5 (m/z 524), and TMA-C5 (m/z 348). 40 mass 
spectra have been acquired for each sample, and each mass spectrum represents an average of 200 
laser shots. 
5.4.6 ROMP Reaction in Water by Using AuNP-HG2 
520 nM of HG2 catalyst encapsulated 2 nm TTMA NPs was mixed with 6 mM of water 
soluble norbornene monomer in 3 ml water. After polymerization, water was lyophilized to yield 
a solid brownish product and THF (0.5 mL) was added to separate NP host and polymer from 
each other. NP host remained insoluble in THF while obtained polymers are transferred into THF 
126 
 
layer. Polymerization reaction was monitored for 1, 4, 6, and 24 h and THF GPC (Agilent 
Technologies 1260 Infinity) was used to calculate molecular weights and PDI values of polymers. 
 
Figure 5.12: Photos of the reaction mixtures including a) NP Host or b) NP Host-HG2 after 24 h 
reactions. 
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Figure 5.13: GPC spectra of the polymers that were synthesized by ROMP in water at different 
time intervals (1, 4, 6, and 24 h). 
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Figure 5.14: GPC spectra of reactions that were performed using free catalysts in acetone/water 
mixture at different time intervals (1, 4, 6, and 24 h). 
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5.4.7 Allyl Carbamate Bond Cleavage Reaction by Using AuNP-Cp*Ru(cod)Cl or AuNP-
(Pd(dppf)Cl2) 
Cp*Ru(cod)Cl or (Pd(dppf)Cl2) encapsulated 2 nm TTMA NPs (194 nM) was mixed 
with caged Rhodamine 110 (220 μM) in a final volume of 1 ml water. Green fluorescence of 
Rhodamine 110 was observed as result of catalytic allycarbamate deprotection reaction. UV 
absorbance of the Rhodamine 110 at a wavelength of 500 nm wavelength was monitor for 
reaction activity. Fluoresence intensity of  Rhodamine 110 was monitored at λex = 480 nm, λem 
= 530 nm, and  λcutoff= 515 nm. 
5.4.8 Hydrogenation of Sodium 4-vinylbenzenesulfonate via AuNP-Wilkinson Catalyst 
Wilkinson catalyst encapsulated 2 nm TTMA NPs (23 μM, 1.2 mL) was mixed with 
sodium 4-vinylbenzenesulfonate (2.3 mg, 0.8 mL) in water under 3 atm H2 at room temperature. 
Reactions were monitored by NMR for various time intervals (1, 3, 6, 24, 48 h). For the 
reusability test, same conditions were applied.  
 
 
 
 
 
 
 
 
 
 
 
 
130 
 
5.5 References
 
(1)  a) Leenders, S. H. A. M.; Gramage-Doria, R.; de Bruin, B.; Reek, J. N. H. Transition 
metal catalysis in confined spaces. Chem. Soc. Rev. 2015, 44, 433–448. b) Butler, R. N.; 
Coyne, A. G. Water: Nature’s Reaction Enforcer—Comparative Effects for Organic 
Synthesis “In-Water” and “On-Water”. Chem. Rev. 2010, 110, 6302–6337. c) Yin, Q.; 
Tan, J. M.; Besson, C.; Geletii, Y. V.; Musaev, D. G. A fast soluble carbon-free 
molecular water oxidation catalyst based on abundant metals. Science 2010, 328, 342–
345. d) Cornils, B.; Hermann, W. A.; Eds; Aueous-Phase Organometallic Catalysis, 
Wiley-VCH: Weinheim, Germany, 2004. 
(2)  a) Rios-Lombardia, N.; Vidal, C.; Liardo, E.; Moris, F.; Garcia-Alvarez, J.; Gonzalez-
Sabin, J. From a Sequential to a Concurrent Reaction in Aqueous Medium: Ruthenium-
Catalyzed Allylic Alcohol Isomerization and Asymmetric Bioreduction. Angew. Chem. 
Int. Ed. 2016, 55, 8691–8695. b) Blackmond, D. G.; Armstrong, A; Coombe, V.; Wells, 
A. Water in Organocatalytic Processes: Debunking the Myths. Angew. Chem. Int. Ed. 
2007, 46, 3798–3800. c) Lindstrom, U. M. Chem. Rev. 2002, 102, 2751. d) Li, C. J.; 
Chan, T. H.  Comprehensive Organic Reactions in Aqueous Media, 2
nd
 ed.; Wiley: New 
York, 2007. 
(3)  Lancaster, M. in Green Chemistry: An Introductory Text (Ed.: M. Lancaster),The Royal 
Society of Chemistry, London, 2002. 
(4)  Hong, S. H.; Grubbs, R. H. Highly Active Water-Soluble Olefin Metathesis Catalyst. J. 
Am. Chem. Soc. 2006, 128, 3508–3509. 
(5)  a) Himeda, Y.; Onozawa-Komatsuzaki, N.; Sugihara, H.; Kasuga, K. Simultaneous 
Tuning of Activity and Water Solubility of Complex Catalysts by Acid−Base 
Equilibrium of Ligands for Conversion of Carbon Dioxide. Organometallics 2007, 26, 
702–712. b) Cole-Hamilton, D. J. Homogeneous catalysis--new approaches to catalyst 
separation, recovery, and recycling. Science 2003, 299, 1702–1706. 
(6)  a) Lynn, D. M.;  Mohr, B.; Grubbs, R. H.; Henling, L. M.; Day, M.W. Water-Soluble 
Ruthenium Alkylidenes:  Synthesis, Characterization, and Application to Olefin 
Metathesis in Protic Solvents. J. Am. Chem. Soc. 2000, 122, 6601–6609. b) Gallivan, J. 
P.; Jordan, J. P.; Grubbs, R. H. A neutral, water-soluble olefin metathesis catalyst based 
on an N-heterocyclic carbene ligand. Tetrahedron Lett. 2005, 46, 2577–2580. 
(7)  a) Toma´s-Gamasa, M.; Martı´nez-Calvo, M.; Couceiro, J. R.; Mascaren˜as, J. L. 
Transition metal catalysis in the mitochondria of living cells. Nat. Commun. 2016, 
7(12538), 1. b) Schaper, L.-A.; Hock, S. J.; Herrmann, W. A.; Kühn, F. E. Synthesis and 
Application of Water-Soluble NHC Transition-Metal Complexes. Angew. Chem. Int. Ed. 
2013, 52, 270–289. c) Samanta, D.; Kratz, K.; Zhang, X.; Emrick, T. A Synthesis of 
PEG- and Phosphorylcholine-Substituted Pyridines To Afford Water-Soluble Ruthenium 
Benzylidene Metathesis Catalysts. Macromolecules 2008, 41, 530–532. d) Nishioka, T.; 
Shibata, T.; Kinoshita, I. Sugar-Incorporated N-Heterocyclic Carbene Complexes. 
 
131 
 
 
Organometallics 2007, 26, 1126–1128. e) Shi, J.-C.; Lei, N.; Tong, Q.; Peng, Y.; Wei, J.; 
Jia, L. Synthesis of Chiral Imidazolinium Carbene from a Carbohydrate and Its 
Rhodium(I) Complex. Eur. J. Inorg. Chem. 2007, 2221–2224. f) Zhang, X.; Qiu, Y.; Rao, 
B.; Luo, M. Palladium(II)−N-Heterocyclic Carbene Metallacrown Ether Complexes: 
Synthesis, Structure, and Catalytic Activity in the Suzuki−Miyaura Reaction. 
Organometallics 2009, 28, 3093–3099. 
(8)  a) Bellini, R.; Chikkali, S. H.; Berthon-Gelloz, G.; Reek, J. N. H. Supramolecular Control 
of Ligand Coordination and Implications in Hydroformylation Reactions. Angew. Chem. 
Int. Ed. 2011, 50, 7342–7345. b) Bellini, R.; Reek, J. N. H. Coordination Studies on 
Supramolecular Chiral Ligands and Application in Asymmetric Hydroformylation. 
Chem.–Eur. J. 2012, 18, 7091–7099. c) Mesnager, J.; Lammel, P.; Jeanneau, E.; Pinel, C. 
Mixed N-heterocyclic carbene and phosphine palladium complexes for telomerization of 
butadiene with methanol. Appl. Catal. A 2009, 368, 22–28. d) Syska, H.; Herrmann, W. 
A.; Kahn, F. E. Water-soluble carbene complexes as catalysts for the hydrogenation of 
acetophenone under hydrogen pressure. J. Organomet. Chem. 2012, 703, 56–62. e) 
Almassy, A.; Nagy, C. E.; Banyei, A. C.; Joa, F. Novel Sulfonated N-Heterocyclic 
Carbene Gold(I) Complexes: Homogeneous Gold Catalysis for the Hydration of Terminal 
Alkynes in Aqueous Media. Organometallics 2010, 29, 2484–2490. f) Godoy, F.; 
Segarra, C.; Poyatos, M.; Peris, E. Palladium Catalysts with Sulfonate-Functionalized-
NHC Ligands for Suzuki−Miyaura Cross-Coupling Reactions in Water. Organometallics 
2011, 30, 684–688. 
(9)  a) Elemans, J. A. A. W.; Bijsterveld, E. J. A.; Rowan, A. E.; Nolte, R. J. M. A host–guest 
epoxidation catalyst with enhanced activity and stability. Chem. Commun. 2000, 2443–
2444. b) Mohr, B.; Lynn, D. M.; Grubbs, R. H. Synthesis of Water-Soluble, Aliphatic 
Phosphines and Their Application to Well-Defined Ruthenium Olefin Metathesis 
Catalysts. Organometallics 1996, 15, 4317–4325. c) Kirkland, T. A.; Lynn, D. M.; 
Grubbs, R. H. Ring-Closing Metathesis in Methanol and Water. J. Org. Chem. 1998, 63, 
9904–9909. d) Lynn, D. M.; Grubbs, R. H. Novel Reactivity of Ruthenium Alkylidenes 
in Protic Solvents:  Degenerate Alkylidene Proton Exchange. J. Am. Chem. Soc. 2001, 
123, 3187–3193. e) Kamer, P. C.; van Leeuwen, P. W.; Reek, J. N. Wide Bite Angle 
Diphosphines:  Xantphos Ligands in Transition Metal Complexes and Catalysis. Acc. 
Chem. Res. 2001, 34, 895–904. f) Linker, T. The Jacobsen–Katsuki Epoxidation and Its 
Controversial Mechanism. Angew. Chem. Int. Ed. Engl. 1997, 36, 2060–2062. 
(10)  Burtscher, D.; Grela, K. Aqueous olefin metathesis. Angew. Chem. Int. Ed. 2009, 48, 
442–454. 
(11)  Horvath, I. T.; Joo, F.; Grubbs, R. H. Eds.; in Aqueous Organometallic Chemistry and 
Catalysis; Kluwer Academic Publishers: The Netherlands, 1995. 
(12)  a) Jouffroy, M.; Gramage-Doria, R.; Armspach, D.; Se´meril, D.; Oberhauser, W.; Matt, 
D.; Toupet, L. Confining Phosphanes Derived from Cyclodextrins for Efficient Regio- 
and Enantioselective Hydroformylation. Angew. Chem. Int. Ed. 2014, 53, 3937–3940. b) 
Guitet, M.; Zhang, P.; Marcelo, F.; Tugny, C.; Jime´nez-Barbero, J.; Buriez, O.; 
 
132 
 
 
Amatore, C.; Mourie`s-Mansuy, V.; Goddard, J.-P.;  Fensterbank, L.; Zhang, Y.; Roland, 
S.; Me´nand, M.; Sollogoub, M. NHC-Capped Cyclodextrins (ICyDs): Insulated Metal 
Complexes, Commutable Multicoordination Sphere, and Cavity-Dependent Catalysis. 
Angew. Chem. Int. Ed. 2013, 52, 7213–7218. c) Hapiot, F.; Tilloy, S.; Monflier, E. Chem. 
Rev. 2006, 106, 767–. d) Breslow, R. Biomimetic Chemistry and Artificial Enzymes: 
Catalysis by Design. Acc. Chem. Res. 1995, 28, 146–153. 
(13)  Ikeda, A.; Shinkai, S. Novel Cavity Design Using Calix[n]arene Skeletons:  Toward 
Molecular Recognition and Metal Binding. Chem. Rev. 1997, 97, 1713–1734. 
(14)  a) Ong, W.; Kaifer, M. G.; Kaifer, A. E. Cucurbit[7]uril:  A Very Effective Host for 
Viologens and Their Cation Radicals. Org. Lett. 2002, 4, 1791–1794. b) Jeon, W. S.; 
Moon, K.; Park, S. H.; Chun, H.; Ko, Y. H.; Lee, J. Y.; Lee, E. S.; Samal, S.; Selvapalam, 
N.; Rekharsky, M. V.; Sindelar, V.; Sobransingh, D.; Inoue, Y.; Kaifer, A. E.; Kim, K. 
Complexation of Ferrocene Derivatives by the Cucurbit[7]uril Host:  A Comparative 
Study of the Cucurbituril and Cyclodextrin Host Families. J. Am. Chem. Soc. 2005, 127, 
12984–12989. c) Lagona, J.; Mukhopadhyay, P.; Chakrabarti, S.; Isaacs, L. The 
Cucurbit[n]uril Family. Angew. Chem. Int. Ed. 2005, 44, 4844–4870. 
(15)  Brown, C. J.; Miller, G. M.; Johnson, M. W.; Bergman, R. G.; Raymond, K. N. High-
Turnover Supramolecular Catalysis by a Protected Ruthenium(II) Complex in Aqueous 
Solution. J. Am. Chem. Soc. 2011, 133, 11964–11966. 
(16)  Fiedler, D.; Leung, D. H.; Bergman, R. G.; Raymond, K. N. Selective Molecular 
Recognition, C−H Bond Activation, and Catalysis in Nanoscale Reaction Vessels. Acc. 
Chem. Res. 2005, 38, 351–358. 
(17)  a) Dwars, T.; Haberland, J.; Grassert, I.; Oehme, G.; Kragl, U. Asymmetric 
hydrogenation in a membrane reactor: recycling of the chiral catalyst by using a 
retainable micellar system. J. Mol. Catal. A-Chem. 2001, 168, 81–86. b) Liu, S.; Weaver, 
J. V. M.; Save, M.; Armes, S. P. Synthesis of pH-Responsive Shell Cross-Linked 
Micelles and Their Use as Nanoreactors for the Preparation of Gold Nanoparticles. 
Langmuir 2002, 18, 8350–8357. c) Liu, Y.; Wang, Y.; Wang, Y.; Lu, J.; Piñón, V.; 
Weck, M. Shell Cross-Linked Micelle-Based Nanoreactors for the Substrate-Selective 
Hydrolytic Kinetic Resolution of Epoxides. J. Am. Chem. Soc. 2011, 133, 14260–14263. 
d) Newkome, G. R.; Shreiner, C. Dendrimers Derived from 1 → 3 Branching Motifs. 
Chem. Rev. 2010, 110, 6338–6342. 
(18)  a) Liu, C.-P.; Wu, T.-H.; Lin, Y.-L.; Liu, C.-Y.; Wang, S.; Lin, S-Y. Tailoring Enzyme-
Like Activities of Gold Nanoclusters by Polymeric Tertiary Amines for Protecting 
Neurons against Oxidative Stress. Small 2016, 12, 4127–4135. b) Deraedt, C.; Pinaud, 
N.; Astruc, D. Recyclable Catalytic Dendrimer Nanoreactor for Part-Per-Million CuI 
Catalysis of “Click” Chemistry in Water. J. Am. Chem. Soc. 2014, 136, 12092–12098. c) 
Ooe, M.; Murata, M.; Mizugaki, T.; Ebitani, K.; Kaneda, K. Dendritic Nanoreactors 
Encapsulating Pd Particles for Substrate-Specific Hydrogenation of Olefins. Nano Lett. 
2002, 2, 999–1002. d) Ooe, M.; Murata, M.; Mizugaki, T.; Ebitani, K.; Kaneda, K. 
 
133 
 
 
Supramolecular catalysts by encapsulating palladium complexes within dendrimers. J. 
Am. Chem. Soc. 2004, 126, 1604–1605. 
(19)  Che, H.; van Hest, J. C. M. Stimuli-responsive polymersomes and nanoreactors. J. Mater. 
Chem. B 2016, 4, 4632–4647.  
(20)  a) Jia, Y.; Shmakov, S. N.; Register, P.; Pinkhassik, E. Size-Selective Yolk-Shell 
Nanoreactors with Nanometer-Thin Porous Polymer Shells. Chem.-Eur. J. 2015, 21, 
12709–12714. b) Dergunov, S. A.; Durbin, J.; Pattanaik, S.; Pinkhassik, E. pH-Mediated 
Catch and Release of Charged Molecules with Porous Hollow Nanocapsules. J. Am. 
Chem. Soc. 2014, 136, 2212–2215. 
(21)  a) Gao, Z.; Dong, M.; Wang, G.; Sheng, P.; Wu, Z.; Yang, H.; Zhang, B.; Wang, G.; 
Wang, J.; Qin, Y. Multiply Confined Nickel Nanocatalysts Produced by Atomic Layer 
Deposition for Hydrogenation Reactions. Angew. Chem. Int. Ed. 2015, 54, 9006–9010. b) 
Chen, Z.; Guan, Z.; Li, M.; Yang, Q.; Li, C. Enhancement of the Performance of a 
Platinum Nanocatalyst Confined within Carbon Nanotubes for Asymmetric 
Hydrogenation. Angew. Chem. Int. Ed. 2011, 50, 4913–4917. c) Mahmoud, M. A.; Saira, 
F.; El-Sayed, M. A. Experimental Evidence for the Nanocage Effect in Catalysis with 
Hollow Nanoparticles. Nano Lett. 2010, 10, 3764–3769. 
(22)  Zhang, S.; Zhao, Y. Artificial metalloenzymes via encapsulation of hydrophobic 
transition-metal catalysts in surface-crosslinked micelles (SCMs). Chem. Commun. 2012, 
48, 9998–10000. 
(23)  Wang, F.; Liu, H.; Cun, L.; Zhu, J.; Deng, J.; Jiang, Y. Asymmetric Transfer 
Hydrogenation of Ketones Catalyzed by Hydrophobic Metal−Amido Complexes in 
Aqueous Micelles and Vesicles. J. Org. Chem. 2005, 70, 9424–9429. 
(24)  a) McQuade, D. T.; Seeberger, P. H. J. Org. Chem. 2013, 78, 6384–; b) Kamata, K.; Lu, 
Y.; Xia, Y. Synthesis and Characterization of Monodispersed Core−Shell Spherical 
Colloids with Movable Cores. J. Am. Chem. Soc. 2003, 125, 2384–2385. 
(25)  a) Bae, Y. H.; Yin, H. Stability issues of polymeric micelles. J. Control. Release 2008, 
131, 2–4. b) Chen, H.; Kim, S.; Li, L.; Wang, S.; Park, K.; Cheng, J. X. Release of 
hydrophobic molecules from polymer micelles into cell membranes revealed by Förster 
resonance energy transfer imaging. Proc. Natl. Acad. Sci. U.S.A. 2008, 105, 6596–6601. 
(26)  Shmakov, S. N.; Pinkhassik, E. Simultaneous templating of polymer nanocapsules and 
entrapped silver nanoparticles. Chem.Commun. 2010, 46, 7346–7348.  
(27)  Lou, X. W.; Archer, L. A.; Yang, Z. Hollow Micro-/Nanostructures: Synthesis and 
Applications. Adv. Mater. 2008, 20, 3987–4019. 
 
134 
 
 
(28)  a) Hu, A.; Liu, S.; Lin, W. Immobilization of chiral catalysts on magnetite nanoparticles 
for highly enantioselective asymmetric hydrogenation of aromatic ketones. RSC Adv. 
2012, 2, 2576–2580. b) Wang, D.; Salmon, L.; Ruiz, J.; Astruc, D. A recyclable 
ruthenium(II) complex supported on magnetic nanoparticles: a regioselective catalyst for 
alkyne–azide cycloaddition. Chem. Commun. 2013, 49, 6956–6958.  
(29)  Dergunov, S. A.; Khabiyev, A. T.; Shmakov, S. N.; Kim, M. D.; Ehterami, N.; Weiss, M. 
C.; Birman, V. B.; Pinkhassik, E. Encapsulation of Homogeneous Catalysts in Porous 
Polymer Nanocapsules Produces Fast-Acting Selective Nanoreactors. ACS Nano 2016, 
10, 11397–11406.  
(30)  Thomas, J. M.; Hernandez-Garrido, J. C.; Raja, R.; Bell, R. G. Nanoporous oxidic solids: 
the confluence of heterogeneous and homogeneous catalysis. Phys. Chem. Chem. Phys. 
2009, 11, 2799–2825.  
(31)  Kim, C. K.; Ghosh, P.; Pagliuca, C.; Zhu, Z.-J.; Menichetti, S.; Rotello, V. M. 
Entrapment of Hydrophobic Drugs in Nanoparticle Monolayers with Efficient Release 
into Cancer Cells. J. Am. Chem. Soc. 2009, 131, 1360–1361. 
(32)  Yan, B.; Zhu, Z.-J.; Miranda, O. R.; Chompoosor, A.; Rotello, V. M.; Vachet, R. W. 
Laser desorption/ionization mass spectrometry analysis of monolayer-protected gold 
nanoparticles. Anal. Bioanal. Chem. 2010, 396, 1025–1035. 
(33)  Lynn, D. M.; Mohr, B.; Grubbs, R. H. Living Ring-Opening Metathesis Polymerization 
in Water. J. Am. Chem. Soc. 1998, 120, 1627–1628. 
(34)  a) Binder, J. B.; Blank, J. J.; Raines, R. T. Olefin Metathesis in Homogeneous Aqueous 
Media Catalyzed by Conventional Ruthenium Catalysts. Org. Lett. 2007, 9, 4885–4888. 
b) Burtscher, D.; Grela, K. Aqueous Olefin Metathesis. Angew. Chem. Int. Ed. 2009, 48, 
442–454.  
(35)  Ulman, M.; Grubbs, R. H. Ruthenium Carbene-Based Olefin Metathesis Initiators:  
Catalyst Decomposition and Longevity. J. Org. Chem. 1999, 64, 7202–7207. 
(36)  Streu, C.; Meggers, E. Ruthenium-induced allylcarbamate cleavage in living cells. 
Angew. Chem. Int. Ed.  2006, 45, 5645–5648.  
(37)  Yusop, R. M.; Unciti-Broceta, A.; Johansson, E. M. V.; Sánchez-Martín, R. M.; Bradley, 
M. Palladium-mediated intracellular chemistry. Nature Chem. 2011, 3, 239–243. 
(38)  Kanaras, A. G.; Kamounah, F. S.; Schaumburg, K.; Kiely, C. J.; Brust, M. Thioalkylated 
tetraethylene glycol: a new ligand for water soluble monolayer protected gold clusters. 
Chem. Commun. 2002, 2294–2295. 
 
135 
 
 
(39)  Brust, M.; Walker, M.; Bethell, D.; Schiffrin, D. J. Synthesis of thiol-derivatised gold 
nanoparticles in a two-phase Liquid–Liquid system. J. Chem. Soc. Chem. Commun. 1994, 
801–802. 
(40)  Park, M.-H.; Agasti, S. S.; Creran, B.; Kim, C.; Rotello, V. M. Controlled and Sustained 
Release of Drugs from Dendrimer–Nanoparticle Composite Films. Adv. Mater. 2011, 23, 
2839–2842. 
(41)  Templeton, A. C.; Wuelfing, W. P.; Murray, R. W. Monolayer-Protected Cluster 
Molecules. Acc. Chem. Res. 2000, 33, 27–36. 
(42)  a) Kim, C. S.; Li, X.; Jiang, Y.; Yan, B.; Tonga, G. Y.; Ray, M.; Solfiell, D. J.; Rotello, 
V. M. Cellular imaging of endosome entrapped small gold nanoparticles. MethodsX 2015, 
2, 306–315. b) Moyano, D. F.; Duncan, B.; Rotello, V. M. Preparation of 2 nm gold 
nanoparticles for in vitro and in vivo applications. Methods Mol. Biol. 2013, 1025, 3–8. 
(43)  Tonga, G. Y.; Jeong, Y.; Duncan, B. ; Mizuhara, T.; Mout, R.; Das, R.; Kim, S. T.; Yeh, 
Y. –C.; Yan, B.; Hou, S.; Rotello, V. M. Supramolecular regulation of bioorthogonal 
catalysis in cells using nanoparticle-embedded transition metal catalysts. Nat. Chem. 
2015, 7, 597–603.   
 
136 
 
CHAPTER 6 
ENHANCING CATALYTIC ACTIVITY OF NANOZYME BY MONOLAYER 
ENGINEERING 
6.1 Introduction 
Transition metal catalysis (TMC) has received considerable attention for the potential 
abiotic reactions in biological system. Their bioorthogonality and high turnover rate can provide 
selective and efficient chemistries in living systems.
1
 Numerous types of TMCs have been 
demonstrated to be used for cell imaging,
2
 enzyme regulation,
3
 protein-,
4
 and cell-labeling
5
 
strategies. Despite these significant advantages, hydrophobicity and low water solubility of TMCs 
result in nonspecific interactions with biomolecules, inducing protein aggregation and 
denaturation.
6
 Additionally, it has been recently reported that free TMC could inhibit the protein 
expression.
7
 As a result, several TMCs with hydrophilic ligands have been developed to improve 
their water solubility, but it adversely decreases cell membrane permeability, reducing the 
potential for intracellular chemistry.
5
 Therefore, the development of catalytic platform which 
prevents TMC from interaction with biological molecules is needed to improve their utility. 
Nanomaterials have been utilized as highly dispersible and biocompatible scaffolds for 
broad range of bio-applications.
8
 These materials commonly possess the surface monolayer to 
improve their solubility and control the biological interactions,
9
 so such layer could provide 
TMCs with a protective environment. Besides, this approach could design the nanomaterial-TMC 
complexes, so-called “nanozyme” with multiple catalytic centers10 which afford the higher local 
concentration of TMC inside cell than free TMC systems. Recently, the groups of Bradley and 
Unciti-Broceta synthesized palladium (0) nanoparticle bound-polystyrene microsphere (0.5-150 
µm) and demonstrated that palladium nanoparticle mediated reaction can induce the activation of 
fluorophore or prodrug.
11
 In the course of our researches, we have utilized gold nanoparticles 
(AuNPs) (ca. 2 nm core size) with surface monolayer featuring two layers such as hydrophobic 
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(green, Scheme 6.1), hydrophilic layers (blue) and found that hydrophobic layer of nanoparticle 
surface can capture the hydrophobic catalyst.
12
 The number of encapsulated catalyst dictates the 
catalytic activity, however, is insufficient, resulting in slow reaction rate. For the efficient 
amplification of catalytic process, the higher catalytic activity is preferred. Nevertheless, the 
structural information to improve the amount of TMC per particle and hence catalytic activity has 
been lacked. In this work, we present the development of five different AuNP-Cp*Ru(cod)Cl 
(Cp* = pentamethylcyclopentadienyl, cod = cyclooctadiene) complexes to provide the structural 
information for an efficient catalytic activity. By examining the chemical structure of 
hydrophobic layer of nanoparticle surface, we have improved the catalyst loading per particle, 
increasing the catalytic efficiency for the activation of profluorogenic N,N’-bisallyloxycarbonyl 
rhodamine 110 in aqueous solution. 
 
Scheme 6.1: Schematic showing the increase in the catalyst loading in three nanozymes used in 
the study. 
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6.2 Results and Discussion 
6.2.1 Design of AuNP Monolayer  
Catalytic scaffold we utilized for previous research has 11-carbon chain which forms a 
hydrophobic layer on AuNP which drives the hydrophobic catalyst encapsulation. For the 
enhanced catalyst loading, we designed four different nanozyme monolayers: C16, Phenyl, 
Naphthyl, and Pyrene AuNP (Figure 6.1). C16-AuNP is obtained by introducing additional 5-
carbon to increase the volume of hydrophobic layer. In addition, we also introduced phenyl, 
naphthyl and pyrene moieties into hydrophobic layer to afford the favorable π-π stacking 
interactions between nanoparticle ligand and Cp*Ru(cod)Cl.  
 
Figure 6.1: Monolayer structures of nanozymes used in the study. 
 
6.2.2 Encapsulation of Hydrophobic Cp*Ru(cod)Cl Catalyst into AuNP 
With newly developed AuNPs, we carried out the encapsulation of Cp*Ru(cod)Cl 
(Figure 6.2). An aqueous solution of AuNPs was mixed with the solution of Cp*Ru(cod)Cl in 
acetone. The mixture was slowly evaporated in vacuo, and sonicated. After the filtration, we 
carried out the dialysis to remove unbound Ru catalyst. Purified AuNPs-Cp*Ru(cod)Cl 
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complexes were subjected to characterization such as dynamic light scattering and are highly 
soluble in aqueous solution.  
 
Figure 6.2: Catalyst encapsulation into the monolayer of nanozyme. 
 
In addition, inductively coupled plasma mass spectrometry (ICP-MS) determined the 
amount of Cp*Ru(cod)Cl encapsulated into each functionalized AuNPs and we detected around 
three times more catalyst in C16 and Phenyl AuNP and around five times more in Naphthyl and 
Pyrene AuNP compared to C11 AuNP (Figure 6.3). These are because of increase of volume of 
hydrophobic pocket as well as the strong π-π interaction between catalyst and hydrophobic pocket 
as expected. 
 
Figure 6.3: Amount of catalyst in nanozymes. All experiments were carried out in triplicate, and 
error bars represent standard deviation. 
 
140 
 
6.2.3 Catalytic Activity of Nanozymes in Solution 
Next, we investigated the catalytic activity of synthesized nanozymes. To examine the 
activity, we used N,N’-allyloxycarbonyl rhodamine 110 as a substrate which is non fluorescent 
molecule and can be activated to fluorescent molecule in the presence of Cp*Ru(cod)Cl catalyst 
(Figure 6.4).  
 
Figure 6.4: Activation of bisallyloxycarbonyl rhodamine 110 catalyzed by AuNP_Ru nanozyme. 
 
Nanozymes (0.5 µM) are dissolved in the solution of N,N’-allyloxycarbonyl rhodamine 
110 (110 µM) in 5 mM phosphate buffer (PB), and tracked the time dependent increase of 
fluorescent (Excitation 485nm, Emission 535 nm, Cutoff 515 nm). As a result, we observed 
enhanced catalytic activity of C16, Phenyl, Naphthyl, and Pyrene-AuNP compared to C11-AuNP. 
C16 showed around 3 times higher catalytic activity than C11 counterpart presumably because of 
the enhancement of catalyst amount per particle as well as increase of surface area of 
hydrophobic pocket by the introduction of additional C5 chain. Naphthyl and Pyrene exhibited 
the highest activity among five nanozymes, showing around 7-8 times stronger activity than 
nanozyme bearing C11 chain (Figure 6.5). Notably, no reaction was observed with the AuNPs 
without catalyst formulation. 
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Figure 6.5: Catalytic activity of nanozymes under ambient temperature. All experiments were 
carried out in triplicate, and error bars represent standard deviation. 
 
6.2.4 Catalytic Activity inside Living Cells 
Having characterized the activity of nanozyme catalysis in solution, we next studied the 
intracellular behavior of these nanozymes. We preformed the activation of prodrugs inside cells 
using nanozymes bearing five different monolayer designs. We protected amine of Doxorubicin 
(Dox) using allylcarbamate moiety to convert toxic Dox into non-toxic prodrug form (Alloc-Dox) 
(Figure 6.6). Deprotection of alloc groups by ruthenium catalyst embedded nanozymes yields the 
toxic Dox, resulting in cell death (Figure 6.7). 
 
Figure 6.6: Activation of pro-Dox using ruthenium catalyst embedded nanozyme. 
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Figure 6.7: Cell viability of Dox versus pro-Dox (Alloc-Dox). 
 
Cell viability studies for prodrug system in the presence of nanozymes were carried out 
using HeLa cells in a 96 well plate. Cells were first incubated with nanozymes (C11, Phenyl, 
Naphthyl, C16, and Pyrene-TTMA) at a concentration of 250 nM in serum-containing media for 
24 h. Then, after multiple washings, cells were incubated with pro-Dox (5 µM) for another 24 h. 
Cells were washed off with PBS buffer three times and 10% Alamar Blue in serum containing 
media was added to each well (220 µL) and further incubated at 37 °C for 4 h. The cell viability 
was then determined by measuring the fluorescence intensity at 570 nm using a SpectraMax M5 
microplate spectrophotometer. Results showed that C11-TTMA nanozyme did not show much 
toxicity as the cell viability was around 90%. However, when nanozymes carrying higher amount 
of catalysts were used, a significant decrease in cell viability was observed (Figure 6.8). The 
highest cell death was obtained when cells were incubated with Pyrene-TTMA. 
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Figure 6.8: Viability of cells incubated with nanozymes with different monolayer structures and 
pro-Dox. 
 
6.3 Summary and Future Outlook 
In summary, we have designed and synthesized three AuNP-Cp*Ru(cod)Cl complexes 
having the different functionalities in the hydrophobic layer of surface monolayer. The catalyst 
loading into those designed AuNPs as well as a catalytic activity of nanozyme can be tuned by 
the chemical structure of hydrophobic pocket, leading us to develop the nanozyme having higher 
catalytic activity for the cleavage reaction of allyloxycarbonyl group than previously reported 
nanozyme. This enhanced catalytic activity could greatly improve the potential of our nanozyme 
system for the future in vitro and in vivo applications.  
6.4 Experimental Section 
6.4.1 General 
All the chemicals were purchased from Sigma-Aldrich or Fischer Scientific, unless 
otherwise specified. The chemicals were used as received. Dichloromethane (DCM) and 
tetrahydrofuran (THF) used as a solvent for chemical synthesis and dried according to standard 
procedures. The yields of the compounds reported here refer to the yields of spectroscopically 
pure compounds after purification. 
1
H NMR spectra were recorded at 400 MHz on a Bruker 
AVANCE 400 machine.  
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6.4.2 Synthesis of Ligands 
 
Figure 6.9: Synthesis of compound S2 from compound S1. 
 
2,2-Dimethyl-3,3-diphenyl-4,7,10,13-tetraoxa-3-silapentadecan-15-oicacid (S2). To a 
solution of compound S1 (5.9 g, 13.6 mmol) and TEMPO (213 mg, 1.36 mmol) in CH2Cl2 (45.8 
mL) was added a solution of KBr (145 mg, 1.22 mmol), tetra-n-butyl-ammonium bromide (219 
mg, 0.68 mmol) in sat. NaHCO3 (27.3 mL). After addition of a solution of NaOCl (5%, 65.9 mL, 
54.4 mmol) in sat. NaHCO3 (15.9 mL) and brine (31 mL) at 0 °C, the mixture was stirred at 0 °C 
for 30 min. CHCl3, H2O, and KHSO4 (5.96 g, 43.5 mmol) were added, and the whole was 
extracted with CHCl3. The mixture was washed with brine (× 2), and dried over MgSO4. After 
concentration, the residue was purified by flash chromatography over silica gel with n-hexane–
EtOAc–AcOH (50:50:0 to 49:50:1) to give the desired compound S2 as pale yellow oil (5.45 g, 
90%). 
1
H-NMR (400 MHz, CDCl3) 1.06 (9H, s, -CH3), 3.62-3.83 (12H, m, -CH2-), 4.15 (2H, s, -
CH2-), 7.39-7.41 (6H, m, Ar), 7.69-7.70 (4H, m, Ar). MALDI-MS: m/z calculated for 
C24H34NaO6Si [M + Na]
+ 
469.202 ; found: 469.199 
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Ligand with Pyrene (12) 
 
Figure 6.10: Synthesis of pyrene ligand. 
 
5,5'-(Pyrene-1,6-diyl)bis(pent-4-yn-1-ol) (2). To a suspension of 1,6-dibromopyrene 
(10.7 g, 29.7 mmol), Pd(PPh3)2Cl2 (1.04 g, 1.5 mmol) and CuI (283 mg, 1.5 mmol) in anhydrous 
THF (252 mL) and triethylamine (degassed, 252 mL) was added 1-pentyn-5-ol (10 g, 119 mmol) 
at rt. After being stirred at 80 °C for 5 h, the mixture was filtered through Celite pad and washed 
with CHCl3. After concentration, CHCl3 and 1M HCl were added, and the mixture was sonicated 
and solid was filtered through filter paper to give the desired compound 2 as pale yellow solid 
(8.66 g, 80%). This compound was used for next step without further purification. 
1
H-NMR (400 
MHz, DMSO-d
6
) 1.83-1.90 (4H, m, -CH2-), 2.73 (4H, t, J = 7.1 Hz, -CH2-), 3.64-3.68 (4H, m, -
CH2-), 4.67 (2H, t, J = 5.2 Hz, -OH), 8.12 (2H, d, J = 8.0 Hz, Ar), 8.27-8.29 (4H, m, Ar), 8.49 
(2H, d, J = 9.0 Hz, Ar). MALDI-MS: m/z calculated for C26H22O2 [M]
+ 
366.162; found: 366.172. 
5,5'-(Pyrene-1,6-diyl)bis(pentan-1-ol) (3). To a suspension of compound 2 (8.66 g, 23.6 
mmol) in MeOH (92.5 mL) and CH2Cl2 (278 mL) was added 5% Pd-C (2.6 g, 1.18 mmol) at rt. 
After being stirred at rt under H2 atmosphere for overnight, the mixture was filtered through 
Celite pad. The solvent was evaporated in vacuo to give the desired compound 3 as pale yellow 
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solid (8.21 g, 93%). This compound was used for next step without further purification. 
1
H-NMR 
(400 MHz, CDCl3) 1.51-1.72 (10H, m, -CH2-, -OH), 1.88-1.95 (4H, m, -CH2-), 3.37 (2H, t, J = 
7.7 Hz, -CH2-), 3.69 (2H, t, J = 6.4 Hz, -OCH2-), 7.87 (2H, d, J = 7.8 Hz, Ar), 8.06-8.12 (4H, m, 
Ar), 8.23 (2H, d, J = 9.2 Hz, Ar). MALDI-MS: m/z calculated for C26H30O2 [M]
+ 
374.225; found: 
374.219. 
Pyrene-1,6-diylbis(pentane-5,1-diyl)-dimethanesulfonate (4). To a suspension of 
compound 3 (8.21 g, 21.9 mmol) and triethylamine (7.9 mL, 54.8 mmol) in CH2Cl2 (62.3 mL) 
was added dropwise methanesulfonyl chloride (4.2 mL, 54.8 mmol) at 0 °C. After being stirred at 
0 °C for 30 min, the mixture was washed with 0.1M HCl, sat. NaHCO3 and brine, and dried over 
MgSO4. The solvent was evaporated in vacuo to give the desired compound 4 as pale yellow 
solid (11.6 g, 99%). This compound was used for next step without further purification. 
1
H-NMR 
(400 MHz, CDCl3) 1.58-1.65 (4H, m, -CH2-), 1.82-1.97 (8H, m, -CH2-), 2.97 (6H, s, -CH3), 3.38 
(4H, t, J = 7.6 Hz, -CH2-), 4.25 (4H, t, J = 6.5 Hz, -CH2-), 7.87 (2H, d, J = 7.8 Hz, Ar), 8.07-8.13 
(4H, m, Ar), 8.22 (2H, d, J = 9.2 Hz, Ar). MALDI-MS: m/z calculated for C28H34O6S2 [M]
+ 
530.180; found: 530.175. 
5-[6-(5-Azidopentyl)pyren-1-yl]pentyl-methanesulfonate (5). To a solution of 
compound 4 (11.6 g, 21.9 mmol) in DMF (200 mL) was added NaN3 (1.42 g 21.9 mmol) at 60 
°C. After being stirred at 60 °C for 2 h, EtOAc was added. The mixture was washed with brine (× 
6), and dried over MgSO4. After concentration, the residue was purified by flash chromatography 
over silica gel with n-hexane–CHCl3 (1:1 to 0:1) to give the desired compound 5 as pale yellow 
solid (5.28 g, 51%). 
1
H-NMR (400 MHz, CDCl3) 1.54-1.74 (6H, m, -CH2-), 1.81-1.96 (6H, m, -
CH2-), 2.96 (3H, s, -CH3), 3.30 (2H, t, J = 6.8 Hz, -CH2-), 3.28-3.39 (4H, m, -CH2-), 4.24 (2H, t, 
J = 6.5 Hz, -OCH2-), 7.85-7.88 (2H, m, Ar), 8.07-8.13 (4H, m, Ar), 8.20-8.23 (2H, m, Ar). 
MALDI-MS: m/z calculated for C27H31N3O3S [M]
+ 
477.209; found: 477.215. 
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5-{6-[5-(Tritylthio)pentyl]pyren-1-yl}pentan-1-amine (7). To a solution of compound 
5 (5.28 g, 11.1 mmol) in CHCl3 (40 mL) was added dropwise a mixture of triphenylmethyl 
mercaptan (6.7 g 24.3 mmol) and NaOEt in EtOH (21%, 7.16 mL, 22.1 mmol) at rt. After being 
stirred at 60 °C for 2.5 h, EtOAc was added. The mixture was washed with sat. NaHCO3 (× 2) 
and brine, and dried over MgSO4. After concentration, the residue was dissolved in THF (110 
mL) and H2O (1.1 mL) and triphenylphosphine (5.8 g, 22.1 mmol) was added. After being stirred 
at 60 °C for 2.5 h, the solvent was evaporated in vacuo. The residue was purified by flash 
chromatography over silica gel with CHCl3–MeOH–NH4OH (100:0:0 to 89:10:1) to give the 
desired compound 7 as orange amorphous (4.14 g, 59%). 1.42-1.93 (14H, m, -CH2-), 2.19 (2H, t, 
J = 6.9 Hz, -CH2-), 2.74 (2H, t, J = 6.6 Hz, -CH2-), 3.26 (2H, t, J = 7.7 Hz, -CH2-), 3.36 (2H, t, J 
= 7.6 Hz, -CH2-), 7.19-7.47 (15H, m, Ar), 7.80 (1H, d, J = 7.8 Hz, Ar), 7.86 (1H, d, J = 7.8 Hz, 
Ar), 8.03-8.11 (4H, m, Ar), 8.08 (1H, d, J = 9.2 Hz, Ar), 8.22 (1H, d, J = 9.2 Hz, Ar). MALDI-
MS: m/z calculated for C45H45NNaS [M + Na]
+ 
654.317; found: 654.340. 
2,2-Dimethyl-3,3-diphenyl-N-(5-{6-[5-(tritylthio)pentyl]pyren-1-yl}pentyl)-4,7,10,13-
tetraoxa-3-silapentadecan-15-amide (8). To a solution of compound 7 (1.5 g, 2.4 mmol), 
compound S2 (1.1 g, 2.4 mmol), diisopropylethylamine (1.3 mL, 7.2 mmol), and HOBt·H2O (368 
mg, 2.4 mmol) in DMF (24 mL) was added EDC·HCl (920 mg, 4.8 mmol) at rt. After being 
stirred at rt for overnight, EtOAc was added. The mixture was washed with 0.1 M HCl (× 2), sat. 
NaHCO3 (× 2) and brine (× 2), and dried over MgSO4. After concentration, the residue was 
purified by flash chromatography over silica gel with n-hexane–EtOAc (1:1 to 0:1) to give the 
desired compound 8 as pale yellow oil (2.1 g, 81%). 
1
H-NMR (400 MHz, CDCl3) 1.05 (9H, s, -
CH3), 1.43-1.63 (8H, m, -CH2-), 1.71-1.92 (4H, m, -CH2-), 2.19 (2H, t, J = 6.8 Hz, -SCH2-), 3.24-
3.38 (6H, m, -CH2-), 3.56-3.64 (10H, m, -OCH2-), 3.80 (2H, t, J = 5.1 Hz, -OCH2-), 3.97 (2H, s, -
OCH2-), 6.98 (1H, br t, J = 5.7 Hz, -NH-), 7.19-7.45 (21H, m, Ar), 7.67-7.70 (4H, m, Ar), 7.80 
(1H, d, J = 7.8 Hz, Ar), 7.84 (1H, d, J = 7.8 Hz, Ar), 8.02-8.09 (4H, m, Ar), 8.16 (1H, d, J = 9.2 
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Hz, Ar), 8.20 (1H, d, J = 9.2 Hz, Ar). MALDI-MS: m/z calculated for C69H77NNaO5SSi [M + 
Na]
+ 
1082.519; found: 1082.597. 
11-Oxo-17-{6-[5-(tritylthio)pentyl]pyren-1-yl}-3,6,9-trioxa-12-azaheptadecyl-
methanesulfonate (10). To a solution of compound 8 (2.0 g, 1.9 mmol) in THF (37.6 mL) was 
added a solution of tetrabutylammonium fluoride in THF (1M, 3.76 mL, 3.8 mmol) at rt. After 
being stirred at rt for 2h, the reaction was quenched with sat. NH4Cl. After concentration, the 
residue was purified by flash chromatography over silica gel with EtOAc–MeOH (1:0 to 4:1). To 
a solution of intermediate and triethylamine (407 µL, 2.8 mmol) in CH2Cl2 (18.8 mL) was added 
dropwise methanesulfonyl chloride at 0 °C. After being stirred at 0 °C for 30 min, EtOAc was 
added. The mixture was washed with 0.1 M HCl, sat. NaHCO3 and brine, and dried over MgSO4. 
After concentration, the residue was purified by flash chromatography over silica gel with -
EtOAc–MeOH (1:0 to 9:1) to give the desired compound 10 as pale yellow oil (1.55 g, 92%). 1H-
NMR (400 MHz, CDCl3) 1.43-1.78 (10H, m, -CH2-), 1.89-1.95 (2H, m, -CH2-), 2.19 (2H, t, J = 
6.8 Hz, -SCH2-), 3.01 (3H, s, -CH3), 3.24-3.38 (6H, m, -CH2-), 3.57-3.70 (10H, m, -OCH2-), 3.98 
(2H, s, -OCH2-), 4.30-4.32 (2H, m, -OCH2-), 6.87 (1H, br t, J = 5.2 Hz, -NH-), 7.19-7.30 (9H, m, 
Ar), 7.41-7.44 (6H, m, Ar), 7.80 (1H, d, J = 7.8 Hz, Ar), 7.86 (1H, d, J = 7.8 Hz, Ar), 8.03-8.11 
(4H, m, Ar), 8.16 (1H, d, J = 9.2 Hz, Ar), 8.21 (1H, d, J = 9.2 Hz, Ar). MALDI-MS: m/z 
calculated for C54H61NNaO7S2 [M + Na]
+ 
922.379; found: 922.413. 
17-[6-(5-Mercaptopentyl)pyren-1-yl]-N,N,N-trimethyl-11-oxo-3,6,9-trioxa-12-
azaheptadecan-1-aminium-methanesulfonate (12). To a solution of compound 10 (500 mg, 
0.56 mmol) in CHCl3 (0.84 mL) was added a solution of trimethylamine in EtOH (2.8 mL) at rt. 
After being stirred at 50 °C for overnight, the mixture was concentrated in vacuo. To a solution of 
residue in CH2Cl2 (3.0 mL) were added trifluoroacetic acid (1.0 mL) and triisopropylsilane (0.25 
mL). After being stirred at rt for 10 min, the mixture was concentrated in vacuo. The residue was 
suspended in n-hexane, and sonicated. After centrifugation, the supernatant was removed. This n-
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hexane-washing step was repeated five times to give the desired 12 as pale yellow oil (395 mg, 
99%). 
1
H-NMR (400 MHz, CDCl3) 1.47-1.77 (8H, m, -CH2-), 1.85-1.92 (4H, m, -CH2-), 2.57 
(2H, q, J = 7.3 Hz, -SCH2-), 2.84 (3H, s, -CH3), 3.14 (9H, s, -CH3), 3.29-3.38 (6H, m, -CH2-), 
3.50-3.64 (10H, m, -OCH2-), 3.86 (2H, br s, -N
+
CH2-), 4.04 (2H, s, -OCH2-), 6.99 (1H, br t, J = 
5.7 Hz, -NH-), 7.86 (1H, d, J = 7.8 Hz, Ar), 7.87 (1H, d, J = 7.8 Hz, Ar), 8.07-8.13 (4H, m, Ar), 
8.22 (1H, d, J = 9.2 Hz, Ar), 8.23 (1H, d, J = 9.2 Hz, Ar). MALDI-MS: m/z calculated for 
C37H53N2O4S [M]
+ 
621.372; found: 621.403. 
Ligand with aliphatic group (21): 
 
Figure 6.11: Synthesis of C16 ligand. 
 
16-(Tritylthio)hexadecyl-methanesulfonate (14). To a suspension of compound 13 (2.6 
g, 5.0 mmol) and triethylamine (1.45 mL, 10 mmol) in CH2Cl2 (10 mL) was added dropwise 
methanesulfonyl chloride (483 µL, 6.3 mmol) at 0 °C. After being stirred at 0 °C for 10 min, the 
mixture was washed with 0.1M HCl, sat. NaHCO3 and brine, and dried over MgSO4. The solvent 
was evaporated in vacuo to give the desired compound 14 as colorless solid (2.33 g, 77%). This 
compound was used for next step without further purification. 
1
H-NMR (400 MHz, CDCl3) 1.19-
1.45 (26H, m, -CH2-), 1.73-1.80 (2H, m, -CH2-), 2.15 (2H, t, J = 7.3 Hz, -SCH2-), 3.02 (3H, s, -
OCH3), 4.24 (2H, t, J = 6.6 Hz, -OCH2-), 7.21-7.32 (9H, m, Ar), 7.42-7.44 (6H, m, Ar).  
(16-Azidohexadecyl)(trityl)sulfane (15). To a solution of compound 14 (2.3 g, 3.9 
mmol) in DMF (19.4 mL) was added NaN3 (503 mg 7.8 mmol) at rt. After being stirred at 50 °C 
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for 2 h, EtOAc was added. The mixture was washed with brine (× 5), and dried over MgSO4. The 
solvent was evaporated in vacuo to give the desired compound 15 as colorless solid (1.81 g, 
86%). This compound was used for next step without further purification. 
1
H-NMR (400 MHz, 
CDCl3) 1.14-1.64 (28H, m, -CH2-), 2.15 (2H, t, J = 7.3 Hz, -SCH2-), 3.28 (2H, t, J = 7.0 Hz, -
OCH2-), 7.20-7.42 (9H, m, Ar), 7.42-7.45 (6H, m, Ar).  
16-(Tritylthio)hexadecan-1-amine (16). To a solution of compound 15 (1.8 g, 3.3 
mmol) in in THF (33 mL) and H2O (0.33 mL) was added triphenylphosphine (1.74 g, 6.6 mmol). 
After being stirred at 40 °C for overnight, the solvent was evaporated in vacuo. The residue was 
purified by flash chromatography over silica gel with CHCl3–MeOH–NH4OH (100:0:0 to 
80:19:1) to give the desired compound 16 as pale yellow solid (1.5 g, 88%). 
1
H-NMR (400 MHz, 
CDCl3) 1.19-1.49 (30H, m, -CH2-, NH2), 2.16 (2H, t, J = 7.3 Hz, -SCH2-), 2.71 (2H, t, J = 7.0 Hz, 
-OCH2-), 7.21-7.42 (9H, m, Ar), 7.43-7.45 (6H, m, Ar). MALDI-MS: m/z calculated for 
C35H49NNaS [M + Na]
+ 
538.348; found: 538.432. 
2,2-Dimethyl-3,3-diphenyl-N-[16-(tritylthio)hexadecyl]-4,7,10,13-tetraoxa-3-
silapentadecan-15-amide (17). To a solution of compound 16 (1.5 g, 2.9 mmol), compound S2 
(1.3 g, 2.9 mmol), diisopropylethylamine (1.6 mL, 8.7 mmol), and HOBt·H2O (444 mg, 2.9 
mmol) in DMF (29 mL) was added EDC·HCl (1.11 g, 5.8 mmol) at rt. After being stirred at rt for 
overnight, EtOAc was added. The mixture was washed with 0.1 M HCl (× 2), sat. NaHCO3 (× 2) 
and brine (× 2), and dried over MgSO4. After concentration, the residue was purified by flash 
chromatography over silica gel with n-hexane–EtOAc (1:1 to 1:2) to give the desired compound 
17 as pale yellow oil (2.6 g, 96%). 
1
H-NMR (400 MHz, CDCl3) 1.07 (9H, s, -CH3), 1.19-1.53 
(28H, m, -CH2-), 2.15 (2H, t, J = 7.3 Hz, -SCH2-), 3.26 (2H, q, J = 6.8 Hz, -NCH2-), 3.61-3.68 
(10H, m, -OCH2-), 3.83 (2H, t, J = 5.3 Hz, -OCH2-), 3.99 (2H, s, -OCH2-), 6.96 (1H, br s, -NH-), 
7.21-7.46 (21H, m, Ar), 7.69-7.71 (4H, m, Ar). MALDI-MS: m/z calculated for C59H81NNaO5SSi 
[M + Na]
+ 
966.550; found: 966.657. 
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20-Oxo-1,1,1-triphenyl-22,25,28-trioxa-2-thia-19-azatriacontan-30-yl-
methanesulfonate (19). To a solution of compound 17 (2.6 g, 2.8 mmol) in THF (55 mL) was 
added a solution of tetrabutylammonium fluoride in THF (1M, 5.5 mL, 5.5 mmol) at rt. After 
being stirred at rt for 2h, the reaction was quenched with sat. NH4Cl. After concentration, the 
residue was purified by flash chromatography over silica gel with EtOAc–MeOH (1:0 to 4:1). To 
a solution of intermediate and triethylamine (596 µL, 4.12 mmol) in CH2Cl2 (27.5 mL) was added 
dropwise methanesulfonyl chloride (316 µL, 4.12 mmol) at 0 °C. After being stirred at 0 °C for 
30 min, EtOAc was added. The mixture was washed with 0.1 M HCl, sat. NaHCO3 and brine, and 
dried over MgSO4. After concentration, the residue was purified by flash chromatography over 
silica gel with EtOAc–MeOH (1:0 to 9:1) to give the desired compound 19 as pale yellow oil 
(2.11 g, 98%). 
1
H-NMR (400 MHz, CDCl3) 1.19-1.57 (28H, m, -CH2-), 2.15 (2H, t, J = 7.3 Hz, -
SCH2-), 3.08 (3H, s, -CH3), 3.30 (2H, q, J = 6.8 Hz, -NCH2-), 3.61-3.80 (10H, m, -OCH2-), 4.01 
(2H, s, -OCH2-), 4.40 (2H, t, J = 4.7 Hz, -OCH2-), 6.85 (1H, br s, -NH-), 7.20-7.31 (9H, m, Ar), 
7.42-7.44 (6H, m, Ar). MALDI-MS: m/z calculated for C44H65NNaO7S2 [M + Na]
+ 
806.410; 
found: 806.487. 
28-Mercapto-N,N,N-trimethyl-11-oxo-3,6,9-trioxa-12-azaoctacosan-1-aminium-
methanesulfonate (21). To a solution of compound 19 (500 mg, 0.64 mmol) in CHCl3 (0.32 mL) 
was added a solution of trimethylamine in EtOH (3.2 mL) at rt. After being stirred at 50 °C for 
overnight, the mixture was concentrated in vacuo. To a solution of residue in CH2Cl2 (3.0 mL) 
were added trifluoroacetic acid (1.0 mL) and triisopropylsilane (0.25 mL). After being stirred at rt 
for 10 min, the mixture was concentrated in vacuo. The residue was suspended in n-hexane, and 
sonicated. After centrifugation, the supernatant was removed. This n-hexane-washing step was 
repeated five times to give the desired compound 21 as colorless oil (380 mg, 99%). 
1
H-NMR 
(400 MHz, CDCl3) 1.26-1.63 (28H, m, -CH2-), 2.54 (2H, q, J = 7.1 Hz, -SCH2-), 2.86 (3H, s, -
CH3), 3.30 (9H, s, -CH3), 3.66-3.71 (10H, m, -OCH2-), 3.98 (2H, br s, -N
+
CH2-), 4.11 (2H, s, -
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OCH2-), 7.09 (1H, br s, -NH-). MALDI-MS: m/z calculated for C27H57N2O4S [M]
+ 
505.403; 
found: 505.407. 
6.4.3 Synthesis of Gold Nanoparticles and Characterization 
Pyrene-AuNP was prepared through place-exchange reaction of 1-pentanethiolprotected 
2 nm gold nanoparticle (Au-C5) according to previously reported procedure.
(3) 
Briefly, to the 
solution of Au-C5 (20 mg) in CH2Cl2 (1 mL) was added the solution of pyrene ligand 1 (72 mg, 
0.1 mmol) in CH2Cl2:MeOH (4:1, 3 mL). After being stirred at rt for 24 h, the solvent was 
evaporated in vacuo. After nanoparticle residue was washed with EtOAc (10 mL×3), the 
nanoparticle was immediately dissolved in MilliQ water and the aqueous solution of the 
nanoparticle was purified by dialysis with distilled water using SnakeSkin
TM
 Dialysis Tubing 
(Thermo Scientific, 10,000 MWCO). The resulting AuNP was lyophilized and dissolved in 
CH2Cl2 (1 mL) and MeOH (3 mL) and additional amount of ligand 1 (72 mg) was added. After 
being stirred at rt for 24 h, the solvent was evaporated in vacuo. After nanoparticle residue was 
washed with EtOAc (10 mL × 3), the nanoparticle was immediately dissolved in MilliQ water 
and the aqueous solution of the nanoparticle was purified by dialysis with distilled water using 
SnakeSkin
TM
 Dialysis Tubing (Thermo Scientific, 10,000 MWCO).; MALDI-MS: m/z calculated 
for C37H53N2O4S [M]
+ 
621.372; found: 621.660. C16, Phenyl, and Naphthyl-TTMA were 
prepared by following the similar procedure to Pyrene-AuNP. 
Size and zeta potential of AuNPs were recorded in 5 mM phosphate buffer (pH 7.4) at 
room temperature at a concentration of 1µM, using a Malvern Zetasizer Nano ZS. 
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Table 6.1: Size and zeta potential of nanozymes used in the study. 
 Size (nm)Sd.(nm)a Size (nm)Sd.(nm)b Zeta potential(mV) 
Sd.(mV) 
Phenyl-TTMA 8.384.35 9.223.88 18.44.12 
Naphthyl-TTMA 8.852.61 8.015.73 15.26.60 
C16-TTMA 8.913.80 8.345.06 15.26.56 
Pyrene-TTMA 8.532.85 7.612.87 18.34.34 
a: Before catalyst encapsulation, b: After catalyst encapsulation. 
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CHAPTER 7 
 SUPRAMOLECULAR REGULATION OF BIOORTHOGONAL CATALYSIS IN CELLS 
USING NANOPARTICLE-EMBEDDED TRANSITION METAL CATALYSTS 
7.1 Introduction 
Bioorthogonal chemistry
1-3
 is a promising strategy for the intracellular generation of 
molecules for therapeutic
4
 and imaging applications
5,6
 unattainable through naturally occurring 
bioprocesses.
7,8
 Transition metal catalysts (TMCs) are excellent candidates for use in 
bioorthogonal processes,
9-11
 rapidly catalyzing transformations that cannot be performed via 
enzymatic processes.
12-15
 However, the application of TMC-mediated reactions in living cells is 
challenging due to issues of biocompatibility, water solubility, catalyst stability, and rapid efflux 
of catalysts from living cells.
12,13
 
Loading of TMCs into nanomaterial scaffolds can be used to provide water solubility and 
a protective environment for TMCs. Bradley et al.
13
 and Unciti-Broceta et al.
16
 used palladium-
catalyst loaded polystyrene beads to catalyze reactions such as Suzuki-Miyaura coupling and 
alkylcarbamate / N-propargyl cleavage inside and outside cells, respectively. The particles used in 
these studies, however, were far larger than normal proteins, creating potential interference in 
cellular processes. Additionally, these particles did not provide the capability of mimicking 
allosteric regulation of enzymes, a key component in cellular homeostasis.
17
 The integration of 
biomimetic size and controlled response into a bioorthogonal catalysis platform would provide 
new avenues for both therapeutics and integrated biological/abiotic cellular systems. 
In this work, we have developed a family of gold nanoparticles (AuNPs) based on ~2 nm 
core size
18-20
 that feature biomimetic size, possess diverse functional properties,
21,22
 and are 
efficiently transport of into cells.
23,24
 In this chapter, we report the use of this AuNP structural 
motif to encapsulate
25
 hydrophobic TMCs, providing NP_Ru (Figure 7.1) or NP_Pd. The 
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resulting nanozymes
26-30
 feature surface moieties that can be reversibly functionalized using host-
guest chemistry
31,32
 to provide NP_Ru_CB[7] or NP_Pd_CB[7]. Complexation of the monolayer 
terminal functionalities by cucurbit[7]uril (CB[7])
33-35
 in this system blocks access to the catalytic 
site, resulting in essentially complete inhibition of catalytic activity. The gatekeeper 
molecules
36,37
 can then be released from the AuNPs using competitive guests,
38
 restoring catalytic 
activity (Figure 7.1). The efficacy of this system was demonstrated in solution and in cells 
through two applications: 1) the gated generation of a fluorophore through deallylation of a non-
fluorescent precursor and 2) the gated activation of a prodrug by cleaving the propargyl 
functionality that has been introduced to block the active side of original drug. Such gated control 
of catalysis has not been demonstrated in cells to date and is important because it allows the 
potential for multiple useful capabilities, such as switching on therapeutics at target tissues and 
regulation of activity to maintain homeostasis for long-term therapeutics. To date, supramolecular 
machines based on gating strategy were designed to entrap the guest molecules in the pore 
reservoir of silica nanoparticles and their release was studied mostly in test tubes
39
 or 
intracellularly
37
 in a few studies however, no gated control of substrate activation was 
demonstrated inside cells.  
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Figure 7.1: Bioorthogonal nanozyme design and supramolecular regulation of intracellular 
catalysis. a) AuNPs, catalyst embedded AuNPs, and CB[7] capped catalyst embedded AuNPs 
used in study. b) Endosomal uptake of nanozymes. c) Intracellular catalysis with NP_Ru 
converting substrate into product. d) CB[7] complexation with the ligand headgroup to provide 
NP_Ru_CB[7] inhibits catalyst activity. e) Nanozyme activity is restored through addition of the 
competitive guest 1-adamantylamine (ADA). f) Structures of the NP platform with the surface 
ligand bearing a dimethylbenzylammonium group to bind the CB[7] gatekeeper, CB[7] 
gatekeeper, and ADA, a competitive guest molecule for CB[7] binding. g) Structures of the non-
fluorescent substrate (rhodamine 110 derivative), fluorescent product (rhodamine 110) obtained 
after catalysis, and embedded catalyst for allylcarbamate cleavage. 
 
7.2 Results and Discussion 
7.2.1 Design and Synthesis of Nanozymes 
We used AuNPs with core diameters of ~2 nm as the scaffold for our catalysts, with the 
goal of creating protein-sized systems with functional monolayers. The monolayer coverage of 
the NP nanoreactor scaffold features three crucial components: 1) a hydrophobic alkane segment 
for catalyst encapsulation, 2) a tetra(ethylene glycol) unit to provide biocompatibility,
40
 and 3) a 
dimethylbenzylammonium group to impart water solubility and bind the non-toxic CB[7] 
gatekeeper (Figure 7.1 (f)).
41,42
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We chose ruthenium-catalyzed deallylation
43,44
 as a model bioorthogonal process to 
regenerate the fluorescence from an allylcarbamate caged fluorophore in solution and inside cells. 
To this end, we immobilized [Cp*Ru(cod)Cl] (Cp* = pentamethylcyclopentadienyl, cod = 1,5-
cyclooctadiene) in the hydrophobic portion of the AuNP monolayer to provide NP_Ru. 
Transmission electron microscopy (TEM) images of the AuNPs before and after encapsulation of 
the catalyst indicated that no aggregation or decomposition of AuNP structure occurred after 
encapsulation, a result that was confirmed by dynamic light scattering (Figure 7.2).  
 
Figure 7.2: TEM images of AuNP with (a) without (b) encapsulation of the ruthenium 
catalysts. No size change or aggregation of nanoparticles was observed from TEM images, 
indicating no morphological change occurred during encapsulation process. 
 
The amount of ruthenium catalyst relative to AuNP was quantified using inductively 
coupled plasma mass spectrometry (ICP-MS)
45
 of 
101
Ru relative to 
197
Au, with 42 ± 3 catalyst 
molecules encapsulated per AuNP. 
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7.2.2 Catalytic Efficacy of NP_Ru Nanozymes in Solution 
The catalytic efficacy of the nanozymes in solution was assessed using the allylcarbamate 
cleavage of bis-N,N’-allyloxycarbonyl rhodamine 110 (Figure 7.1 (g)). Fluorescence started to 
increase immediately for NP_Ru after the addition of substrate, while no significant change in 
fluorescence was observed for NP_Ru_CB[7] (Figure 7.3).  
 
Figure 7.3: Bar graph of intensities of NP_Ru and NP_Ru_CB[7] at 5 different time points for 2 
h. 
 
After 24 h bright fluorescence was observed using the NP_Ru nanozymes (Figure 7.5 
(a)). However, only minimal fluorescence was observed for the NP_Ru_CB[7], which originated 
from the background of caged fluorophore as observed at 0 h (Figure 7.4).  
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Figure 7.4: Photo of the reaction mixtures in water with NP_Ru and NP_Ru_CB[7] under UV 
light at 0 h. 
 
As expected no reaction occurred with the control particle NP that lacked embedded 
catalysts (Figure 7.5), as the [Cp*Ru(cod)Cl] was insoluble in water, preventing study of the 
catalyst alone. Additionally, fluorogenesis of NP_Ru and NP_Ru_CB[7] taken after 5 days 
confirmed the long term stability of  the gated catalysis system in solution (Figure 7.6).  
 
Figure 7.5: Reaction mixtures including a, the nanozyme and caged rhodamine 110 and b, AuNP 
and caged rhodamine 110 after 24 h. 
 
Figure 7.6: Photo of the reaction mixtures in water with NP_Ru and NP_Ru_CB[7] under UV 
light after 5 days. 
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7.2.3 Supramolecular Control of Catalysis 
With catalytic efficacy of the nanozymes established, we next explored CB[7] 
complexation of the ligand headgroups to act as the gatekeepers in NP_Ru_CB[7]. Isothermal 
titration calorimetry (ITC)
46
 indicated that 60 ± 5 CB[7] molecules bound per NP, with KD = 11.3 
± 2.4 µM (Figure 7.7).  
 
Figure 7.7: ITC titration of CB[7]s into the NP solution. The circles represent the integrated heat 
changes during complex formation and the lines represent the curve fit to the binding isotherm. 
 
Complexation with CB[7] effectively shut down catalysis in NP_Ru_CB[7], as minimal 
fluorogenesis was observed with nanozymes after addition of CB[7] (Figure 7.8). Kinetic studies 
(Figure 7.8 (a)) verified this observation, indicating essentially complete inhibition of catalysis by 
CB[7] complexation. This inhibition was reversible: after the addition of 1-adamantylamine 
(ADA), a competitive guest molecule for CB[7], catalytic activity was completely restored 
(Figure 7.8 (b), (c)).  
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Figure 7.8: Catalytic activity of nanozymes in solution. a) Fluorescence was generated by 
NP_Ru after the cleavage of profluorophore bis-Alloc-rhodamine 110, while NP_Ru_CB[7] 
showed no significant change. b) After adding ADA, catalytic activity of NP_Ru_CB[7] was 
restored and no significant effect was observed for the activity of NP_Ru. c) The reaction rates of  
NP_Ru and NP_Ru_CB[7] before and after adding ADA showing catalytic activity for 
NP_Ru_CB[7] was fully recovered after the addition of ADA. The reaction rate experiments were 
performed in triplicate. Error bars represent standard deviations of these measurements. d) Photo 
of the reaction mixtures in water with NP_Ru and NP_Ru_CB[7] under UV light. 
 
Control studies of the free catalyst in an acetone/water solution showed that catalyst 
efficiency was unaffected by either CB[7] or ADA (Figure 7.9), demonstrating that particle-
CB[7] gating controls the catalytic process.  
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Figure 7.9: Activity assay of allylcarbamate cleavage of the [Cp*Ru(cod)Cl] in acetone/water 
(1:1 v/v). No catalytic activity change was observed in presence of CB[7] or CB[7] + ADA, 
indicating CB[7] or ADA cannot affect the catalytic activity of the catalysts directly. 
 
7.2.4 Kinetic Analysis of the NP_Ru Nanozymes Using Lineweaver–Burk Analysis 
The analogy between controlled regulation of the nanozymes and their enzyme 
counterparts was explored through kinetic analysis of the nanozymes using Lineweaver–Burk 
analysis (LBA).
47,48
 These studies indicate that CB[7] complexation results in competitive 
inhibition of reactor activity (Figure 7.10 and Figure 7.11), presumably by blocking access to the 
[Cp*Ru(cod)Cl] "active site".  
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Figure 7.10: Lineweaver-Burk plot showing competitive binding of CB[7] to nanozyme. Kinetic 
studies of NP_Ru and NP_Ru_CB[7] in sodium phosphate buffer (5 mM, pH 7.4) indicate that 
CB[7] inhibits catalyst activity through a competitive inhibition mechanism, with CB[7] affinity 
and stoichiometry consistent with ITC binding studies. Numbers calculated on a per particle 
basis. Kinetic experiments with each nanozyme were repeated in triplicate. Error bars represent 
standard deviations of these measurements. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.11: The dependence of reaction rates on the concentration of the CB[7] (a)0 μM; b) 4 
μM; c) 16 μM; and d) 80 μM). e) The fitting curve of the reaction rate vs. concentration of the 
substrates. 
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Little change in activity was observed for CB[7]:NPs ratios greater than ~60:1, consistent 
with the ITC results (Figure 7.12 and Figure 7.13). Likewise, the value of Ki from the LBA (11.4 
± 4.3 µM) is essentially identical to the affinity obtained by ITC (11.3 ± 2.4 µM). Taken together, 
these studies demonstrate the direct correlation between CB[7]-AuNP equilibrium binding 
processes and kinetic behavior of the nanozyme. 
 
Figure 7.12: The dependence of reaction rate on the concentration of CB[7]. 
 
 
 
 
 
 
Figure 7.13: The reaction curve for relative activity versus [CB[7]]/[NP]. 
 
7.2.5 Catalytic Efficacy of NP_Pd Nanozymes in Solution 
To demonstrate the versatility of this catalysis platform, we chose a second catalyst: 
hydrophobic palladium catalyst: (1,1'- Bis(diphenylphosphino) ferrocene)palladium(II)dichloride. 
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This palladium catalyst was encapsulated in the hydrophobic portion of the AuNP monolayer to 
provide NP_Pd. The amount of palladium catalyst relative to AuNP was quantified using ICP-MS 
of 
106
Pd relative to 
197
Au. It was calculated that 32 ± 1 catalyst molecules encapsulated per AuNP. 
Similar to NP_Ru nanozyme, NP_Pd can also cleave the allylcarbamate of bis-N,N’-
allyloxycarbonyl rhodamine 110.
13
 After 6 h, fluorescence was generated for the NP_Pd, 
however; NP_Pd_CB[7] showed only a slight background fluorescence of caged fluorophore 
(Figure 7.14). 
 
Figure 7.14: Photos of the reaction mixtures in water with NP_Pd and NP_Pd_CB[7] under UV 
light at a) 0 h and b) 6 h. 
 
Kinetic studies for NP_Pd and NP_Pd_CB[7] indicated the inhibition of catalysis by 
CB[7] complexation. Followed by the addition of ADA, the catalytic activity of nanozyme was 
restored (Figure 7.15). These findings supported that gated catalysis is efficiently working for 
different catalyst systems. 
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Figure 7.15: Kinetics of palladium catalyst embedded nanozymes. Fluorescence generation by 
NP_Pd and NP_Pd_CB[7] a) before ADA addition and b) after ADA addition. 
 
7.2.6 Catalytic Activity inside Living Cells 
Having characterized the activity and gating of nanozyme catalysis in solution, we next 
studied the intracellular behavior of these nanozymes using HeLa cells. The cellular uptake of the 
nanozymes was quantified by tracking [
197
Au] using ICP-MS, with NP_Ru_CB[7] particles 
demonstrating a slightly more efficient (1.7-fold greater) uptake than uncomplexed NP-Ru 
(Figure 7.16). Significantly, little to no toxicity was observed at the concentrations used for our 
studies with either NP or NP_Ru (Figure 7.17).  
 
Figure 7.16: Nanozyme uptake assay by tracking gold amount through ICP-MS. 
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Figure 7.17: Cytotoxicity of the NP_Ru and NP at various concentrations. 
 
We then probed the catalytic activity of the nanozymes inside the living cells. HeLa cells 
were incubated with the nanozyme for 24 h in serum-containing media and then washed multiple 
times to remove adsorbed particles on the cell surface. Fresh media containing the substrate was 
added, followed by 24 h incubation and washing. As shown in Figure 7.18 (a), flow cytometry 
indicated that there was a significant increase in fluorescence with NP_Ru relative to the control 
NP. Confocal microscopy (Figure 7.18 (d)) showed that the cells treated with NP_Ru had bright 
punctate fluorescence. This fluorescence co-localized with LysoTracker® (Figure 7.19), 
indicating that the deallylation reaction occurred in the endosomes and cleaved fluorophore 
stayed in the endosomes. This outcome is expected given the endosomal uptake pathway
49,50
 
previously observed for similar nanoparticles, coupled with the limited membrane permeability of 
the cleaved dye.
51
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Figure 7.18: Triggered allylcarbamate cleavage in living cells using gated nanozymes. a) Flow 
cytometry of NP_Ru, NP_Ru_CB[7], and controls (only cell and NP) revealing NP_Ru showed 
significant increase in fluorescence while NP_Ru_CB[7] was completely inhibited. b) Addition of 
ADA to NP_Ru_CB[7] treated cells recovered the catalysis and resulted in increase in 
fluorescence. c-f) Confocal microscopy images of HeLa cells showing the supramolecularly 
regulated intracellular chemical reactions, a punctate fluorescence was observed for NP_Ru and 
NP_Ru_CB[7] + ADA treated cells as the indication of catalysis while no fluorescence was 
obtained for only substrate and NP_Ru_CB[7] (scale bars = 10 μm). 
 
We next investigated the intracellular gating of the nanozyme by CB[7] complexation. 
Flow cytometry showed that the NP_Ru_CB[7] particles were completely inhibited, indicating 
intracellular stability of the complexes (Figure 7.18 (a), (e)). Treatment with ADA (400 µM) 
restored nanozyme activity, with even higher activity observed in the cells after treatment with 
ADA than was observed with NP_Ru (Figure 7.18 (b)). This increased catalytic efficiency is 
echoed in the micrograph (Figure 7.18 (f)) and potentially arises from enhanced protection of the 
catalyst by the CB[7] coverage in serum and inside the cell.  
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Figure 7.19: The confocal images of the cell treated with a) the nanozyme, substrate, and 
lysotracker; b) the nanozyme-bound-CB[7], substrate, ADA, and lysotracker. 
 
We further tested the control of gated catalysis through the treatment of cells with free 
CB[7]. First, HeLa cells were incubated with the NP_Ru for 24 h and then after multiple 
washings, free CB[7] in serum-containing media was treated to cells for 24 h before the addition 
of the substrate. A significant decrease in the fluorescence was observed indicating the 
complexation of CB[7] with NP_Ru and blocking access to the catalytic site (Figure 7.20). 
 
 
 
 
 
 
 
 
 
Figure 7.20: Confocal microscopy images of HeLa cells incubated with only substrate (a), 
NP_Ru + substrate (b), and NP_Ru nanozyme + free CB[7] + substrate (c) (scale bars = 20 μm). 
Fluorescence intensities were obtained from confocal images using ImageJ program (d). 
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Palladium catalyst embedded nanozymes were likewise used for intracellular controlled 
activation of the caged fluorophore. NP_Pd effectively performed the intracellular catalysis, 
while as expected the gated NP_Pd_CB[7] did not. ADA addition into cells that were previously 
incubated with NP_Pd_CB[7] resulted in the recovery of intracellular catalysis (Figure 7.21). 
 
 
 
 
 
 
 
Figure 7.21: Intracellular gated-catalysis using NP_Pd/NP_Pd_CB[7] (scale bars = 10 μm). 
 
7.2.7 NP_Pd Nanozymes for Prodrug Activation 
Bioorthogonal activation of prodrugs using TMC-loaded nanomaterials was recently 
demonstrated by Unciti-Broceta and co-workers.
16
 Although prodrug activation was successfully 
achieved, no gated control over this activation was shown. We have bioorthogonally 
demonstrated gated-activation of a prodrug inside cells using NP_Pd/NP_Pd_CB[7]. 5-
fluorouracil (5FU) is a chemotherapeutic drug used in cancer treatment including breast, stomach, 
pancreatic, and skin cancers. Although it has an established history in cancer treatment, it shows 
toxic side effects due to its limited safety profile.
52
 These side effects can be eliminated or at least 
minimized if a prodrug strategy coupled with gated-intracellular catalysis were to be available. 
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By this gated catalysis, activation of prodrugs will be achieved on demand upon reaching to site 
of action thus eliminating the off target effects.   
5FU can be converted into a prodrug via functionalization on its N1 position, as 
modification at this position will block the activity of 5FU and render it non-toxic.
16
 We 
introduced a propargyl moiety to turn 5FU into an inactive prodrug ‘pro-5FU’ (Figure 7.22 (a)). 
First, through palladium mediated chemocatalysis propargyl masking unit is intracellularly 
cleaved to yield 5FU followed by the enzymatic reactions to convert 5FU into cytotoxic 
nucleotidic metabolites ‘fluorouridine monophosphate’ via functionalization on its N1 position.53 
These active metabolites work through misincorporation into RNA and DNA molecules and 
irreversibly inhibit the nucleotide synthetic enzyme thymidylate synthase to disrupt cell functions 
and induce cytotoxicity. Overall, this process is an example of the integration of chemocatalysis 
and enzymatic biochemistry in a one-pot chemical sequence.
54,55 
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Figure 7.22: Prodrug activation in living cells using gated nanozymes. a) Structures of pro-5FU, 
5FU and the palladium catalyst used for prodrug activation. b) Viability of cells treated with 5FU 
and pro-5FU at various concentrations, showing a nice therapeutic window was obtained between 
5FU and pro-5FU. c) NP_Pd and ADA treated NP_Pd_CB[7] showed increasing intracellular 
toxicity as a result of more conversion of prodrug into 5FU drug at higher pro-5FU 
concentrations, while NP_Pd_CB[7] did not show any toxicity at any prodrug concentration used 
due to the blocking catalysis. Also, only prodrug, NP_Pd, NP_Pd_CB[7], and NP_Pd_CB[7] + 
ADA did not cause any toxicity into the system at zero prodrug concentration. Cell viability 
experiments were performed in triplicate. Error bars represent standard deviations of these 
measurements. 
 
Cleavage of propargyl group on pro-5FU (1 mM) in the presence of NP_Pd (100 nM) 
was monitored using matrix-assisted laser desorption/ionization (MALDI)-MS. Most of the pro-
5FU was converted in 5FU after 48 h (Figure 7.23). After confirming the cleavage, the toxicity 
profile of 5-FU and pro-5FU were investigated performing a cell viability assay. Cells were 
treated with various concentrations from 10 nM to 1 mM. While 5-FU showed toxicity as 
concentration increased, pro-5FU retained high cellular viability at all concentrations studied. 
(Figure 7.22 (b)).   
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Figure 7.23: Cleavage of propargyl functionality of prodrug was monitored using MALDI-MS at 
(a) 15, (b) 48, and (c) 72 h. 
 
Cell viability studies for prodrug system in the presence of nanozymes were carried out 
using HeLa cells in a 96 well plate. Cells were first incubated with NP_Pd or NP_Pd_CB[7] at a 
concentration of 100 nM in serum-containing media for 24 h. Then, after multiple washings, cells 
were incubated with different concentrations of pro-5FU (0, 0.05, 0.1, 0.25, 0.5 and 1 mM) while 
some of the cells that were incubated with NP_Pd_CB[7], were treated with pro-5FU and ADA at 
the same time. Cells that were incubated with NP_Pd and NP_Pd_CB[7] + ADA showed elevated 
toxicity at higher concentration of pro-5FU while NP_Pd_CB[7] retained ~100 % cell viability 
even at higher concentration of pro-5FU (Figure 7.22 (c)). As expected, pro-5FU was not toxic at 
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any concentrations used. Likewise, NP_Pd, NP_Pd_CB[7], and  NP_Pd_CB[7] + ADA at zero 
pro-drug concentration were not toxic indicating toxicity was coming from the intracellular 
conversion of pro-5FU into 5-FU using gated-catalysis but not the nanozyme itself. 
7.3 Summary and Future Outlook 
In conclusion, we have described the fabrication of an AuNP based, bioorthogonal 
nanozyme that uses transition metal catalysis to effect transformations of imaging and therapeutic 
relevance without biological counterparts. These catalysts were built upon a platform featuring 
biomimetic size and surface functionality, making them attractive components for both in vitro 
and in vivo applications. The ability to control the activity of these nanozymes through host-guest 
interactions of CB[7] molecules with the benzyl headgroup of the AuNP ligands likewise 
provides an efficient and reversible means of regulating catalysis. This bioorthogonal catalysis 
can be employed not only in therapeutic applications such as the activation of prodrugs at the site 
of action but also in treating non-cancerous chronic diseases where the goal is not to kill the cell 
but to kill an infective agent or to restore a malfunctioning pathway. This platform enables to 
introduce an inactive reservoir of a bioorthogonal catalyst that would remain dormant between 
successive administrations of a bioorthogonal substrate, thus reducing potential interference of 
the catalyst with cell constituents and protecting the metal from poisoning, release, systemic 
distribution and/or clearance. Furthermore, our protein-sized system demonstrates biomimetic 
behavior and yet performs totally abiotic chemistry that can be controlled intracellularly through 
a very simple host-guest feature. In conclusion, this system integrates biomimetic and 
bioorthogonal design elements to provide a new platform for imaging and therapeutic 
applications as well as pharmacological treatments integrating biological activity with man-made 
synthetic tools. 
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7.4. Synthesis of Materials and Experimental Sections 
7.4.1 Synthesis of the Benzyl Ligand 
 
Scheme 7.1: Synthetic scheme of the benzyl ligand for the functionalization of the nanoparticle. 
 
Compound 2: 11-bromo-1-undecanol (1, 10 g, 39.8 mmol) was dissolved in 1:1 
ethanol/toluene mixture (200 ml). Triphenylmethanethiol (13.2 g, 47.77 mmol) dissolved in 1:1 
ethanol/toluene (50 ml) was added to 11-bromo-1-undecanol in solution. Then NaOH (2.38 g, 
59.7 mmol) dissolved in 3 ml water was slowly added to the mixture. The reaction mixture was 
stirred for 24 h at 50°C. Upon completion, the reaction mixture was extracted with a saturated 
solution of NaHCO3 twice. The organic layer was extracted, dried over Na2SO4, and concentrated 
by evaporation of the solvent. The crude product was purified by column chromatography over 
silica gel using hexane/ethyl acetate (1:1, v/v) as the eluent. The solvent was removed in vacuum 
to obtain compound 2 as colorless oil (Yield 16.42 g, 92%). 
1
H NMR (400 MHz, CDCl3, TMS) of 
Compound 2 : δ 7.48-7.40 (m, 6H, HAr-), 7.37-7.27 (m, 6H, HAr-), 7.26-7.18 (m, 3H, HAr-), 
3.65 (t, J = 6.7Hz, 2H,CH2OH), 2.16 (t, J = 7.2Hz, 2H,-CH2-), 1.66-1.52 (m, 2H, -SCH2CH2) , 
1.44-1.12 (m, 16H, -CH2CH2OH + -(CH2)8 CH2OH). 
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Figure 7.24: 
1
H NMR spectrum (400 MHz) of compound 2 in CDCl3 (D, 99.8%). 
 
Compound 3: Compound 2 (16.42 g, 36.76 mmol) in dry dichloromethane (DCM, 200 
ml) was mixed with triethylamine (5.58 g, 7.66 mL, 55.14 mmol), followed by dropwise addition 
of methanesulfonyl chloride (4.64 g, 3.13 mL, 40.47 mmol) in ice bath. After 30 min the reaction 
mixture was warmed up to room temperature and stirred overnight. After the reaction was 
completed (according to thin layer chromatography; TLC), solvent was evaporated. The 
compound was again diluted with DCM and extracted with 0.1 M HCl twice. The organic layer 
was collected, treated with a saturated solution of NaHCO3, and washed three times. Following 
extraction, the organic layer was dried over Na2SO4 and concentrated at reduced pressure. The 
crude product was purified by column chromatography over silica gel using hexane/ethyl acetate 
(1:1, v/v) as the eluent. Solvent was removed in vacuum to obtain mesylated compound as light 
yellow oil (Yield 17.4 g, 90%). To synthesize compound 3, NaOH (1.59 g, 39.8 mmol) solution 
(1.5 mL) was added to 115 mL of tetraethyleneglycol (128.93 g, 66.37 mmol) and stirred for 2 h 
at 80°C. To this reaction mixture, 17.4 g of 11-(tritylthio)undecyl methanesulfonate (30.03 mmol) 
was added and stirred for 24 h at 100°C. The product was extracted in hexane/ethyl acetate (100 
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ml, 4:1, v/v) six times. Then, the organic layer was concentrated at reduced pressure and the 
crude product was purified by column chromatography over silica gel using ethyl acetate as the 
eluent. The solvent was removed in vacuum to obtain compound 3 as light yellow oil (Yield 11.6 
g, 62%). 
1
H NMR (400 MHz, CDCl3, TMS) of Compound 3: δ 7.47-7.40 (m, 6H, HAr-), 7.34-
7.26 (m, 6H, HAr-), 7.25-7.19 (m, 3H, HAr-), 3.77-3.57 (m,16H, -CH2-(OCH2CH2)4-OH), 3.46 (t, 
J = 6.8 Hz, 2H, -CH2-(OCH2CH2)4-OH), 2.95 (br, s, 1H, -TEG-OH), 2.15 (t, J = 7.2Hz, -SCH2-), 
1.59 (p, J = 7.2Hz, 2H, -CH2CH2TEG-OH), 1.4 (p, J = 7.6Hz, 2H, -SCH2CH2-), 1.35-1.13(m, 
14H, -(CH2)7 CH2CH2TEG-OH). 
 
Figure 7.25: 
1
H NMR spectrum (400 MHz) of compound 3 in CDCl3 (D, 99.8%). 
 
Compound 4: Triethylamine (2.6 g, 3.6 mL, 25.6 mmol) was added to compound 3 (8 g, 
12.8 mmol) in dry DCM (80 ml) in an ice bath. Methanesulfonyl chloride (2.22 g, 1.49 mL, 19.28 
mmol) was added dropwise to the reaction mixture in an ice bath. After 30 min the reaction 
mixture was warmed up to room temperature and stirred 12 h. The organic layer was extracted 
twice with a saturated solution of NaHCO3 (100 ml) and twice with 0.1 M HCl solution (100 ml). 
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The extracted DCM layer was dried over Na2SO4 and concentrated at reduced pressure. The crude 
product was purified by column chromatography over silica gel using ethyl acetate as the eluent. 
Solvent was removed in vacuum to obtain compound 4 as light yellow oil (Yield 8.2 g, 91 %). 
1
H 
NMR (400 MHz, CDCl3, TMS) of Compound 4: δ 7.44-7.37 (m, 6H, HAr-), 7.31-7.23 (m, 6H, 
HAr-), 7.22-7.16 (m, 3H, HAr-), 4.40-4.34 (m, 2H, -CH2OSO3CH3), 3.78-3.54 (m, 14H, CH2-
(OCH2CH2)3-CH2CH2OSO3CH3), 3.44 (t, J = 6.8Hz, 2H, CH2-CH2-(OCH2CH2)3-), 3.07 (s, 3H, -
OSO3CH3), 2.12 (t, J = 7.2Hz, 2H, -SCH2-), 1.56 (p, J = 7.2Hz, 2H, -CH2CH2TEG-N(CH3)2), 
1.38 (p, J=7.6Hz, 2H, -SCH2CH2-), 1.32-1.11 (m, 14H, -(CH2)7CH2CH2TEGOSO3 CH3). 
 
Figure 7.26: 1H NMR spectrum (400 MHz) of compound 4 in CDCl3 (D, 99.8%). 
 
Compound 5: Compound 4 (1 g, 1.42 mmol) was added to dimethylbenzylamine (0.58 
g, 0.65 ml, 4.28 mmol) in ethanol-DCM mixture (4:1,v/v, 5 ml). The reaction mixture was stirred 
at 40°C for 48 h. After evaporating ethanol at reduced pressure, the light yellow residue was 
purified by successive washings with hexane (four times) and hexane/diethylether (1:1 v/v, six 
times) and then dried under high vacuum. The product formation was around 100% and the 
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product was confirmed by NMR. 
1
H NMR (400MHz, CDCl3, TMS) of Compound 5: δ 7.64-7.58 
(m, 2H, HAr-), 7.38-7.32 (m, 9H, HAr-), 7.24-7.17 (m, 6H, HAr-), 7.16-7.09 (m, 3H, HAr-), 4.9 
(s, 2H, -CH2-C6H5), 3.94 (s, br, 2H, -OCH2CH2N(CH3)2-), 3.8 (s, br, 2H, -OCH2CH2N(CH3)2-), 
3.77-3.22 (m, 12H, -(OCH2CH2)3-CH2CH2N(CH3)2-), 3.33 (t, J = 6.8Hz, 2H, -CH2CH2O-),  3.23 
(s, 6H, -N(CH3)2-), 2.06 (t, J = 7.2Hz, 2H, -SCH2-), 1.51-1.42 (p, J = 6.8Hz, 2H, -CH2CH2O-), 
1.36-1.28 (p, J = 7.6Hz, 2H, -SCH2CH2-)  1.24-1.08 (m, 14H, -(CH2)7 CH2CH2O-).  
 
Figure 7.27: 
1
H NMR spectrum (400 MHz) of compound 4 in CDCl3 (D, 99.8%). 
 
Compound 6: An excess of trifluoroacetic acid (TFA, 20 equivalents, 3.07 g, 2.08 mL, 
27 mmol) was added to compound 5 (1 g, 1.12 mmol) in dry DCM (5 ml). The color of the 
solution was turned to yellow-orange upon addition of TFA. Then, triisopropylsilane (TIPS, three 
equivalents, 0.64g, 0.83 mL, 4.05 mmol) was added to the reaction mixture and the color of the 
solution turned to clear. The reaction mixture was stirred 5 hr under N2 at room temperature. The 
solvent, most of TFA, and TIPS were evaporated under reduced pressure. The yellow residue was 
purified by hexane washings (four times) and dried under high vacuum. The final product 
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formation was around 100% and the structure of compound 6 was confirmed by NMR. 
1
H NMR 
(400 MHz, CDCl3, TMS) of Compound 6: δ 7.57-7.47 (m, 5H), 4.61 (s, 2H, -CH2-C6H5), 4.01 (s, 
br, 2H, -OCH2CH2N(CH3)2-), 3.74-3.48 (m, 14H, -(OCH2CH2)3-CH2CH2N(CH3)2-), 3.41 (t, J = 
6.8Hz, 2H, -CH2CH2O-), 3.14 (s, 6H, -N(CH3)2-), 2.52 (q, J = 7.2Hz, HSCH2-), 1.65-1.48 (m, 4H, 
-CH2CH2O- + HSCH2CH2-), 1.43-1.20 (m, 15H, -(CH2)7 CH2CH2O- + HS-). 
 
Figure 7.28: 
1
H NMR spectrum (400 MHz) of benzyl ligand in CDCl3 (D, 99.8%). 
 
7.4.2 Synthesis of Benzyl-Ligand-Protected Gold Nanoparticle (AuNP)  
First, Brust-Schiffrin two-phase synthesis method
 
was used to synthesize pentanethiol-
coated AuNPs with core diameter ca. 2 nm.
56,57
 Murray place-exchange method
58
 was followed to 
obtain the benzyl-ligand-protected AuNPs. Pentanethiol-conjugated AuNPs (10 mg) and thiol 
ligand (compound 5) (30 mg) were dissolved in a mixture of dry DCM (3 mL) and methanol (1 
mL) and stirred under N2 atmosphere for 3 days at room temperature. The DCM was removed 
under reduced pressure and the resulting precipitate was washed with hexane (15 mL) three times 
and DCM (15 mL) twice. Then the precipitate was dissolved in distilled water (~ 5 mL) and 
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dialyzed for three days (membrane molecular weight cut-off =10,000, volume of the dialysis 
bucket is 5 L) to remove excess ligands, pentanethiol, acetic acid, and other salts present in the 
nanoparticle solution. After dialysis, the particle was lyophilized to yield a solid brownish 
product. The particles were then re-dispersed in deionized water. 
1
H NMR-spectra in D2O showed 
substantial broadening of the proton peaks with no sign of free ligands. The presence of ligands 
was also confirmed by mass spectroscopy. 
 
Figure 7.29: 
1
H NMR spectrum (400 MHz) of benzyl-AuNPs in D2O (D, 99.8%). 
 
7.4.3 Mass Spectrometric Characterization of Ligand Composition 
Matrix assisted laser desorption/ionization mass spectroscopy (MALDI-MS) has been 
performed to characterize the surface ligand on the Benzyl-AuNP.
59
 A saturated α-Cyano-4-
hydroxycinnamic acid (α-CHCA) stock solution was prepared in 70% acetonitrile, 30% H2O, and 
0.1% trifluoroacetic acid. An equal volume of 2 μM NP solution was added to the matrix stock 
solution. 2.5 μL of this mixture was applied to the sample carrier, and then the MALDI-MS 
analysis was performed on a Bruker Autoflex III mass spectrometer. The molecular ions (MH
+
, 
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m/z =498) was detected, and the disulfide ion formed by the benzyl ligand and the original 
pentanethiol was also detected at m/z 600.  
 
Figure 7.30: MALDI-MS spectrum of benzyl-AuNP. 
 
7.4.4 Catalyst Encapsulation into the Monolayer of AuNPs 
3 mg of the catalyst, [Cp*Ru(cod)Cl] or (1,1'- Bis(diphenylphosphino) 
ferrocene)palladium(II)dichloride was dissolved in 5 ml acetone and the AuNP (20 μM, 0.5 mL) 
were diluted to a final concentration  of 5 μM with DI water (2 ml). Then, the catalyst and the 
AuNP solutions were mixed together and acetone was slowly removed by evaporation. During 
the evaporation hydrophobic catalyst was encapsulated in the particle monolayer to yield to 
NP_Ru or NP_Pd. Excess catalysts which precipitated in water removed by filtration (Millex-GP 
filter; 25 mm PES, pore Size: 0.22µm). Further purifications were followed by multiple filtrations 
(five times, Amicon
®
 ultra 4, 10K) and dialysis (Snake Skin
®
 dialysis tubing, 10K) against water 
(5 L) for 24 h to remove free catalysts. The amount of encapsulated catalysts was measured by 
ICP-MS by tracking 
101
Ru relative to 
197
Au for NP_Ru and 
106
Pd relative to 
197
Au for NP_Pd.   
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7.4.5 Transmission Electron Microscopy (TEM) Measurement of the Nanoparticle Before 
and After the Encapsulation of the Catalysts 
TEM samples of AuNP and [Cp*Ru(cod)Cl] catalysts encapsulated AuNP were prepared 
by placing one drop of the desired solution (1 μM) on to a 300-mesh Cu grid-coated with carbon 
film. These samples were analyzed and photographed using JEOL CX-100 electron microscopy. 
The average diameter of Au core is 2.5 ± 0.4 nm. 
7.4.6 Size and Zeta Potential of the NP 
Hydrodynamic diameter and zeta potential of the NPs were measured by dynamic light 
scattering (DLS) in DI water and 5 mM phosphate buffer (pH=7.4) respectively, using a Malvern 
Zetasizer Nano ZS instrument. The measurement angle was 173° (backscatter). Data were 
analyzed by the “multiple narrow modes” (high resolution) based on non-negative-least-squares 
(NNLS).  
 
 
 
 
 
 
 
 
 
Figure 7.31: Characterization of the functionalized AuNP. a) Size (diameter) of AuNP was 
measured by DLS before and after catalyst encapsulation. DLS measurement shows that size of 
the NP after catalyst encapsulation stays same. b) Zeta potential of AuNP was measured by DLS. 
The overall charge of AuNP is measured as 25.5 ± 1 mV from three independent replicates. 
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7.4.7 Inductively Coupled Plasma Mass Spectrometry (ICP-MS) Instrumentation for 
Ruthenium Catalyst 
The ICP-MS analyses were performed on a Perkin-Elmer NexION 300X ICP mass 
spectrometer. 
197
Au and 
101
Ru were measured under the standard mode. Operating conditions are 
listed as below: nebulizer flow rate: 0.95 L/min; rf power: 1600 W; plasma Ar flow rate: 18 
L/min; dwell time: 50 ms. Standard gold and ruthenium solutions (concentration: 0, 0.2, 0.5, 1, 2, 
5, 10, and 20 ppb) were prepared for the quantification. 
7.4.7.1 ICP-MS Sample Preparation for the Quantification of Gold and Ruthenium 
0.5 mL of fresh aqua regia was added to the 10 μL sample solution and then the sample 
was diluted to 10 mL with de-ionized water. 
Table 7.1: Ruthenium amount in the nanozyme using ICP-MS measurement. 
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